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Breast and prostate cancers are the most common cancers in Australian women and men, 
respectively. The dysregulation of zinc (Zn2+) homeostasis is an intriguing hallmark for both 
cancers, e.g., hyper-accumulation of Zn2+ in breast cancer compared to normal breast tissue 
and low level of cellular Zn2+ in prostate cancer in comparison to normal prostate tissue. Such 
opposite profiles of zinc in breast and prostate cancer cells point to the potential involvement 
of zinc in cancer development. This study takes advantage of such characteristic feature 
between breast and prostate cancer cells to explore their molecular details in zinc homeostasis.  
In this study, protein kinase CK2 (CK2) was firstly analysed in breast and prostate cancer 
cells, by dissecting the distinct roles of CK2 subunits (CK2α, CK2α’ and CK2β) in zinc 
homeostasis. Using CK2 inhibitors 4,5,6,7-tetrabromobenzotriazole (TBB) and CX-4945, 
siRNA-mediated knockdown and zinc ion specific fluorophores (FluoZin-3 AM), this study 
demonstrated that zinc accumulation was elevated in PC3 and DU145 prostate cancer cells 
due to knockdown of the gene expression for CK2α’, while the opposite was observed in 
MCF-7 and MDA-MB-231 breast cancer cells. Furthermore, siRNA knockdown of individual 
CK2 subunits showed that individual subunits of CK2 have distinct roles in zinc homeostasis 
in breast and prostate cancer cells. These findings demonstrated that CK2 is indeed involved 
in zinc homeostasis in breast and prostate cancer cells, as well as that of individual CK2 
subunits play distinct roles.  
To gain a holistic view of the molecular details of zinc homeostasis, I carried out the 
transcriptomic analysis by the means of high throughput next-generation RNA sequencing 
(RNA-seq). Breast cancer cells (MCF-7) were subjected to extracellular zinc exposure (320 
µM) and then analysed by RNA-seq at three time points (T0, T30 and T120) in the time course. 
xix 
 
The findings revealed a significant increase in gene expression, up to 869-fold, for 
metallothioneins (MT1B, MT1F, MT1X and MT2A) and the zinc exporter ZnT1 (SLC30A1) 
at T30, continuingly through to T120. Similarly, the dynamic expression pattern was also found 
for the autophagy-related gene (VMP1) and numerous genes for zinc finger proteins (e.g., 
RNF165, ZNF365, ZBTB2, SNAI1, ZNF442, ZNF547, ZNF563 and ZNF296). These findings 
point to the all-hands-on-deck strategy adopted by the cancer cells for maintaining zinc 
homeostasis. The stress-responsive genes encoding heat shock proteins (HSPA1A, HSPA1B, 
HSPA1L, HSPA4L, HSPA6, HSPA8, HSPH1, HSP90AA1 and HSP90AB1) were also 
differentially up-regulated at T120, suggesting the critical role of heat shock proteins in dealing 
with zinc exposure. Furthermore, the genes encoding protein kinase CK2 subunits 
(CSNK2A1, CSNK2A2 and CSNK2B) were found unchanged. These results provide 
significant molecular clues which contributes to our understanding of zinc homeostasis and 
cancer development. 
The transcriptomic findings were validated by quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) and further extended to a panel of breast and prostate cancer cells 
as well as normal breast and prostate epithelial cells. The top differentially expressed genes 
from RNA-seq (MT1B, MT1F, MT1X, MT2A, SLC30A1, VMP1, ZNF850, HSPA6 and 
HSPA90AA1) were quantified via qRT-PCR. The results revealed that the expression of 
metallothionein genes (MT1B, MT1F, MT1X and MT2A) was increased at T30 and T120 
following IC50 ZnSO4 treatment, which agrees with the transcriptomic RNA-seq dataset.  
The gene for ZnT1 (SLC30A1) was expressed higher in the basal type of breast cancer cells 
(MDA-MB-231) compared to the luminal MCF-7 cells. As ZnT1 is the sole zinc efflux 
transporter residing in the plasma membrane and is functionally non-redundant in the 
maintenance of zinc homeostasis. Its higher expression in MDA-MB-231 cells than MCF-7 
xx 
 
may relate to the degree of their malignancy. Additionally, the expression of CK2 subunit 
genes was elevated in breast cancer cells compared to the normal breast epithelial cells, 
indicating its intrinsic role in the zinc homeostasis of the cancer cells. Furthermore, the 
expression of the zinc-related genes in prostate cancers is not as robust as the breast cancer 
cells, indicating that prostate cancer cells are naturally programmed to inhabit in low-zinc 
environment compared to breast cancer cells.  
Taken together, the results of this study demonstrated the involvement of CK2 in zinc 
homeostasis in breast and prostate cancer cells. The RNA-seq dataset confers a holistic view 
at the molecular level on how the cancer cell responds to the extracellular zinc exposure. The 
findings of this study provide molecular insights into zinc homeostasis of breast and prostate 
cancer cells. As zinc is critical for the structure and function of ~3000 human proteins, the 
molecular details described in this thesis should open multitudes of avenues for cancer 
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1 LITERATURE REVIEW 
1.1 General introduction 
This thesis seeks to investigate the involvement of zinc and protein kinase CK2 (CK2) in 
breast and prostate cancer cells, by dissecting the distinct roles of CK2 subunits (CK2α, 
CK2α’ and CK2β) in zinc homeostasis of breast and prostate cancer cells. Furthermore, 
revealing the rounded molecular details for zinc in breast cancer cells by the means of 
next-generation RNA sequencing and extending the discovery in breast cancer cells to 
prostate cancer cells.   
The basis of this project comes from previous studies in our lab, with the model organism 
Saccharomyces cerevisiae. Deletion of the CKA2 gene (the yeast equivalent of mammalian 
CSNK2A2 encoding CK2α’) was found to render the deletion mutant (cka2∆) resistant to 
zinc toxicity, suggesting that CK2α’ is involved in regulating zinc uptake and such a 
process is interrupted in cka2∆ hence resulting in resistance to zinc exposure. Moreover, 
the latter finding by inductively-coupled plasma mass spectrometry (ICP-MS) confirmed 
CK2α’ indeed plays a role in zinc uptake (Johnson et al., 2017). 
Further work in mouse neuroblastoma cells (Neuro-2a) extends our previous finding in 
yeast to mammalian cells. I found that CK2α’ was the predominant CK2 subunit in 
regulating zinc uptake of neuronal cells (Zaman et al., 2016). The knockdown of CK2α’ 
gene (CSNK2A2) by its specific small interfering RNA (siRNA) leads to increased 
tolerance to the zinc level. With the aid of the confocal microscope, I discovered that 
Neuro-2a cells treated with individual specific siRNA targeting the genes encoding CK2 
subunits α, α’ and β respectively exhibited a significant reduction of intracellular zinc, 
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whilst the knockdown of CK2α’ was the most prominent. Such a decrease of intracellular 
zinc correlated with the healthy morphology of the neuronal cells treated with CK2α’ 
siRNA as compared to the cells treated with zinc sulfate alone (Zaman et al., 2016). These 
findings demonstrate the involvement of CK2 in zinc homeostasis.  
Altered zinc profiles are linked to the development and progression of breast and prostate 
cancers (Margalioth et al., 1983; Rizk and Sky-Peck, 1984; Costello and Franklin, 2006). 
Studies have determined that zinc levels differ in various cancer types. It has been 
demonstrated that the zinc level in cancers of the breast is distinctly increased compared 
to normal breast epithelial cells (Margalioth et al., 1983; Rizk and Sky-Peck, 1984). In 
contrast, the zinc level in cancers of the prostate has been shown to be lower when 
compared to normal prostate epithelial cells (Costello and Franklin, 2006; Franklin and 
Costello, 2007; Franklin and Costello, 2009). Hence, dysregulation of zinc homeostasis is 
an intriguing hallmark for breast and prostate cancers, e.g., hyper-accumulation of Zn2+ in 
breast cancer and low levels in prostate cancer. Such diametrical opposite profiles of zinc 
in breast and prostate cancer cells provide an ideal tool to explore the role of protein kinase 
CK2 and zinc in these two types of cancer cells.  
Both CK2 and the zinc ion are key players in cell biology and oncogenesis (Vallee, 1983; 
Vallee and Auld, 1990; Litchfield, 2003) and this study demonstrates that CK2 and Zn2+ 
are intricately linked to breast and prostate cancer cells. Herein, a systematic experimental 
approach was employed, including experiments using CK2 inhibitors 4,5,6,7-
tetrabromobenzotriazole (TBB) and CX-4945, siRNA-mediated knockdown and zinc ion 
specific fluorophores (FluoZin-3 AM) were carried out to identify CK2’s involvement in 
regulating zinc toxicity of breast and prostate cancer cells. Next-generation RNA 
sequencing was conducted on the MCF-7 breast cancer cell line, followed-up by qRT-
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PCR, to determine the main genes involved in regulating zinc ion homeostasis. ICP-MS 
allowed me to determine the cellular content of zinc upon IC50 ZnSO4 treatment alone and 
in the presence of the CK2 inhibitor TBB, allowing me to explore the role of CK2 in zinc 
uptake. Prominent genes found to be involved in zinc ion homeostasis were further 
investigated via qRT-PCR. In this study the role of CK2 in zinc homeostasis was 
investigated in the breast (MCF-7 and MDA-MB-231) and prostate (PC3 and DU145) 
cancer cells, along with normal breast (MCF10A) and prostate (RWPE-1) epithelial cells. 
The findings of this study should have a direct bearing on cancer research.   
1.2 Chemistry of zinc 
Zinc is a transitional metal in the d block of the periodic table, with an atomic number of 
30. The underlying chemistry for the versatility of zinc, when compared to other metal 
ions like copper, iron and calcium, is found in its properties such as the completely filled 
d-shell and its ability to have different coordination numbers and a variety of coordinating 
ligands including the amino acid residues histidine and cysteine (Colvin et al., 2003; 
Cousins et al., 2006). The coordination chemistry of zinc permits its binding to a range of 
biological proteins due to its property as a Lewis acid, which makes it structurally suitable 
to preform protein-protein interactions (Vallee and Auld, 1990; Yamasaki et al., 2007). 
Lack of unpaired electrons in zinc means it is stable and does not participate in redox 
reactions, in contrast to the redox-active transition metal ions such as copper and iron 
(Laity et al., 2001).  
The stability of zinc is beneficial to the biological environment, intracellularly and 
extracellularly. As is known, the internal milieu of the cell is dynamic, containing both 
reducing and oxidative chemicals or metabolites (Koh and Choi, 1994; Hershfinkel et al., 
2001). A redox-inert metal ion like zinc provides stability, whether in enzymatic reactions 
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or in maintaining protein structures (Laity et al., 2001). Its versatility in coordination is 
also a valuable trait utilised by the cell for its role in regulating protein functions (Vallee 
and Auld, 1990; Ebert and Altman, 2008; Maret, 2012). With respect to its catalytic 
functions, zinc has been found to serve as a cofactor in numerous enzymes, with carbonic 
anhydrase being the first enzyme discovered in 1940 for using zinc as cofactor (Keilin and 
Mann, 1940; Ho and Ames, 2002). Studies have determined intracellular free zinc ion 
concentration at picomolar (pM) levels ranging from 60-500 pM, with pancreatic β-cell 
lines 110-250 pM (Qin et al., 2013; Chabosseau et al., 2014) and 400 pM in INS-1 rat 
pancreatic β-cells (Vinkenborg et al., 2009). 
1.3 Zinc ion homeostasis  
Arguably, zinc is one of the most important trace metal ions in organisms ranging from 
the single-celled S. cerevisiae to humans. Chronologically, zinc was first found essential 
to living organisms in 1869, by Jules Raulin, a student of Louis Pasteur (Raulin, 1869). 
Over the ensuing years, zinc has been found to be involved in multitudes of biological 
functions, including catalysis as a cofactor for enzymes, as a structural component in 
proteins and in signal transduction as a second messenger (Hershfinkel et al., 2001; Laity 
et al., 2001; Maret, 2001; Taylor et al., 2012). As mentioned previously, the first zinc-
binding enzyme discovered was carbonic anhydrase (Keilin and Mann, 1940). It is 
estimated that, in the cell’s proteome, there are at least 3000 zinc-binding proteins (Maret, 
2012). About 40% of these proteins are transcription factors, which often contain the 
famous zinc-finger motifs, allowing the proteins to bind DNA (Vallee and Auld, 1990; 
Ebert and Altman, 2008). The other 60% of zinc-binding proteins are mainly enzymes, 
structural proteins and ion transporters (Ebert and Altman, 2008).  
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Consequently, zinc is required for life on earth (Vallee and Auld, 1990). When compared 
against other micronutrients (e.g., iron, manganese and copper), zinc is quite distinctive in 
its functional diversity (Laity et al., 2001; Yamasaki et al., 2007; Prasad et al., 2009). 
Studies have catalogued the cellular functions which requires zinc such as gene expression 
(Vallee, 1983), the stabilisation of protein and nucleic acid structure (Vallee and Auld, 
1990), subcellular organelle integrity (Vallee, 1983; Vallee and Auld, 1990; Guerra and 
Issinger, 1999) and involvement in the activity of numerous enzymes (Grummt et al., 
1986; Vallee and Auld, 1990; Franklin and Costello, 2007). Zinc ion homeostasis in the 
cell is maintained through three highly regulated processes. They include zinc uptake by a 
family of ZRT/IRT-like protein transporters (ZIP), zinc storage in metallothioneins (MT) 
and subcellular compartments and zinc export to the extracellular space or into the 
subcellular organelle via a family of zinc transporters (ZnT) (Fig. 1.1) (Nelson, 1999; 
Guerinot, 2000; Colvin et al., 2003; Kirschke and Huang, 2003; Maret, 2003; Desoize, 





Fig 1.1 Diagram of general mechanisms of zinc uptake, storage and export 
Zinc ions enter the cell through ZIP transporters (denoted by 1), their sub-cellular location 
is controlled by zinc transporters embedded in organelles (2). They may form structural 
components of enzymes or participate as co-factors in metabolic processes (3). Specific 
proteins, such as metallothioneins may sequester zinc if concentrations are too high (4). 
Efflux of zinc is facilitated by ZnT transporters (5). 
 
A specific set of transporters functions in the plasma and subcellular organellar membranes 
to provide a delicate balance of transport activities for maintaining zinc ion homeostasis 
(Nelson, 1999). As previously asserted, intracellular zinc is critical for the functioning of 
biological processes including DNA transcription, cellular proliferation, cell signaling and 
apoptosis (Cousins et al., 2006; Kambe et al., 2014). Hence, the tight control of 
intracellular zinc, or maintaining its homeostasis, is essential for cell survival (Vallee and 
Auld, 1990; Choi and Bird, 2014). Mounting evidence implicates the dyshomeostasis of 
cellular zinc in cancers of the breast, prostate, liver, ovaries and pancreas, as zinc 
concentration in cancer tissues being disparate from the surrounding normal tissues (Table 
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1.1) (Colvin et al., 2003; Desoize, 2004; Franklin et al., 2005; Cousins et al., 2006; Kagara 
et al., 2007; Prasad et al., 2009; Lopez et al., 2011; Grattan and Freake, 2012). 
Understanding the molecular mechanisms for zinc homeostasis, an objective for this 
thesis, is critical in understanding the relationship between the dyshomeostasis of zinc and 
















Table 1.1 Comparison of zinc level in cancer and normal tissue 
Tissue/cells Zinc level comparison References 
Breast cancer 
cells 
Higher intracellular zinc level 
compared to normal breast 
epithelial cells 
(Margalioth et al., 1983; 
Rizk and Sky-Peck, 1984) 
Prostate cancer 
cells 
Lower intracellular zinc level 
compared to normal prostate 
epithelial cells 
(Liang et al., 1999; Costello 
and Franklin, 2006) 
Hepatocellular 
cancer tissue 
Lower intracellular zinc level 
compared to benign liver tissue 
(Ebara et al., 2000) 
Ovarian cancer 
tissue 
Lower intracellular zinc level 
compared to benign ovarian tissue 




Higher intracellular zinc level 
compared to normal pancreatic 
epithelial cells 








1.4 Regulation of zinc transport in the cell 
1.4.1 Transporters involved in zinc uptake 
For zinc to fulfil the myriad of roles in enzymatic activities, protein structures and signal 
transduction, nutrient zinc has to be transported into the cell (Cousins et al., 2006). As a 
charged cation, zinc itself cannot cross the plasma membrane by simple diffusion (Nelson, 
1999). As a result, there are numerous transporters involved in zinc uptake. They include 
the (ZIP1-14 family) which are represented in Table. 1.2 (Guerinot, 2000). Herein, ZRT 
is an abbreviation for zinc-regulated transporter, whilst IRT is for iron-regulated 
transporters. ZIP proteins are predicted to have eight transmembrane domains with 
extracellular N- and C- termini (Kagara et al., 2007). ZIP transporters increase intracellular 
zinc concentrations, [Zn2+]i, by promoting zinc uptake from extracellular space and 
vesicular zinc release into the cytoplasm.  
Zinc is tightly controlled in the cell by the 14 ZIP proteins as well as the other transporters 
such as ZnTs, which are to be described in the following section (Vallee and Auld, 1990; 
Mackay and Crossley, 1998; Kagara et al., 2007). As mentioned previously, it is essential 
for cells to regulate zinc influx, storage/sequestration and efflux to maintain homeostasis 
and prevent the onset of diseases such as cancers (Vallee and Auld, 1990; Mackay and 
Crossley, 1998; Kagara et al., 2007). Over-expression of several zinc transporters (ZIP6, 
ZIP7 and ZIP10) is associated with zinc hyper-accumulation in breast tumours and several 
breast cancer cell lines (Mackay and Crossley, 1998; Kirschke and Huang, 2003; Kagara 
et al., 2007; Prasad et al., 2009; Song and Ho, 2009; Lopez et al., 2011). Comparatively, 
ZIP6 over-expression has been noted in estrogen-responsive subtypes and is associated 
with less aggressive breast tumours (Vallee and Auld, 1990; Mackay and Crossley, 1998; 
Kagara et al., 2007). 
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*SLC denotes solute carrier. ZIP 1-14 belongs to family 39 of SLC superfamily of 
membrane-bound transport proteins.   
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1.4.2 Transporters associated with the decrease of intracellular zinc  
Zinc transporters (ZnT1-10) function in the opposite direction to ZIP, being responsible 
for decreasing [Zn2+]i by promoting zinc efflux from the cytoplasm to the extracellular 
space or into subcellular compartments (Colvin et al., 2003; Huang and Tepaamorndech, 
2013). The first ZnT to be discovered is ZnT1, which is located in the plasma membrane 
and its gene expression is mapped to chromosome 1 in both humans and mice (Guerinot, 
2000). Most ZnT proteins have six transmembrane domains (TMDs) and are predicted to 
have cytoplasmic amino and carboxyl termini. Furthermore, a classic characteristic of ZnT 
proteins is the long histidine rich loop between TMDs IV and V, which could potentially 
represent a metal binding domain (Vallee and Auld, 1990). The main ZnT transporters that 
have been studied are ZnT1 and ZnT2, while the other members of ZnTs are yet to be fully 
investigated.   
ZnT1 displays a ubiquitous tissue distribution, although it is highly expressed in tissues 
involved in zinc acquisition and transport such as within the basolateral surface of 
enterocytes lining the villi of the small intestine (Guerinot, 2000). It is important to take a 
big-picture view here, regarding this particular characteristic for ZnT1 expressed in 
basolateral face of enterocytes. The zinc ions absorbed into the enterocytes are transported 
out of these enterocytes via ZnT1 into the tissue and eventually into the blood stream. 
Therefore, ZnT1 is in fact involved in zinc acquisition in humans. In terms of the cancer 
cells, ZnT1 is responsible for transporting intracellular zinc out of the cells, hence 
decreasing [Zn2+]i. While ZnT2 is localised on vesicles and allows the storage and 
sequestration of zinc when the cytoplasm is replete with zinc (Kelleher and Lönnerdal, 
2003; Lopez et al., 2011). There is evidence to suggest ZnT2 is involved in mammary 
gland zinc metabolism where an abundance of ZnT2 at the basolateral surface appears to 
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remain the same, whilst the expression of ZnT2 at the apical membrane of the mammary 
gland decreases through lactation (Kelleher and Lönnerdal, 2003). In breast cancer cells, 
zinc accumulation coincides with ZnT2 overexpression and an increase in vesicular zinc 
pools (Mackay and Crossley, 1998; Guerinot, 2000; Kagara et al., 2007; Prasad et al., 
2009). In contrast to the elevated ZnT2 expression level in breast cancer cells, its 
expression level is decreased in prostate cancer cells (Song and Ho, 2009; Lopez et al., 
2011). Currently, there is a lack of evidence for the mechanistic roles of ZnTs in the 
maintenance and regulation of zinc homeostasis, hence it is necessary for further research 
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1.4.3 Metallothioneins and zinc homeostasis  
Apart from ZIP and ZnT, another player in maintaining zinc homeostasis is the cytosolic 
metallothioneins (MTs) (Maret, 2003). MTs are a class of small, cysteine-rich, metal 
binding proteins that play a role in essential metal ion homeostasis, detoxification of non-
essential metal ions and protect against intracellular oxidative stress (Adams et al., 2002). 
There are eight functional isoforms of MTs identified in humans (MT1A, MT1B, MT1E, 
MT1F, MT1G, MT1H, MT1X and MT2A) (Werynska et al., 2013). The cysteine residues 
in MTs are involved in zinc-binding, thereby allowing metallothioneins to serve as zinc 
buffering proteins (Vallee and Auld, 1990; Nelson, 1999). MT expression is positively 
regulated by zinc exposure through the activation of metal responsive elements (MREs) in 
the promoter of metallothionein genes (MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, 
MT1L, MT1M, MT1X, MT2, MT3 and MT4) (Suhy et al., 1999). MRE is the binding site 
for the DNA transcription factor metal-responsive transcription factor 1 (MTF-1) (Nelson, 
1999). MTF-1 responds to changes in zinc metal ion concentration by coordinating the 
expression of genes involved in uptake, distribution and storage of zinc such as ZIP, ZnT 
and MTs (Fig. 1.2) (Nelson, 1999; Rutherford and Bird, 2004). Not only do MTs bind and 
sequestrate Zn2+, they also bind and detoxify a variety of heavy metals such as lead and 
copper (Suhy et al., 1999).  
In relation to cancer, both MTs and MTF-1 are over-expressed in radiation-resistant 
tumours, suggesting their possible role in zinc homeostasis for cancer development (Suhy 
et al., 1999). Despite the importance of MTs for cell survival, their expression in varying 
cell types, normal and cancerous, differs by upwards of 400-fold (Suhy et al., 1999; Achary 
et al., 2001; Rutherford and Bird, 2004; Song and Ho, 2009). Like zinc transport proteins 
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(ZIP and ZnT), MTs and MTF-1 were also known to be involved in the dysregulation of 
zinc in cancer cells (Suhy et al., 1999; Rutherford and Bird, 2004; Song and Ho, 2009).  
 
Fig 1.2 Zinc transport and zinc-binding proteins in the cell 
As is shown, the function of the ZnT and ZIP transporter families is to reduce and increase 
the cytoplasmic zinc concentration, respectively. The diagram also depicts other zinc 
related transporters and their relative locations. Such diverse distributions of these proteins 
suggest individual roles in executing the catalytic, structural and regulatory roles of zinc. 
Also shown is the mechanism of sequestration facilitated by metallothioneins. Metal 
transcription factor 1 (MTF-1) binds the metal responsive element (MRE), resulting in the 








1.4.4 Zinc ion dyshomeostasis and its role in cancer 
Dysregulation of zinc homeostasis is detrimental to the cell. A considerably higher zinc 
level is found in breast cancer cells compared to normal breast cells (Alam and Kelleher, 
2012). Higher [Zn2+]i correlates with high malignancy for breast cancer (Margalioth et al., 
1983; Rizk and Sky-Peck, 1984; Kagara et al., 2007). Its accumulation is concomitant with 
abnormal expression of ZIP6, ZIP7, ZIP10, ZnT1 and ZnT2 (Kagara et al., 2007; Taylor 
et al., 2008; Lopez et al., 2011). In clear contrast, [Zn2+]i is lower in prostate cancer cells 
compared to normal prostate cells and down-regulation of transporter expression such as 
ZIP1 in malignant prostate tissue correlates with marked depletion of intracellular zinc 
levels (Franklin et al., 2005; Song and Ho, 2009). In normal prostate, zinc is thought to be 
involved in reproductive functions by aiding in the accumulation of citrate, a component 
of semen (Chyan et al., 2014). Within mitochondria of epithelial prostate cells, the high 
concentration of zinc has been shown to inhibit the metabolic enzyme aconitase which 
catalyses the isomerisation of citrate to isocitrate in citric acid cycle. By blocking the 
activity of aconitase, the citric acid cycle is impeded and citrate is accumulated (Vallee 
and Auld, 1990; Suhy et al., 1999; Rutherford and Bird, 2004; Prasad et al., 2009; Song 
and Ho, 2009). However, when prostate cells become cancerous, zinc concentration is 
lowered in mitochondria (Song and Ho, 2009). Consequently, the citric acid cycle is no 
longer inhibited. As a result, more ATP molecules are produced and cancer cells 
proliferate faster with the availability of energy.  
In this study, four cancer cell lines including breast (MCF-7 and MDA-MB-231) and 
prostate (PC3 and DU145) along with normal breast (MCF10A) and prostate (RWPE-1) 
epithelial cells were studied to gain a better understanding of zinc homeostasis and CK2 
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in these two types of cancer cells, which have diametrically opposite zinc profiles as 
described earlier.  
1.4.5 Zinc and metal-regulatory transcription factor 1 (MTF-1) 
Zinc homeostasis can be regulated at the level of gene expression. In this regard, MTF-1, 
a nucleocytoplasmic shuttling transcription factor, is the critical regulator (Choi and Bird, 
2014). It is basically a zinc sensor and it can sense the intracellular zinc level. When [Zn2+]i 
is high, MTF-1 is phosphorylated and then translocated into the nucleus where it binds to 
the promoters containing an MRE and activates the gene expression relevant to zinc export 
and sequestration such as the ZnT and MT genes (Fig. 1.3). Interestingly, it has been shown 
that in the presence of increased zinc metal ions the transcription factor MTF-1 can be 
phosphorylated by CK2 (Adams et al., 2002). Upon phosphorylation by CK2, cytoplasmic 
MTF-1 translocates to the nucleus where it activates genes such as metallothioneins 
(Adams et al., 2002). This phosphorylation of MTF-1 ultimately leads to the activation of 
metallothionein transcription (Adams et al., 2002). Metallothioneins are a class of 
cysteine-rich metal binding protein that play a role in metal ion homeostasis and 
detoxification of toxic metal ions (Nelson, 1999; Adams et al., 2002). At the gene level, 
CK2 may be influencing metal ion uptake through phosphorylation and activation of the 
metal transcription factor, which then regulates genes that are involved in metal ion uptake, 
storage and/or binding or it may be directly activating zinc transporters such as ZIP/ZnTs 
(Fig. 1.3). Evidence has shown that the phosphorylation of endoplasmic reticulum (ER) 
zinc channel ZIP7 is due to the action of CK2. This phosphorylation results in the gated 





Fig 1.3 Schematic of the mechanisms in response to extracellular zinc 
Zinc ions enter the cell through ZIP ion transporters (1). The increase of [Zn2+]i leads to 
sequestration via metallothioneins in the cytoplasm and ZnT in organelles to reduce 
cytosolic zinc concentrations (2). The cell undergoes up-regulation of metallothionein and 
ZnTs that sequester zinc ions into organelles for detoxification (3). Up-regulation of ZnT 









1.5 Potential regulation of zinc homeostasis in the cell by protein kinase 
CK2 
As alluded previously, zinc homeostasis can also be regulated at the protein level 
(Hershfinkel et al., 2001; Laity et al., 2001). In response to the extracellular stimuli such 
as hormones or growth factors, CK2 was found to phosphorylate the zinc channel, ZIP7, 
which is located in the membrane of the endoplasmic reticulum (Taylor et al., 2012). 
Consequently, zinc ions in ER store were released and intracellular concentration of zinc 
increased, triggering a cascade of downstream signal transduction. This finding 
demonstrates that CK2 is involved in regulating zinc homeostasis. However, further 
investigation is necessary to unravel CK2’s potential role in regulating other zinc transport 
proteins.    
The emerging evidence from our laboratory and that of others, demonstrates that CK2 
regulates the cell’s response to other metal or metalloid ions such as aluminium (Adams 
et al., 2002; Becaria et al., 2002), arsenic (Johnson et al., 2016) and chromium (Johnson, 
2016). By employing the non-biased high throughput functional genomics platform – 
genome-wide deletion mutant screening of S. cerevisiae, my lab has screened a panel of 
metal ions (Al3+, As3+ and Cr6+) with 4873 gene deletion mutants in the past years. A 
striking finding from these three datasets is that CK2 deletion mutants (cka1∆, cka2∆, 
ckb1∆ and ckb2∆) showed diverse phenotypes against the metal ions. The deletion of the 
CKA2 gene (the yeast equivalent to the mammalian CSNK2A2 which encodes CK2α’) 
leads to a significant resistance to Al3+, whilst the deletion of CKB1 or CKB2 (the yeast 
counterpart of mammalian CSNK2B encoding for CK2β) renders the yeast tolerant to As3+ 
and Cr6+ (Johnson et al., 2016). CKA2 was found to be involved in regulating zinc transport 
in S. cerevisiae (Tun et al., 2014; Johnson et al., 2016). Biochemical analysis by ICP-MS 
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demonstrates that the resistant phenotype of these CK2 subunit deletion mutants is due to 
the significantly reduced intracellular accumulation of Al3+, As3+, Cr6+ and Zn2+ (Johnson 
et al., 2016). Therefore, all these findings demonstrate that CK2 regulates metal ion uptake 
and toxicity. Furthermore, as mentioned earlier, in Neuro-2a cells, CK2α’ is shown to 
regulate zinc uptake (Zaman et al., 2016). Consequently, this study seeks to investigate the 
role of CK2 and zinc in breast and prostate cancer cells.   
The characteristics of Al3+, As3+, Cr6+ and Zn2+ are diverse, which offers no clue to the 
underlying reason shared by all of these metals in regards to their regulation by CK2 in 
the cell. For example, aluminium is a post-transition metal belonging to the P block of the 
periodic table, with an atomic number of 13. Al3+ is toxic and has no proven biological 
roles. Trace quantities of aluminium are present in drinking water and foods (de Paiva et 
al., 2020; Edzwald, 2020). Aluminium can accumulate in the body through ingestion and 
is linked to multiple neurological disorders such as Alzheimer’s disease (Exley and 
Clarkson, 2020; Van Dyke et al., 2021). Arsenic is a metalloid that also belongs to the P 
block of the periodic table, with an atomic number of 33. As3+ is very toxic and can be 
present in the contaminated ground and drinking water, air and foods (Medunić et al., 
2020). Its mining and industrial usage lead to the increased contamination of water and 
crops (McCarty et al., 2011; Sohn, 2014).  
Chromium is a transition metal belonging to the d block of the periodic table, with an 
atomic number of 24. It has adverse effects on living organisms such as lung cancer 
amongst chromate-exposed workers (Coyle et al., 2006; Beveridge et al., 2010; Poonia et 
al., 2021). Chromium’s biological roles are complicated due to the properties of its two 
prominent oxidation variants, the hexavalent Cr6+ and the trivalent Cr3+. Cr6+ is found to 
be highly toxic whilst Cr3+ is considered as a micronutrient and commonly used in health 
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supplements (Urbano et al., 2012; Liu et al., 2015; Wu et al., 2016). In contrast, zinc is a 
transitional metal in the d block of the periodic table, with an atomic number of 30. Zn2+ 
is the most crucial trace metal ion after iron (Fe2+/3+) to all living organisms (Tang et al., 
2017; He et al., 2018; Zeng et al., 2019). The biological functions of Zn2+ have been known 
for a long period of time, such as its involvement in gene expression (Vallee, 1983; 
Chasapis et al., 2020), the stabilisation of proteins and nucleic acids structure (Vallee and 
Auld, 1990; Bafaro et al., 2017), subcellular organelle (Vallee and Auld, 1990; Bafaro et 
al., 2017), the activity of numerous enzymes (Eide, 1998; Bafaro et al., 2017) and signal 
transduction as a second messenger (Grummt et al., 1986; Bafaro et al., 2017). It has been 
projected that roughly 10% of all proteins in eukaryotic cells bind zinc, which suggests 
there are roughly 3000 zinc proteins in humans (Andreini et al., 2006; Maret, 2012; Bafaro 
et al., 2017). 
The role of CK2 in regulating metal ions in the cell requires more research, and this is 
exactly what this project is about. I have focused on zinc because of its prominence in 









1.6 Protein kinase CK2 
1.6.1 The structure of CK2 
In mammalian cells, CK2 is a heterotetramer comprised of dual catalytic (α and/or α’) 
subunits bound to a central homodimer of non-catalytic regulatory (β) subunits (Fig. 1.4) 
(Meggio and Pinna, 2003). Zinc plays an essential role here to hold the two β subunits 
together. The two catalytic isoforms are designated as CK2α and CK2α’ (Litchfield, 2003). 
In contrast to mammalian CK2β, two β subunits of CK2, designated as CKB1 and CKB2, 
have been found in S. cerevisiae (Litchfield, 2003). As shown in Fig. 1.4, with mammalian 
CK2, tetrameric CK2 complexes may exist in three different tetramers (ααββ, αα’ββ and 
α’α’ββ) (Litchfield, 2003). In S. cerevisiae, CK2 can also be in three different quaternary 
makeups (ααβ1β2, αα’β1β2 and α’α’β1β2) (Meggio and Pinna, 2003). For mammalian 
cells, the size of catalytic subunits varies between 36 and 44 kDa, whereas the size of the 





Fig 1.4 Tetrameric isoforms and monomeric subunits of CK2 in mammalian cells 
In mammalian cells the CK2 tetramer has three potential isoforms ααββ (1), αα’ββ (2) and 
α’α’ββ (3). The preliminary step in tetramer formation is the development of a β 
homodimer to which the catalytic subunits α or α’ affix. The various combinations of 
catalytic subunits α (4) and α’ (5) attach to the β regulatory subunit (6) which accounts for 








Through crystallographic studies it has been shown that the enzyme CK2 consists of a fold 
formed by two domains; β-sheet based N-terminal domain and a C-terminal domain that 
contains several α-helices, as can be seen in Fig. 1.5 (Pechkova et al., 2003; Bischoff et 
al., 2011). Moreover, the active site of CK2 is located in a cleft between the two domains 
(Bischoff et al., 2011). The differences in the α and α’ subunits give rise to different three 
dimensional configurations (Bischoff et al., 2011). The characteristics of CK2β subunits 
include four cysteines in a zinc finger-like arrangement (Allende and Allende, 1995). The 
zinc finger motif plays a role in dimerisation of β subunits which mediate interactions 
between CK2 and its substrate proteins (Mackay and Crossley, 1998).  
Like any other protein kinase involved in signal transduction, the reversible 
phosphorylation of protein substrates is a major mechanism for the regulation of a broad 
spectrum of fundamental cellular processes such as the cell cycle and gene expression 
(Meggio and Pinna, 2003). As is known, the human genome encodes several hundred 
distinct protein kinases, hence it is not surprising that a third of all cellular proteins appear 
to be phosphorylated and that many proteins appear to be phosphorylated at several 
specific sites or signature sequences (Litchfield, 2003). Accordingly, on average, each 
protein kinase may phosphorylate a few dozen proteins within the cell (Litchfield, 2003; 
Meggio and Pinna, 2003). Intriguingly, at present, well over 300 potential physiological 
protein targets of CK2 have been identified (Meggio and Pinna, 2003). Why can CK2 
phosphorylate such a large quantity of proteins? The possible reason behind it could be 
due to the shared signature sequence amongst protein substrates (Meggio and Pinna, 2003). 
As the list of likely protein targets of CK2 continues to accumulate, it becomes 
increasingly evident that CK2 has the potential to participate in the regulation of a diverse 
selection of cellular processes such as cell proliferation or apoptosis. Along this line of 
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reasoning, CK2 could potentially phosphorylate certain ZIP and ZnT proteins apart from 
ZIP7 which has already been demonstrated (Taylor et al., 2012).    
 
Fig 1.5 Structural illustration of CK2 tetrameric holoenzyme 
A ribbon diagram representation of the crystal structure of tetrameric CK2 (ααββ) obtained 
from Protein Data Bank (PDB ID 4DGL). The catalytic α subunits flank the central 
homodimer of regulatory CK2β subunit. AMPPNP is the competitive inhibitor of ATP, 









1.6.2 Biological roles of CK2 
Studies in the past decades indicate that CK2 plays multiple roles in regulating cellular 
functions, including cell proliferation (Guerra and Issinger, 1999; Meggio and Pinna, 
2003; Kappes et al., 2004). CK2 is required for progression through both the G1/S and 
G/M transition (Zatta et al., 2009). Additional evidence for the role of CK2 in the G2/M 
transition and mitosis comes from the observation that CK2 is associated with the mitotic 
spindle and with centrosomes (Litchfield, 2003). The demonstration that CK2α and CK2β 
are phosphorylated in mitotic cells provides a further indication that CK2 is a regulatory 
participant in the life of a cell (Zatta et al., 2009). The fact that CK2 is constitutively active 
demonstrates its prominence and necessity to cell survival (Schnitzler et al., 2014). Since 
its discovery, CK2 has been implicated in the phosphorylation of DNA and RNA 
polymerase, DNA topoisomerase, the oncogene products of fas, myc and SV-40 large T 
and of the p53 tumour suppressor gene (Pinna, 1990; Meggio and Pinna, 2003). In 
addition, several reports have presented evidence linking CK2 with the regulation of the 
cell cycle and with the induction of cell growth (Allende and Allende, 1995). Interestingly, 
it has been proposed that the proteins phosphorylated by CK2 may make up one quarter of 
the eukaryotic phosphoproteome (Meggio and Pinna, 2003). Despite the many years of 
research however, several aspects of CK2 are yet to be elucidated such as regulatory 
mechanisms involving the role of CK2 in metal ion uptake and toxicity. Within this study, 
the focus will be on the role of CK2 subunits in modulating zinc homeostasis in the cancer 
cells.   
As of 1984 it has been identified that the function of CK2 is intensified in rapidly 
proliferating tissue (Guerra et al., 1999). Studies have established that CK2 expression is 
up-regulated in all cancers examined and this correlation has prompted studies on CK2’s 
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role in oncogenesis (Trembley et al., 2009). Interestingly, it has been demonstrated that 
elevated levels of CK2 in cancer tissue is an indicator of dysplasia instead of implying 
increased proliferation (Faust et al., 1999). Dysregulation of CK2 invokes unwarranted 
oncogenic capability on cells even though CK2 is not officially classed as an oncogene 
(Trembley et al., 2009). It has been discovered that over-expression of CK2α coupled with 
TAL1, a transcription factor, resulted in accelerated leukemogenesis in mice (Kelliher et 
al., 1996). CK2 over-expression has been linked to the development of lymphoma and this 
is synergistic with co-expression of the c-myc oncogene (Seldin and Leder, 1995). 
Moreover, over-expression of CK2α and loss of p53, a tumour suppressor gene, resulted 
in marked increase of lymphoma in mice (Landesman-Bollag et al., 1998). Furthermore, 
it has been discovered that CK2 can phosphorylate β-catenin and is a progressive regulator 
of the Wnt signaling pathway (Seldin et al., 2005). Interestingly, it has been revealed that 
CK2 regulates the basal NFκB through phosphorylation of IKB (Landesman-Bollag et al., 
2001).  
Regarding cancer development, changes in cellular zinc concentration are likely the result 
of alterations in the activation and/or expression of zinc transporters ZIPs and ZnTs, which 
may involve CK2. In prostate cancer, a potential mechanism for the dramatically 
diminished concentration of zinc in malignant tissue is found with the down-regulation of 
ZIP1 (Guerinot, 2000; Prasad et al., 2009; Song and Ho, 2009). Conversely, it has been 
reported that zinc accumulation experimentally induced through over-expression of ZIP4, 
leads to enhanced progression of established pancreatic cancer (Grattan and Freake, 2012). 
Similarly, ZIP6 overexpression and/or activation has been observed to be of importance 
for breast, pancreatic, cervical and prostate cancer (Guerinot, 2000; Kagara et al., 2007; 
Song and Ho, 2009; Grattan and Freake, 2012). It is unclear if CK2 is involved in the 
expression of ZIP1, ZIP4 and ZIP6.  
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1.7 Breast anatomy and breast cancer  
1.7.1 Anatomy and function of adult female breast   
Adult female breasts are made up of fatty, lymph nodes, connective and glandular tissues. 
It is comprised of approximately 15-20 lobules (glands) which are arranged in clusters 
(Fig. 1.6). Each lobule is made up of alveoli. All lobules are linked by a network of ducts 
(Stone and Wheeler, 2015). For lactation to occur, hormones such as estrogen, prolactin 
and progesterone are involved for milk production and secretion to occur (Geddes, 2007).   
 
Fig 1.6 Anatomy of female breast 
The adult female breast has lobules that branch out from the nipple. Each lobule holds tiny 




1.7.2 Breast cancers   
Breast cancers often initiate in the ducts (ductal carcinoma) or within the lobules (lobular 
carcinoma) due to uncontrolled cellular growth under various carcinogenic influences 
(Kelsey et al., 1993). Studies have classified breast cancer as the second highest in terms 
of incidence (2,088,849 cases) and the fifth highest mortality rate (626,679 deaths) 
amongst the ten most prominent cancers in humans worldwide (Bray et al., 2018). There 
are various risk factors such as genetic alteration/mutations, aging, estrogen, family history 
and unhealthy lifestyle (Grattan and Freake, 2012). Molecularly, breast cancer is a 
heterogeneous disease and through gene expression analysis, four subtypes of breast 
cancer are classified based on markers such as estrogen receptors (ERs), progesterone 
receptors (PR), human epidermal growth factor receptor 2 (HER2), including Luminal A 
(ER+/PR+/HER2-), Luminal B (ER+/PR+/HER2+), Basal (ER-/PR-/HER2-) and HER2-
enriched (ER-/PR-/HER2+) (Ambion; Ebara et al., 2000; Desoize, 2004; Grattan and 
Freake, 2012). These terms, “luminal” and “basal”, refers to the outer basal cells and inner 
luminal cells in the epithelial glandular network (lobules) of breast. These different breast 
cancer subtypes vary in incidence, aggressiveness and response to treatment. Studies have 
shown that basal breast cancer tumours express higher levels of metallothioneins, ZIP4, 
ZIP14 genes and lower levels of ZIP6, ZIP9, ZIP11 compared to luminal and HER2 
overexpression tumours (Chandler et al., 2016). However, the underlying molecular 
mechanism for such findings was not clear then and remains to be investigated.  
It is important to note that Zn2+ accumulation in breast cancer cells directly correlates with 
abnormal expression of ZIP6, ZIP7, ZIP10 and SLC30A2 (Kagara et al., 2007; Taylor et 
al., 2007; Taylor et al., 2008; Lopez et al., 2011; Taylor et al., 2012; Taylor et al., 2016). 
This implies that various types of breast cancers might have their unique signature of genes 
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for zinc homeostasis. MCF-7 luminal breast cancer cell line is less aggressive and 
categorised as non-invasive compared to the MDA-MB-231 breast cancer cell line, 
categorised as aggressive, invasive and a poorly differentiated form of triple-negative 
breast cancer (Chandler et al., 2016). Triple-negative breast cancer is a type of breast 
cancer that is negative to the hormones estrogen and progesterone along with a protein 
receptor called HER2 (Foulkes et al., 2010; Garrido-Castro et al., 2019). Clinically, triple-
negative breast cancer patients have limited treatment options with a high possibility of 
relapse (Chandler et al., 2016; Reddy et al., 2018). More research is required to understand 
the involvement of zinc homeostasis in breast cancer progression and malignancies. 
Not surprisingly, many genes are strongly linked with breast cancer development such as 
breast cancer type 1 (BRCA1) and 2 (BRCA2), human epidermal growth factor 2 (HER2), 
epidermal growth factor receptor (EGFR), Ras gene family (H-ras, K-ras and N-ras), p53, 
retinoblastoma protein 1 (RB1), phosphatase and tensin homolog (PTEN), ataxia-
telangiectasia mutated (ATM), cyclin D1 (CCND1), cadherin-1 (CDH1), nucleoside 
diphosphate kinase A (NME1), phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit alpha (PIK3CA), fragile histidine triad protein (FHIT) etc. have been linked to 
breast tumour initiation and development (Kagara et al., 2007; Prasad et al., 2009; Grattan 
and Freake, 2012; Stephens et al., 2012).  
As previously mentioned, studies have determined that zinc levels are substantially 
increased in breast cancer tissue compared with normal breast tissue (Costello and 
Franklin, 2006). A study by Rizk and Sky-Peck (1984) also showed elevated zinc levels 
in neoplastic human breast tissue compared to normal breast tissue. Studies utilising 
invasive basal-like breast cancer cell lines MDA-MB-231 and MDA-MB-435S confirmed 
higher expression of ZIP10 and increased zinc level compared to less invasive luminal-
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like breast cancer cells such as MCF-7, T47D, ZR75-1 and ZR75-30 (Costello and 
Franklin, 2006; Kagara et al., 2007; Franklin and Costello, 2009). Consistent with this 
notion, it has been discovered that increased ZIP10 and ZIP6 (LIV1) expression correlates 
with increased aggressiveness, progression and metastasis of breast cancer (Grattan and 














1.8 Prostate gland anatomy and prostate cancer  
1.8.1 Anatomy and function of the prostate gland  
The adult prostate is a walnut-sized exocrine gland of the male reproductive system which 
consists of four zones: anterior, transition/periurethral (making up 5%), peripheral 
(making up 70%) and central (making up 25%) zones (Fig. 1.7) (McNeal et al., 1988; 
Kumar and Majumder, 1995). Histologically, the prostate gland is mainly divided into 
central and peripheral zones (Kumar and Majumder, 1995). The unique metabolic and 
functional activity of the prostate is the accumulation of higher concentration of zinc and 
citrate (Kumar and Majumder, 1995; Yamasaki et al., 2007; Song and Ho, 2009). The 
prostate is responsible for the secretion of prostatic fluid (pH 6.4) comprising 20% volume 
in semen containing lipids, metal ions, amines and enzymes (e.g., fibrinolysin, coagulum 
lysing enzymes, coagulase etc.) essential for ensuring the homeostatic environment for 
spermatozoa (Kumar and Majumder, 1995; Grattan and Freake, 2012; Kambe et al., 2015).  
 
Fig 1.7 Anatomy of the male prostate 
The male prostate is a walnut-sized exocrine gland of the male reproductive system. It is 
comprised of distinct regions, transition zone, central zone and peripheral zone.   
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1.8.2 Prostate cancer   
Prostate cancer develops when cells of the prostate gland grow in an abnormal and 
uncontrolled manner (Ferlay et al., 2018). Strikingly, epidemiological studies have 
demonstrated that prostate cancer is the second highest diagnosed type of cancer after lung 
cancer among 10 commonly occurring cancers in men worldwide (Torre et al., 2015). It 
has been estimated that one in six men will be diagnosed with prostate cancer over the age 
of 85, with 63% of cases diagnosed in men over the age of 65 (Costello and Franklin, 
2006; Bray et al., 2018; Ferlay et al., 2018). Prostate carcinoma commonly arises in the 
peripheral zone whilst benign prostate hyperplasia (BPH) usually arises in central and 
transitional zones of the prostate gland (Ferlay et al., 2018). Adenocarcinoma type of 
prostate cancer accounts for approximately 80% of all cancers of the prostate, which is 
developed from the secretory epithelial cells of the peripheral zone (Song and Ho, 2009; 
Torre et al., 2015; Ferlay et al., 2018). The malignant cells commonly grow and spread to 
the bladder, bone, lymph nodes and other organs of the body via the blood-stream (Torre 
et al., 2015; Ferlay et al., 2018).         
Interestingly, studies have demonstrated that normal prostate epithelial cells are zinc 
accumulating cells and contain elevated zinc level in comparison to malignant cells of the 
prostate (Franklin et al., 2005; Costello and Franklin, 2006; Cousins et al., 2006). ZIP1 is 
down-regulated in human malignant prostate cancer cells derived from metastatic prostate 
cancer tissue (PC3, DU145 and LNCaP) (Franklin et al., 2005; Zou et al., 2011; Kambe et 
al., 2014). Similarly, it has been determined that zinc importers ZIP2, ZIP3, ZIP4 and ZIP9 
transporters are down-regulated in prostate cancer cells, while up-regulated in normal 
epithelial cells of the prostate (Rishi et al., 2003; Franklin et al., 2005; Costello and 
Franklin, 2006; Franklin and Costello, 2009; Huang and Tepaamorndech, 2013). This 
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indicates that prostate cancer cells evade the tumour suppression effects of zinc, such as 
suppression of abnormal cell proliferation and apoptosis induction in cells by maintaining 
low cellular zinc levels (Franklin et al., 2005; Costello and Franklin, 2006; Cousins et al., 















1.9 Experimental approach 
1.9.1 Utility of breast and prostate cancer cell lines 
Cell lines are a workhorse in research and play an invaluable role as in vitro models in 
cancer research. In order to identify the roles of zinc and CK2 in cancer cells, this study 
employs breast (MCF-7 and MDA-MB-231) and prostate (PC3 and DU145) cancer cell 
lines and normal breast (MCF10A) and prostate (RWPE-1) epithelial cell lines (Table 1.4). 
The two cancer types are of opposite zinc profiles as described previously, which should 
serve as an effective tool for this project.  
The MCF-7 cell line was initially isolated from a 69-year-old Caucasian woman named 
Frances Mallon who died in 1970 from a malignant luminal breast cancer. Dr. Soule and 
colleagues established the MCF-7 cell line in 1973 from the pleural effusion of Frances 
Mallon with metastatic cancer (Soule et al., 1973). In the 1970’s, a major focus was 
directed towards finding definitive proof that estrogen directly stimulated tumour growth 
(Levenson and Jordan, 1997). There was a major breakthrough in breast cancer research 
when it was discovered that certain types of breast cancer were estrogen receptor positive 
(ER+) and that the anti-estrogen drug Tamoxifen was found to inhibit the growth of MCF-
7 breast cancer cells (Soule et al., 1973; Levenson and Jordan, 1997). In relative recency, 
it was revealed that the MCF-7 breast cancer cell line was ER+, progesterone receptor 
(PR+) and belonged to the Luminal A molecular subtype of breast cancer (Baguley and 
Leung, 2011; Shirazi et al., 2011). The MCF-7 cell line is a less aggressive and non-
invasive cell line compared to the MDA-MB-231 breast cancer cell line. 
The MDA-MB-231 cell line was established from a pleural effusion of a 51-year-old 
Caucasian female with metastatic mammary basal adenocarcinoma (Cailleau et al., 1978). 
The cell line is extremely aggressive, invasive and a poorly differentiated form of triple-
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negative breast cancer, as the cell line is ERˉ, PRˉ and HER2ˉ (Liu et al., 2003; Chavez et 
al., 2010). Initially, the MDA-MB-231 cell line was classed as a form of basal breast cancer 
due to being ERˉ, PRˉ and HER2ˉ. It was later discovered to also exhibit down-regulation 
of Claudin-3 and Claudin-4, low expression of the Ki-67 proliferation, markers for 
epithelial-mesenchymal transition and expression features associated with mammary 
cancer stem cells, such as the CD44+CD24ˉ/low phenotype (Holliday and Speirs, 2011). 
Moreover, it was demonstrated to be E-cadherin negative and express mutated p53 (Liu et 
al., 2003; Chavez et al., 2010). Clinically, triple-negative breast cancer patients have 
limited treatment options with a high possibility of relapse. For this reason, many studies 
utilise the MDA-MD-231 breast cancer cell line in their research.            
The PC3 prostate cancer cell line was established in 1979 from a 62-year-old Caucasian 
male from a lumbar vertebral (bone) metastasis stage four prostate cancer (Kaighn et al., 
1979). Studies thereafter have revealed that PC3 cells do not respond to androgens, 
fibroblast growth factors or glucocorticoids, but rather are influenced by epidermal growth 
factors (Ching et al., 1993; Tai et al., 2011). It has been discovered that PC3 cells express 
low levels of testosterone-5-alpha reductase and do not express prostate-specific antigens 
(PSA) (Tai et al., 2011). Overall, PC3 cells are hormone insensitive and do not show 
androgen receptor nor expression of PSA mRNA, however, the cells show high levels of 
transforming growth factor-alpha (TGF-α) and epidermal growth factor receptor mRNA 
expression (Ching et al., 1993). Considering the expression profile and morphological 
characteristics, PC3 cells can be classified as a poorly differentiated adenocarcinoma 
(Ching et al., 1993; Tai et al., 2011). The PC3 prostate cancer cell line has been identified 
to have a higher metastatic potential compared to the DU145 prostate cancer cell line 
(Pulukuri et al., 2005).  
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The DU145 prostate cancer cell line was derived in 1975 from a 69-year-old male with a 
metastatic brain tumour (Stone et al., 1978). It has been identified that prostatic acid 
phosphatase (PAP) expression is modestly expressed in DU145 cells, but androgen 
receptor, PSA mRNA and protein expression are non-existent in DU145 cells (Sherwood 
et al., 1990). However, the cells do express cytokeratin-7 (CK-7), CK-8, CK-18 and CK-
19 (Stone et al., 1978; Sherwood et al., 1990). Studies have demonstrated that 
subcutaneous injection of DU145 cells into nude mice have produced tumours that 
maintained their phenotype and genotype (Mickey et al., 1977; Bastide et al., 2002).     
1.9.2 Utility of normal breast and prostate cell lines 
The MCF10A cell line was isolated from the mammary gland of a 36-year-old Caucasian 
woman with extensive fibrocystic disease, comprising of increased mammary fibrous 
stroma containing numerous dilated mammary ducts (Soule et al., 1990). Furthermore, 
MCF10A cells are a non-tumuorigenic mammary epithelial cell line derived from benign 
proliferative breast tissue that is widely used as in vitro model for studying normal breast 
cell function and transformation (Soule et al., 1990; Tait et al., 1990). Studies have 
determined that MCF10A cells do not express the estrogen receptor, but is responsive to 
insulin, glucocorticoids, cholera endotoxin and epidermal growth factor (EGF) (Keller et 
al., 2010). Morphologically, MCF10A cells display characteristics of luminal cells but not 
of myoepithelial cells (Neve et al., 2006).   
The RWPE-1 cell line was derived from a 54-year-old Caucasian male, with epithelial 
cells isolated from the peripheral zone of the prostate (Webber, 1979). RWPE-1 cells are 
a great model to investigate the molecular mechanisms underlying the proliferation of 
benign prostatic epithelial cells. RWPE-1 cells express androgen receptor, cytokeratin 18, 
cytokeratin 8 tumour suppressor gene p53 (Bello et al., 1997). The RWPE-1 cell line was 
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immortalised with the human papillomavirus (HPV) with subsequent isolation and 
propagation (Ambion; Webber, 1979; Webber et al., 1999). Moreover, RWPE-1 cells 
typically respond to EGF, TGF-β treatment and do not form tumours in mice (Webber, 

















Table 1.4 The cell lines utilised in this study 




The chromosome numbers of MCF-7 
breast cancer cell line range from 
hypertriploidy to hypotetraploidy 
(modal number = 82; range = 66 to 
87). 
(Rondón-Lagos 
et al., 2014). 
MDA-
MB-231 
Basal breast cancer 
The MDA-MB-231 breast cancer cell 
line has been derived from aneuploid 
female (modal number = 64, range = 
52 to 68), with chromosome counts 
in the near-triploid range. 
(Cailleau et al., 
1976) 
PC3 
Prostate cancer with 
high metastatic 
potential 
The PC3 cell line has a near-triploid 
characteristic with a modal number 
of 62 chromosomes. 




Prostate cancer with 
moderate metastatic 
potential 
The DU145 cell line has a 
hypotriploid karyotype with 62 
chromosomes. 





The MCF10A normal breast cell line 
has a diploid karyotype. 
(Soule et al., 





The RWPE-1 normal prostate cell 
line has a diploid karyotype. 
(Webber, 1979; 




1.9.3 The relevance of breast and prostate cancer cell lines to 
clinical cancers  
Cancer cell lines play a significant role in the field of cancer research. Researchers in 
multiple prestigious institutes worldwide have utilised both breast (MCF-7 and MDA-MB-
231) and prostate (PC3 and DU145) cancer cell lines in their research. For example, the 
use of breast cancer cell lines along with the use of mouse models was essential in the 
discovery of the drug Tamoxifen which has played a pivotal role in the treatment of all 
stages of oestrogen-receptor-positive breast cancer (Clemons et al., 2002; Jordan, 2003; 
Meiser et al., 2017). Millions of breast cancer patients worldwide have benefited from 
using Tamoxifen for the treatment of their breast cancer. Similarly, by employing the 
cancer cell lines, the anticancer drug, Cisplatin, was developed. It was the first FDA-
approved platinum compound for cancer treatment in 1978 (Kelland, 2007; Frezza et al., 
2010).  
Cancer cell lines and their normal counterparts are routinely used in studying the molecular 
mechanisms of cancer development (Sakallı Çetin et al., 2017; Nguyen et al., 2018; Sun 
et al., 2018; Zhu et al., 2018; Kim et al., 2020). Therefore, this study employed MCF-7 
and MDA-MB-231 breast cancer cell lines and PC3 and DU145 prostate cancer cell lines, 
as well as the MCF10A normal breast and RWPE-1 normal prostate cell lines. The findings 
to be obtained from these cell lines should contribute to our knowledge and understanding 
of zinc homeostasis in breast and prostate cancer cells and provide avenues for future 
studies on breast and prostate cancers. 
1.9.4 Inhibition of CK2 activity 
In order to unravel the role of CK2 in regulating zinc homeostasis, breast and prostate 
cancer cell lines were treated biochemically with CK2-specific inhibitors 4,5,6,7-
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tetrabromobenzotriazole (TBB) (Calbiochem-Millipore) or CX-4945 (Adooq bioscience) 
(Fig. 1.8) TBB and CX-4945 block the ATP-binding site in CK2 kinase (Duncan et al., 
2008; Cozza et al., 2009). CK2 inhibition has been the subject of intensive study (Duncan 
and Litchfield, 2008; Jacob P. T., 2013). Studies of CK2 structure have revealed the ATP 
binding domains are highly conserved between monomeric subunits and the tetrameric 
holoenzyme (Chantalat et al., 1999; Litchfield, 2003). By using CK2 inhibitors TBB and 
CX-4945 and zinc treatment, it was expected that we could determine valuable information 
about CK2’s involvement in zinc homeostasis. 
 
 




1.9.5 Manipulation of CK2 expression by siRNA  
To determine the role of specific CK2 subunits in zinc homeostasis, I utilised subunit-
specific siRNA to manipulate the expression of CK2 subunits. siRNA is a powerful tool 
for gene knockdown. In 1998, Andrew Fire, Craig Mello and colleagues discovered a way 
to turn off specific genes in the organism, Caenorhabditis elegans (Kumar. D. L, 2007). 
This was achieved via injecting double-stranded RNA interference (RNAi) in the embryos 
and was found to block the synthesis of the target proteins (Mello. C, 2004). Further studies 
confirmed that it is double-strand RNA (dsRNA) and not single-stranded RNA (ssRNA) 
that was responsible for gene silencing, however exact molecular mechanisms were yet to 
be uncovered at the time of discovery (Kumar. D. L, 2007).  
Since its discovery, siRNAs have been found to be comprised of short segments of dsRNA, 
about 21-24 nucleotides long, with phosphorylated 5’ ends and hydroxylated 3’ end 
overhangs (Mello. C, 2004). The endonuclease dicer enzyme (RNase III) has been found 
to interfere with the translation of proteins by binding to and promoting the degradation of 
messenger RNA (mRNA) at specifically desired sequences (Aagaard. L, 2007). Once dicer 
is complexed with the TAR-RNA binding protein (TRBP), it positions the siRNA to the 
RNA-induced silencing complex (RISC) which contains the slicing protein Argonaute2 
(Ago2). Ago2 cleaves the target mRNA molecule amongst bases 10-11, in accordance to 
the 5’ end of the antisense siRNA strand (Kumar. D. L, 2007). The degraded mRNA can 
no longer be translated into a functional polypeptide. Consequently, siRNAs prevent the 





Fig 1.9 siRNA mechanism of knockdown expression 
Illustration of siRNA where the Dicer enzyme cuts large double-stranded molecules or 
RNA into smaller sections of small interfering RNA, which through enzymatic actions of 
Ago2, cleaves mRNA and has a silencing effect. 
Provided that the target mRNA sequences are known, researchers can utilise siRNAs to 
silence gene expression in mammalian somatic cells as a research tool (Mello. C, 2004). 
Currently, several oncogenic and mutant tumour suppressor genes present potential targets 
for the siRNA interference approach. For instance, the p53 protein is mutated in over 50% 
of human malignancies and specific elimination of p53 mutant protein by siRNA has been 
shown to result in the restoration of wild-type function (Aagaard. L, 2007). Additionally, 
siRNA techniques have been widely implemented in studies as a method to reduce the 
expression of individual genes in order to establish a link between the gene and the gene 
function (Almedia. R, 2005; Aagaard. L, 2007). By observing the effects of blocking a 
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gene through siRNA, further insights into the role of the gene in biological pathways can 
be established.   
There are many companies such as Dharmacon (USA) and Sigma-Aldrich (Australia) 
which provide predesigned and tested siRNA for experimental application. A study by 
Yamane and Kinsella utilised three specific siRNA’s to specifically knockdown 
expression of CK2 catalytic subunits. These siRNAs were purchased from Dharmacon 
(USA) (Yamane and Kinsella, 2005). Within this project, the knockdown of CK2 subunit 
expression (CK2α, CK2α’ and CK2β) by their specific siRNA was pursued to dissect the 
role of individual CK2 subunits in zinc homeostasis.  
1.9.6 Next-generation RNA sequencing for identification of genes 
involved in zinc homeostasis     
Next-generation RNA sequencing (RNA-seq) is a high throughput technology, 
increasingly being used in transcriptomic analysis for discovering differentially expressed 
genes in varieties of biological contexts. The procedure of RNA-seq involves RNA being 
extracted from samples of interest, then conversion of pure RNA into cDNA fragments 
and finally performing sequencing which results in millions of reads mapped to the 
transcriptome (Ozsolak and Milos, 2011). Once reads are determined and analysed, one 
needs to identify the differentially expressed genes between samples e.g., controls versus 
treatments. In this study RNA-seq is employed on the MCF-7 breast cancer cell line to 
identify the key genes involved in zinc homeostasis. In doing so, we will gain valuable 
insight into how the MCF-7 breast cancer cells respond to zinc exposure.    
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1.9.7 qRT-PCR validation    
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) is a frequently 
used biological technique for quantification of nucleic acid molecules in samples (Fleige 
and Pfaffl, 2006). The technique relies on the detection of a fluorescent reporter signal that 
is generated equivalent to the amplification of the PCR product. This in turn allows the 
visualisation of the exponential part of the PCR reaction (Bustin, 2002). Accurate 
quantification of the fluorescent signal is reliant on the capacity to obtain cycle threshold 
(CT) values. When the PCR achieves the exponential amplification phase, concentration 




Fig. 2.1 Depiction of the fundamental principle of TaqMan technology 
Once double-stranded DNA melts at 95°C, the reaction is cooled to the annealing 
temperature (60°C) where the primers and probe bind to the target sequences in the cDNA 
template. Taq polymerase then catalyses the extension of the primer along the template 
strand. Upon reaching the probe, it relocates the reporter. After the reporter is no longer 
close to the quencher, it can fluoresce. During each consecutive cycle, higher levels of 
reporter are released from their vicinity to the quencher and therefore each cycle is 
characterised by an increase in fluorescence. 
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1.9.8 Confocal microscopy visualising the zinc ion    
Fluorescence confocal microscopy is widely utilised in the research of in vitro studies. In 
essence, fluorescence microscopy uses synthetic fluorophores that are specific for the 
target molecules and are able to fluoresce when bound to the target and stimulated by light 
(Patel and McGhee, 2007). The technology can provide details of subcellular location of 
the target molecules in nuclei, cytoplasm, endoplasmic reticulum or mitochondria (Brelje 
and Sorenson, 1992). The excitation of light that stimulates the fluorophores for confocal 
microscopy is usually provided by a laser that is set at a specific wavelength for excitation 
(Levoy et al., 2004). The fluorophores emission and excitation wavelength of light pass 
through the same objective but the emission of light eventually hits the light detector. A 
pinhole is utilised to eliminate scattered light which commonly occurs when conducting 
fluorescence microscopy. The result is that light is collected from a highly focused point, 
forming high resolution images of specimens (White et al., 1987).   
In this study fluorescent imaging using a confocal microscope was employed to quantify 
zinc ion uptake using a fluorophore specific for zinc. The intracellular localisation of zinc 
can be accomplished through the use of fluorophores such as Zinquin and FluoZin-3 AM 
(Colvin. R et al., 2006). The FluoZin-3 AM probe specific for Zn2+ detection was 
performed in this study to visualise intracellular zinc ions and elucidate the involvement 





1.9.9 Quantifying cellular zinc ion uptake by ICP-MS    
Inductively coupled plasma mass spectrometry (ICP-MS) is an analytical technique 
utilised to quantify elements like metal ions. It is widely used for the quantification of 
essential biological elements such as iodine, manganese, iron, copper, selenium, calcium, 
zinc etc. (Geldmacher-von Mallinckrodt and Meissner, 1994). Even though the first 
developed and functional ICP-MS machine was established close to 40-years ago, current 
ICP-MS machines are more advanced and can offer high sample through-put, precision 
and short analysis time of samples (Houk et al., 1980). Essentially, the ICP-MS analyser 
is made up of six distinct segments which include the sample introduction system, 
inductively coupled plasma (ICP), interface, ion optics, mass analyser and finally the 
sensitive detector (Montaser, 1998).  
Samples are usually dissolved in a low percentage of nitric acid and are first nebulised in 
the sample introduction system, generating a delicate aerosol that is later transported to the 
argon plasma. The high temperature of the plasma (approximately 6000 °C) atomises and 
ionises the sample, producing ions that are then separated through the interface segment 
and into a set of electrostatic lenses referred to as ion optics (Wilschefski and Baxter, 
2019). The ion optics then directs the ion beam into the quadrupole mass analyser. Then 
the mass analyser divides ions according to their mass-charge ratio (m/z) and finally, these 
ions are measured via the detector which can accurately detect ions in parts per billion 
(ppb) (Houk et al., 1980; Montaser, 1998). ICP-MS analysis will be employed in this study 
to precisely determine the intracellular zinc levels in the cell lines under control condition 
and IC50 zinc treatment. This would provide insight into the zinc levels in breast and 
prostate cancer cells. 
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1.10 Significance of this study 
From the above account, it is evident that zinc homeostasis is linked to breast and prostate 
cancers and that CK2 is related to zinc homeostasis as well as cancers. This study 
investigates the role of zinc and CK2 in breast and prostate cancer cells. The findings 
reported here should have a pronounced bearing to basic biology and cancer research. By 
utilising breast (MCF-7 and MDA-MB-231) and prostate (PC3 and DU145) cancer cell 
lines and normal breast (MCF10A) and prostate (RWPE-1) epithelial cell lines, the two 
cancer types with opposite zinc profiles, the molecular details on the roles of zinc and CK2 
in cancer cells are obtained, providing meaningful insights and understanding of these two 
major cancers. 
The novelty of this study involves the use of six well established cell lines mentioned 
above which to date have not been used side by side in any study to better understand the 
role of zinc homeostasis in breast and prostate cancer cells. Deployment of CK2 inhibitors 
TBB and CX-4945, siRNA-mediated knockdown and zinc ion specific fluorophores 
demonstrate the thoroughness of the experimental approach in this project.                
In this study, I investigated the transcriptomic response of the breast cancer cells (MCF-
7) to the exposure of extracellular zinc using the high throughput next-generation RNA 
sequencing. The dataset was collected for three time points (T0, T30 and T120) in the time 
course of zinc treatment. The comprehensive approach, in combination with the time 
course, is novel for the study of zinc homeostasis in cancer cells. The dataset acquired 
should provide in-depth molecular details in zinc homeostasis and contribute to the future 




1.11 Hypothesis  
• It is hypothesised that CK2 is involved in zinc ion homeostasis.  
• It is also hypothesised that the contrasting zinc profiles in breast and prostate cancer 
cells are useful in understanding zinc homeostasis in cancer cells.     
1.12 Aims 
1 To investigate the involvement of CK2 in zinc homeostasis in two breast (MCF-7 and 
MDA-MB-231) and two prostate (DU145 and PC3) cancer cell lines.    
2 To identify differentially expressed genes involved in zinc homeostasis in the MCF-7 
breast cancer cell line through next-generation RNA sequencing. 
3 To validate the differentially expressed genes identified in the above step using qRT-
PCR in the six cell lines, including four cancer cells (breast cancer cell lines MCF-7 
and MDA-MB-231 along with prostate cancer cell lines PC3 and DU145) and two 










2 MATERIALS AND METHODS 
2.1 General materials 
General reagents and consumables utilised in this study were sourced from Sigma-Aldrich 
(Sydney, Australia), Life Technologies (Australia), Lonza (Switzerland), Applied 
Biosystems (Australia), CHOICE Analytical (Australia), Labcon (North America) and 
Greiner Bio-One (Germany). Specific chemicals and solvents were obtained from 
commercial suppliers detailed in the methods below and they were of analytical grade or 
higher. Deionised water from a MilliQTM system (Millipore, Australia) was used in the 
preparation of buffers and stock solutions.  
2.2 Modus operandi of general experimental practice throughout this 
study 
General tissue culture practices, such as passaging cells, plating and treating cells, were 
carried out aseptically in a class II biological safety cabinet (Gelaire AS-2252.2). Tissue 
culture media and components of media (e.g., FBS, penicillin/streptomycin) were 
purchased in sterile form and maintained as such throughout experimental work. Tissue 
culture reagents, instruments, materials and necessary miscellaneous items were sterilised 
by autoclaving for 35 min at 121 °C (Tuttnauer 3150EL, Australia). Maintenance of a 
sterile working space within the class II biological safety cabinet was achieved through 45 
minutes of UV exposure and cleaning with 70% (v/v) ethanol immediately before and post 
experimental work. The non-sterile exterior of all materials that entered the sterile space 
within the cell culture cabinet was thoroughly sterilised with 70% (v/v) ethanol. 
Experimental work was always methodically planned and conducted with great attention 
to detail to prevent any cross contaminations. 
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2.3 Growth and maintenance of mammalian cell lines 
2.3.1 Maintaining and passaging conditions 
Two cell lines for breast cancer (MCF-7 and MDA-MB-231) and one normal breast cell 
line (MCF10A), as shown in Table 2.1, were used herein. MCF-7 (human breast 
adenocarcinoma, Cat. No. ATCC® CRL HTB-22™) cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Life Technologies, Australia) supplemented with 
10% (v/v) foetal bovine serum (FBS) (Life Technologies, Australia) and 1% (v/v) 
antibiotics (penicillin/streptomycin) (Life Technologies, Australia). MDA-MB-231 
(human breast adenocarcinoma, Cat. No. ATCC® CRL HTB-26™) cells were cultured in 
Leibovitz’s L-15 medium (Life Technologies, Australia) supplemented with 10% (v/v) 
FBS and 1% (v/v) antibiotics. MCF10A (human normal mammary gland epithelial cells, 
Cat. No. ATCC® CRL-10317™) were cultured in DMEM/F12 Ham’s medium (Life 
Technologies, Australia) supplemented with 5% (v/v) horse serum (Life Technologies, 
Australia), SingleQuots™ kit (Cat: CC-4136), (Lonza, North America) containing 
Epidermal Growth Factor (EGF) (20 ng/mL), Insulin (10 µg/mL) 1% (v/v) antibiotics and 
cholera toxin (100 ng/mL) (Sigma-Aldrich Sydney, Australia). 
Two cell lines for prostate cancer (PC3 and DU145) and one normal prostate cell line 
(RWPE-1), as shown in Table 2.1, were used in this study. PC3 (human prostate 
adenocarcinoma, Cat. No. ATCC® CRL-1435™) cells were cultured in RPMI 1640 (Life 
Technologies, Australia) supplemented with 10% (v/v) FBS and 1% (v/v) antibiotics. 
DU145 (human prostate carcinoma, Cat. No. ATCC® HTB-81™) cells were cultured in 
DMEM supplemented with 10% (v/v) FBS and 1% (v/v) antibiotics. RWPE-1 (human 
normal prostate epithelial cells, Cat. No. ATCC® CRL-11609™) were cultured in 
keratinocyte serum free medium (K-SFM) kit (Cat: 17005-042, Life Technologies, 
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Australia) supplemented with bovine pituitary extract (BPE) at 0.05 mg/mL, human 
recombinant epidermal growth factor (EGR) at 5 ng/mL and 1% (v/v) antibiotics. Cells 
were grown at 37 °C in 5% CO2 incubator and observed daily until 80% confluence was 
achieved. The cells were then washed with 5 mL phosphate-buffered saline (PBS) (137 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 2 mM KH2PO4 at pH 7.4), trypsinised with 
1 mL trypsin (Life Technologies, Australia), counted using a haemocytometer (LW 
Scientific) and seeded into appropriate flasks or plates for experimentation. 
Approximately 2.1 × 106 cells were seeded into a 75 cm2 tissue culture flask (Greiner Bio-
One, Germany) with 12 mL complete medium and incubated at 37 oC with 5% CO2 
(Thermo Scientific, HERA 150). The cells were examined regularly under an inverted 
microscope (Olympus CKX41) at 40x magnification to monitor the cell’s health and 
confluence. When 80% confluency was reached, the cells were passaged into new flasks. 
The cells were first washed with 5 mL PBS then trypsinised with 1 mL of trypsin solution 
as previously described and incubated at 37 oC with 5% CO2 for approximately 3 min and 
monitored every minute thereafter. Once all cells were detached, 12 mL complete medium 
was added and then cells were thoroughly re-suspended by pipetting up and down multiple 
times. Preparation of cells for experiments was accomplished by counting cells with a 








Table 2.1 List of mammalian cell lines used in this study 




















































2.3.2 Cryopreservation of mammalian cells 
Frozen stocks of the cells for individual cell lines were prepared and stored for future 
experiments in cryovials (Greiner Bio-One, Germany) in liquid nitrogen storage at -196 
oC. Cells were grown in 75 cm2 tissue culture flasks in complete medium until reaching 
80% confluency. Cells were then washed with 5 mL PBS and trypsinised with 1 mL of 
trypsin solution and incubated at 37 oC with 5% CO2 for 3 min. Once the cells were 
detached, 12 mL of complete medium was added into the tissue culture flask and the cells 
were thoroughly resuspended by pipetting. The cell suspension was then transferred into 
a sterile 50 mL falcon tube and centrifuged (Allegra X-15R) at 900 g for 5 min. The 
supernatant was removed and cells were resuspended in 3 mL of freshly prepared freezing 
medium containing 70% (v/v) un-supplemented medium, 20% (v/v) FBS and 10% (v/v) 
dimethyl sulfoxide (DMSO). One millilitre of cell suspension was aliquoted per cryovial 
and placed in a rack in an insulated (Styrofoam) container. The cells were then gradually 
brought to -196 °C by first placing the insulated container in the -80 oC freezer (Thermo 
Scientific -80C ULT) overnight, then transferred to the liquid nitrogen tank at -196 oC for 
long term storage. 
2.3.3 Thawing mammalian cells from cryopreservation  
The cryovials were removed from liquid nitrogen storage and were immediately thawed 
in a 37 oC water bath (LAB-Tech, Australia). Caution was taken to ensure that the cryovial 
was not submerged in water to prevent any possible contamination. Once thawed, vials 
were taken into a clean class II biological safety cabinet, wiped with 70% (v/v) ethanol 
and cells were immediately pipetted into a sterile 50 mL falcon tube with 10 mL of 
complete medium and centrifuged at 900 g for 5 min. The supernatant was discarded and 
the cell pellet was re-suspended in 12 mL complete medium. The cell suspension was then 
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transferred into a 75 cm2 sterile tissue culture flask and incubated at 37 oC with 5% CO2
 
until cells reached to 80% confluency. 
2.4 Experimental work using the mammalian cells 
2.4.1 MTT assay and cell enumeration 
Cells were seeded into 96-well plates (Greiner Bio-One, Germany) with 190 µL of 
complete medium containing 7,000 cells per well. The plates were then incubated at 37 °C 
and 5% CO2 for 32 h before treatment with zinc sulfate (ZnSO4). The stock solutions of 
ZnSO4 were made at 20x concentrations and filter-sterilised by passing through a 0.22 µm 
filter. The cells were treated with 0, 20, 50, 100, 150, 200, 250, 300, 350, 400 and 500 µM 
concentration of ZnSO4. After treatment, the plates were incubated for 6 h and then 50 µL 
of MTT [3-(4,5-dimethyliazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide, 5 mg/mL in 
PBS] was added per well, followed by further incubation for 2 h at 37 °C in 5% CO2 
incubator. The medium was aspirated and formazan crystals in each well were solubilised 
in 100 µL of DMSO. Plates were then mixed gently before the absorbance was measured 
at 600 nm (A600) using a spectrophotometer (Multiskan EX, Thermo Electron). The cell 
viability was quantified from the collected data and the online AAT Bioquest tool 
(https://www.aatbio.com/tools/ic50-calculator) was used to generate the half-maximal 
inhibitory concentration (IC50) values and further confirmed by plotting a graph using 
Excel. 
For cell enumeration, the cells were grown, prepared and treated in the same way as 
described previously. Following the 6 h incubation of ZnSO4 treatments, the medium from 
each 96-well plate was aspirated and wells were washed with 200 µL of PBS, trypsinised 
with 15 µL of trypsin and then incubated for 3 min at 37 °C in 5% CO2 incubator. Then 
185 µL of medium was pipetted into each well, cells were carefully re-suspended and 
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transferred to microfuge tubes. An equal volume of 0.4% (v/v) trypan blue dye (Life 
Technologies, Australia) was added to each tube and thoroughly mixed by pipetting prior 
to cell counting with a haemocytometer under a light microscope. Both live and dead cells 
were counted to calculate the percentage of viable cells. Cell viability was plotted using 
the Bioquest website for IC50 determination and further validated through plotting a graph 
in Excel. 
2.4.2 Inhibition of CK2 activity and zinc treatment 
Multiple 96-well plates were prepared by seeding 7,000 cells per well with 190 µL of 
complete medium and incubated for 32 h. Prior to the addition of ZnSO4, the cells were 
treated with CK2 inhibitors TBB (4,5,6,7-tetrabromo-1H-benzotriazole) (Calbiochem-
Millipore) or CX-4945 (Sigma-Aldrich, Australia) resuspended in DMSO. A final 
concentration of 20 µM TBB and 5 µM CX-4945 were used for CK2 inhibition. The 
dosage was chosen for these two inhibitors due to the lack of toxicity to the cells based on 
a titration I preformed and further supported by the literature (Cozza et al., 2009; Zwicker, 
Ebert, Huber, Debus, & Weber, 2011). After the addition of TBB or CX-4945, the cells 
were incubated at 37 °C with 5% CO2 for 3 h. This was followed by 6 h incubation with 
ZnSO4 at various IC50 concentration (MCF-7 320 µM, MDA-MB-231 350 µM, MCF10A 
195.5 µM, PC3 110 µM, DU145 150 µM and RWPE-1 187 µM). At the end of the 
incubation, the plates were observed under an inverted microscope and the cell viability 




2.4.3 Knockdown of CK2 gene expression by siRNA 
SMARTpool siRNA targeting each gene of CK2 subunits [CSNK2A1 (CK2α), CSNK2A2 
(CK2α’) and CSNK2B (CK2β)] were purchased from Dharmacon, USA (Table 2.2). The 
optimum concentration of each siRNA for the CK2 subunit gene knockdown study was 
determined by optimisation experiments in our laboratory (Zaman et al., 2019), in 
conjunction with the manufacturer’s instructions (Dharmacon, USA) and the literature 
(Cannon et al., 2017). The efficiency of the knockdown was measured by qRT-PCR in 
Chapter 3. Each siRNA sequence is comprised of four targeting nucleotides for each 
gene of CK2 subunits. The targeting sequences for CSNK2A1 encoding CK2α are 
UGAAUUAGAUCCACGUUUC, GCAAUUGUACCAGACGUUA, 
CAGAAAGCUUCGGCUAAUA, AGACUAUGACAUUCGAUUU. The targeting 
sequences for CSNK2A2 encoding CK2α’ are GCAAGUAUAGUGAAGUAUU, 
CAACAGAGAUUGACCGCCA, GGUGGAACAAAUAUCAUUA, 
GAACUAUAUGGUUAUCUGA. The targeting sequences for CSNK2B encoding CK2β 
are CAGCUGAGAUGCUUUAUGG, CCAAGUGCAUGGACGUGUA, 
GGUAAUGAAUUCUUCUGUG, GCAGGGAGACUUUGGCUAC. Each siRNA stock  
(10 µM) was prepared in siRNA buffer (pH 7.3) containing 300 mM potassium chloride, 
31 mM HEPES and 2.1 mM magnesium chloride. For each siRNA transfection, two 
microfuge tubes were prepared, with tube 1 containing 20 µL of 10 µM siRNA and 480 
µL OPTI-MEM (Life Technologies, Australia) and tube 2 containing 20 µL 
lipofectamine 2000 (Invitrogen, Australia) transfection reagent and 480 µL OPTI-MEM. 
After 5 min incubation at room temperature, the contents of tube 1 was pipetted into tube 
2 for each siRNA and left at room temperature for 20 min. A mock tube with no siRNA 
containing 980 µL OPTI-MEM with 20 µL lipofectamine was also prepared as a control.  
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When cells reached 80% confluence, cells were washed with sterile PBS at room 
temperature, trypsinised (1 mL) and 5 mL of fresh complete medium was added. The cells 
were counted and 2 × 106 cells in 5 mL were prepared into each tube designated as tube 1 
CK2α siRNA, tube 2 CK2α’ siRNA, tube 3 CK2β siRNA, tube 4 mock control and tube 5 
untreated control, respectively. After the incubation, the cells were centrifuged at 900 g 
for 5 min. The supernatant was removed, cells were then washed with 5 mL PBS and 
centrifuged again with the supernatant discarded. Each cell pellet was resuspended in 1 
mL of each siRNA mixture which was resuspended and allowed to incubate at room 
temperature for 20 min. Afterwards, 9 mL of OPTI-MEM was added, the cells were 
thoroughly mixed and aliquoted 100 µL per well into 96-well plates. The plates were 
incubated for 72 h at 37 oC with 5% CO2. To measure IC50 of ZnSO4, 5 µL per well were 
used to treat the transfected cells in the plates and incubated at 37 oC with 5% CO2 for 6 










Table 2.2 siRNA targets and sequences for human CK2 subunits 























2.4.4 Purification of RNA for quantitative reverse transcription-
polymerase chain reaction (qRT-PCR) 
Cells were grown in 75 cm2 flasks for 32 h and then medium was aspirated and replaced 
with 11.9 mL of fresh complete medium. ZnSO4 at 120x stock concentration was prepared 
and filter-sterilised through a 0.22 µm filter. Each flask was treated with 100 µL of the 
predetermined IC50 dose of ZnSO4, or 100 µL of H2O to serve as a control. Flasks were 
incubated at 37 °C with 5% CO2 for three time points, i.e., T0, T30 and T120 min respectively 
for each treatment. After the incubation, the medium was discarded, cells were washed 
with 5 mL PBS and 1 mL of TRIzolTM reagent (Thermofisher, Australia) added directly 
into the flasks. After gently mixing several times, the lysates were homogenised and 
transferred to 2 mL microfuge tubes. The resultant lysates were incubated for 5 min at 
room temperature to allow complete dissociation of the nucleoprotein complex. Then, 200 
µL of chloroform (Sigma-Aldrich, Australia) was added, followed by a further 3 min 
incubation at room temperature. Samples were then centrifuged for 15 min at 12,000 g, 4 
°C for 15 min to separate into three phases.  
The RNA containing upper phase was transferred into a new tube and precipitated by 
adding 0.5 mL of isopropanol (Sigma-Aldrich, Australia). After 10 min incubation the 
sample was centrifuged for 10 min at 12,000 g, 4 oC. The supernatant was then discarded 
and the RNA pellet was washed in 1 mL 75% (v/v) ethanol (Sigma-Aldrich, Australia) by 
vortexing for 5 sec then centrifugation for 5 min at 7,500 g, 4 oC. The resultant pellet was 
allowed to air dry for about 20 min, then the RNA pellets were dissolved in 30 µL of 
diethylpyrocarbonate (DEPC) treated water (Sigma-Aldrich, Australia) and the RNA 
concentration was determined by measuring the UV absorbance (A260/A280) by Nanodrop 
spectrometer (Thermo Fisher Scientific, Australia).   
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2.4.5 cDNA synthesis by reverse transcriptase  
cDNA was synthesised using high-capacity cDNA reverse transcription kits (Thermo 
Fisher Scientific, Australia) according to the manufacturer’s instructions. First, in a clean 
PCR tube 10 µL of master mix was prepared with 2 µL 10x reverse transcription buffer, 
0.8 µL 25x dNTP mix, 2 µL 10x reverse transcription random primers, 1 µL Multiscribe™ 
reverse transcriptase and 4.2 µL DEPC-treated water. Then, 10 µL of master mix was 
combined with 10 µL of 100 ng/µL total RNA from a given sample prepared in Section 
2.4.4. The reaction tube was mixed and then run on a Veriti 96-well thermal cycler 
(Applied Biosystems) with the following setting: step 1 at 25 °C for 10 min, step 2 at 37 
°C for 120 min, step 3 at 85 °C for 5 sec. cDNA synthesis was quantified by measuring 
the UV absorbance (A260, A280, A260/A280). 
2.4.6 Real time quantitative reverse transcriptase polymerase 
chain reaction (qRT-PCR) 
qRT-PCR was carried out using TaqMan real-time PCR reagents (Thermo Fisher 
Scientific, Australia) according to the manufacturer’s instructions. Each 20 µL reaction 
mix contained 1 µL 20x TaqMan assay which includes specific primer/probe combination 
for a given gene, 10 µL master mix, 1 µL of cDNA synthesised previously for a given 
sample (500 ng/µL) prepared in Section 2.4.5 and 8 µL DEPC-treated water (9 µL for the 
no cDNA template control). Each cDNA of individual time points in the time course was 
run in triplicate. The reaction mix was heated at 95 °C for 10 min, then followed with each 
cycle at 95 °C for 15 sec and 60 °C for 1 min, for 40 cycles in total (Table 2.3). The relative 
expression of the differentially expressed genes of interest was quantified against the house 




The qRT-PCR data were analysed by the 2-ΔΔCT method (Schmittgen and Livak, 2008). 
ΔCTc is calculated first, where the cycle threshold for the gene of interest in control 
condition was subtracted by the cycle threshold of the house-keeping gene GAPDH in 
control condition. ΔCTe is then calculated where the cycle threshold of the gene of interest 
under each treatment was subtracted by the cycle threshold of GAPDH under each 
experimental treatment. Finally, ΔΔCT is calculated by subtracting ΔCTc from ΔCTe. 2-
ΔΔCT represents fold change of the gene expression relative to GAPDH.   
Table 2.3 Run parameters for the qRT-PCR thermal cycler 
Stage Temp (°C) Time (mm:ss) 
Hold 50 2:00 











2.4.7 Comparison of gene expression in cancerous against normal 
cells via qRT-PCR 
The differentially expressed genes discovered by RNA-seq was compared against their 
expression in cancer and normal cells, calculated according to the Schmittgen and Livak 
report (Schmittgen and Livak, 2008). Firstly, the CT values of GAPDH was subtracted 
from the CT value of each gene of interest in cancer and normal cells to get ΔCT for each 
gene separately. Then, 2-ΔCT values of each gene of interest were generated to achieve the 
mean ± SD of 2-ΔCT. The mean of 2-ΔCT of each gene of interest in cancer cells was divided 
by the mean of 2-ΔCT of the same gene in normal cells to achieve fold change comparison 
of gene expression in cancerous against normal cells.  
2.4.8 Next-generation RNA sequencing 
MCF-7 cells were grown in 25 cm2 flasks for 32 h at 80% confluency, then the medium 
was aspirated and replaced with 5.9 mL of fresh complete medium. ZnSO4 at 60x stock 
concentration was prepared and filter-sterilised through a 0.22 µm filter. Each flask was 
treated with either 100 µL of the predetermined IC50 dose of ZnSO4 (320 µM), or 100 µL 
of H2O to serve as control (Zaman et al., 2019). Flasks were incubated at 37 °C with 5% 
CO2 for T0, T30 or T120 min respectively for each treatment. Immediately after incubation, 
medium was discarded, RNA was extracted as mentioned earlier and then RNA samples 
were prepared with DEPC-treated water to 100 ng/µL and sent to the Ramaciotti Centre 
for Genomics (University of New South Wales, Australia) for next-generation RNA 
sequencing.  
At the University of New South Wales (UNSW), Ramaciotti Centre for Genomics, the 
quality of the RNA samples was further checked with the Tapestation (Agilent) for 
integrity and the Nanodrop for quantification and purity. Samples were then prepared 
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using the TruSeq Stranded mRNA-seq kit (Illumina) using 1 µg of total RNA as input. 
The number of PCR cycles was reduced from 15 to 12, to minimise PCR duplicates in the 
data. The generated libraries had a median insert size of 180bp (range 100-370bp) and 
were pooled in equal amounts for the sequencing run. Once sequencing run with NextSeq 
500 was performed using a NextSeq 500/550 High Output v2 kit and sequenced to produce 
75bp single reads. Fastq files were generated in Basespace using bcltofastq 2.18. The run 
generated over 450M reads (40-50M per sample) and quality specification Q30 was 93%.     
2.4.9 Quantification of gene expression levels and differential 
expression analysis in MCF-7 breast cancer cells 
Bioinformatic analysis to identify differentially expressed genes was performed at the 
systems biology Initiative (UNSW). The RNA reads were mapped to the Ensembl Home 
sapiens genome (GRCh38). The mapping was performed with Tophat2 (v 2.0.12) (Kim et 
al., 2013) and calling Bowtie2 (v 2.2.3) (Langmead and Salzberg, 2012). The 
featureCounts of Subread (v 1.4.6-p5) (Liao et al., 2014) was used to generate counts of 
reads uniquely mapped to annotated genes using the GRCh38 gtf file. Differential 
expression analysis was performed using the Bioconductor packages edgeR (v 3.18.1) 
(Robinson et al., 2010). Generalised linear models were used for differential expression 
analysis. In all cases, differentially expressed genes were defined as those genes with a 
Benjamini-Hochberg corrected p-value less than 0.05 (Benjamini and Hochberg, 1995). 
The fold change (FC) is expressed in Log2FC. The genes with over 0.6 of Log2FC are 
identified as the up-regulated genes, whilst the genes with lower than -0.6 of Log2FC as 
the down-regulated genes. The advantage to use Log2FC here rather than arithmetic fold 




2.4.10 Imaging of intracellular zinc ion by confocal microscopy 
During confocal imaging, all glass-bottom culture dishes (MatTek, USA) were treated 
with 20 µL of gelatin (Sigma-Aldrich, Australia) and allowed to dry for 2 h in a class II 
biological safety cabinet. Cells in complete medium with 25 mM HEPES buffer were 
seeded at 40, 000 cells per mL into each imaging dish at a final volume of 1 mL. Cells 
were incubated at 37 oC with 5% CO2 for 32 h. CK2 inhibitor TBB at 20 µM or CX4945 
at 5 µM final concentration was added into all except the control dishes and allowed to 
incubate for 3 h. The metal treatment, using IC50 for ZnSO₄ were then added. After 1 h of 
exposure to the metal ion treatment, medium was removed and 1 mL fresh live cell 
imaging medium (Life Technologies) containing 140 mM NaCl, 2.5 mM KCl, 1.8 mM 
CaCl2, 1 mM MgCl2 in 20 mM HEPES buffer pH 7.4 was added. Then 100 µg of FluoZin-
3 AM zinc probe (Life Technologies) was dissolved in 200 µL of DMSO and 2 µL of 50% 
(v/v) pluronic acid F127 (Life Technologies). The probe stocks were sonicated for 5 min 
and then 15 µL of FluoZin-3 AM stocks were applied to the imaging dishes. The confocal 
imaging dishes were further incubated at 37 °C with 5% CO2 for 1 h. The medium was 
then replaced with 1 mL of fresh imaging medium and allowed to incubate at 37 °C with 
5% CO2 for 30 min before imaging was performed. Images were acquired using an LSM-
5 Confocal Microscope system (Carl Zeiss Pty Ltd, North Ryde, Australia), with excitation 
at 488 nm and emission at 510-530 nm. Gain settings for fluorescence imaging were 
maintained constant to allow for quantification of intracellular fluorescence intensity 
through Image-J software. 
Confocal imaging was also conducted for CK2 subunit knockdown using CK2α, CK2α’ 
and CK2β siRNA. siRNA transfected cells were prepared as previously described and 
seeded into imaging dishes at a final volume of 1 mL. Cells were incubated at 37 oC with 
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5% CO2 for 32 h followed by a 1 h metal treatment of ZnSO₄ at IC50. The medium was 
then removed, 1 mL of fresh imaging medium was added and FluoZin-3 AM was loaded 
into their respective dishes as described above.  
2.4.11 Quantification of zinc ion content in mammalian cells by 
inductively coupled plasma-mass spectrometry (ICP-MS) 
Cells were cultured in 25 cm2 flasks at 37 °C with 5% CO2 until 80% confluence. 
Aspiration of spent medium was conducted and 5.9 mL of complete medium was added. 
Post zinc treatments, flasks designated with CK2 inhibition were treated with 50 µL of 
TBB at a final concentration of 20 µM for a period of 3 h. For zinc treatments alone, 100 
µL of 60x IC50 ZnSO₄ concentration was added, while 50 µL of 120x IC50 ZnSO₄ 
concentration for cells pre-treated with TBB. Control flasks were treated with H2O. Three 
biological treatments were performed in the time course at the following time points: T0, 
T30, T120 h. Upon completion of treatments, medium was aspirated and cells were washed 
with 5 mL of PBS. Then 0.5 mL of trypsin was added, flasks were incubated for 3 min at 
37 °C with 5% CO2. Following trypsinisation, cells were resuspended in 3 mL of complete 
medium and counted using a haemocytometer. Once cell numbers were counted, the cells 
were centrifuged at 900 g for 5 min and medium was decanted. The cell pellet was washed 
once with 5 mL of 2 µM EDTA solution prepared in PBS by centrifugation at 900 g for 5 
min and washed once in 1 mL of PBS in 1.5 mL microfuge tubes by centrifugation at 12, 
000 g for 5 min. The supernatant was decanted and the cells were lyophilised using a 
SpeedVac Concentrator for 3-6 h.  
Following lyophilisation, the cell pellets were acid-digested. Dried pellets were firstly 
suspended in 1 mL of 70% (v/v) ultra-pure nitric acid (CHOICE Analytical, Australia). 
The resultant suspensions were transferred to acid-washed glass tubes and placed in a 
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heating block (Perkin Elmer) at 120 ᵒC for approximately 4 h. Acid alone and water alone 
controls were also included in each round of acid digestion, serving to identify residual 
metal contamination in glass tubes, if any. The acid digested samples were then re-
suspended in 5 mL of 2% (v/v) ultra-pure nitric acid and analysed using a NexION 300X 
ICP-MS (Perkin Elmer). 
2.4.12 Data analysis 
Where statistical analysis was conducted, means were compared to identify significant 
differences using SPSS statistical software and Excel. When means of two different groups 
needed to be compared, a student t-test was performed; while comparing multiple groups, 












3 PROTEIN KINASE CK2 IS INVOLVED IN ZINC 
HOMEOSTASIS IN BREAST AND PROSTATE CANCER 
CELLS 
3.1 Introduction 
As explained in Chapter 1.6, the ubiquitous and pleiotropic serine/threonine kinase CK2 
plays roles in cell proliferation, differentiation and apoptosis, therefore it is implicated in 
diseases such as cancers (Guerra et al., 1999; Guerra and Issinger, 1999; Litchfield, 2003). 
CK2 has been regarded as the most pleiotropic kinase in eukaryotic organisms due to its 
numerous substrates which possibly make up one quarter of the eukaryotic 
phosphoproteome (Pinna, 1993; Meggio et al., 1994; Litchfield, 2003; Meggio and Pinna, 
2003). Despite such enormous progress in the characterisation of CK2, many aspects of 
its function remain yet to be fully elucidated such as its role in regulating zinc homeostasis 
in cancer cells. 
Previous studies utilising the model organism S. cerevisiae, discovered that the CK2α 
subunit is involved in Zn2+ sequestration (Johnson et al., 2017). I further demonstrated that 
CK2 plays a role in Zn2+ uptake and toxicity in neuronal cells (Zaman et al., 2016). Taylor 
et al. (2003) showed CK2 phosphorylates the zinc channel ZIP7 located in the membrane 
of endoplasmic reticulum, allowing Zn2+ to be released into the cytoplasm. The work in 
this chapter aims to investigate the role of CK2 in zinc homeostasis in breast and prostate 
cancer cells. My experimental approach is to target CK2 with its specific inhibitors at the 
protein level and its specific siRNA at the gene level in breast cancer cell lines (MCF-7 
and MDA-MB-231) and prostate cancer cell lines (PC3 and DU145). The effects of such 
CK2 manipulation in combination of zinc exposure are then observed by MTT cell 
viability assay and confocal microscopy for intracellular zinc level quantification. As 
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mentioned in Section 2.4.2, the chosen concentration of TBB in this study is 20 µM, which 
had little effect on the cell viability of breast cancer cell lines (MCF-7 and MDA-MB-231) 
and the prostate cancer cell lines (PC3 and DU145). The findings reported below provide 


















3.2.1 IC50 of ZnSO4 in the cancer cell lines 
In order to measure the effect of zinc on the cancer cells, its IC50 for each cancer cell line 
was firstly determined by MTT assay. As shown in Fig. 3.1, the overall patterns for the 
breast cancer cell lines (MCF-7 and MDA-MB-231) and prostate cancer cell lines (PC3 
and DU145) in response to the zinc exposure are divergent. The IC50 values of ZnSO4 for 
MCF-7 (320 µM) and MDA-MB-231 (350 µM) are much higher than that of PC3 (110 
µM) and DU145 (150 µM) (Fig. 3.1A). These IC50 values are used in the following 
experiments. For each cell line the IC50 of ZnSO4 was also determined via cell counting, 
which confirms the trend observed by MTT assay as shown in Fig. 3.1B. 
 
Fig 3.1 Determination of IC50 of ZnSO4 by MTT assay 
MTT cell viability assay is represented by (A) and cell viability determined by cell 
counting (B). IC50 of ZnSO4 at 6 h for all four cancer cell lines was determined by MTT 
assay. IC50 for MCF-7 cells (green) is 320 µM, MDA-MB-231 cells (blue) 350 µM, PC3 
cells (red) 110 µM and DU145 cells (purple) 150 µM. The trend observed by MTT assay 
(A) was confirmed by cell counting using trypan blue (B). Error bars denotes standard 




3.2.2 Effect of CK2 inhibitors on Zn2+ homeostasis under exposure 
of IC50 ZnSO4 
To uncover the role of protein kinase CK2 in regulating zinc homeostasis, the specific 
inhibitors TBB and CX-4945 were used. As shown in Fig. 3.2, CK2 inhibitor alone with 
TBB (20 µM) or CX-4945 (5 µM) had little effect on the cancer cell viability. The dosage 
was chosen for these two inhibitors due to their benign effect on the cells according to the 
titration in this study and the literature (Cozza et al., 2009; Zwicker et al., 2011; Zaman et 
al., 2019). The inhibitor plus IC50 of ZnSO4 reduced the viability of both breast (MCF-7, 
MDA-MB-231) and prostate (PC3, DU145) cancer cells (P<0.001) and prostate cancer 
cells exhibited higher sensitivity to the treatment of CK2 inhibitor plus zinc exposure. 
In this study, prostate cancer cells were found to be more sensitive to zinc exposure, 
compared to the breast cancer cells, following the inhibition of CK2 activity by TBB (20 
µM) and CX-4945 (5 µM) coupled with IC50 zinc sulfate treatment (Fig. 3.2). This finding 
correlates well with the zinc sulfate IC50 values obtained by MTT cell viability assay. The 
IC50 values of zinc sulfate for PC3 (110 μM) and DU145 (150 μM) prostate cancer cells 
are much lower than the breast cancer cells MCF-7 (320 μM) and MDA-MB-231 (350 
μM). The molecular mechanism for the higher sensitivity of prostate cancer cells is not 
clear. How CK2 regulates zinc transport proteins at either the gene or protein level remains 
to be further investigated. This is one reason as to why RNA-seq transcriptomic analysis 




Fig 3.2 Effect of CK2 inhibitors on cancer cell viability under exposure of IC50 ZnSO4 
Cells were treated with 20 µM TBB or 5 µM CX-4945 inhibitor for 3 h and then incubated 
for 6 h with the IC50 of ZnSO4. The cell viability was determined by MTT assay. Error 
bars denotes standard deviation of three biological replicates for each treatment and each 
biological replicate has three technical replicates. P-values were calculated by one-way 











3.2.3 Efficacy of CK2 gene expression knockdown by siRNA 
Relative expression of CK2 subunit genes (CSNK2A1, CSNK2A2 and CSNK2B) was 
determined with reference to the expression of housekeeping gene GAPDH. Fold change 
1 means no change of the gene expression. Fold change >1 means increase of the gene 
expression whilst fold change <1 means decrease of the gene expression. Fig. 3.3 shows 
the percentage knockdown of CSNK2A1 (encoding CK2α) is 80.7% for MCF-7, 59.4% for 
MDA-MB-231, 58.7% for PC3 and 65.7% for DU145 cells. The percentage knockdown 
of CSNK2A2 (CK2α’) is 70.5% for MCF-7, 67.1% for MDA-MB-231, 72.5% for PC3 and 
61.4% for DU145 cells. The percentage knockdown of CSNK2B (CK2β) is 78.2% for 
MCF-7, 75.2% for MDA-MB-231, 76.4% for PC3 and 76% for DU145. In all the four cell 
lines, knockdown of one CK2 gene does not affect the other two, except in MCF-7 cells 
where knockdown CK2β leads to reduction in expression of CK2α and α’ and knockdown 
α’ leads to reduction in expression of β, as well as in DU145, knockdown of α’ caused 
reduction in expression of α.  
The possible explanation for the reduction of CK2α and CK2α' gene expression in MCF-
7 breast cancer cells following knockdown of CK2β subunit may be due to the 
stoichiometry of CK2 holoenzyme. As is known, CK2 holoenzyme is a tetramer 
comprising two catalytic subunits and a CK2β dimer. The knockdown of CK2β subunit 
would disrupt the stoichiometry, less amount of CK2β might lead to lower requirement of 
CK2α and CK2α'. This notion could be supported by the finding by (Franchin et al., 2018), 




Similarly, the possible explanation for the reduction of CK2α gene expression in DU145 
prostate cancer cells following knockdown of CK2α’ subunit might also relate to the 
stoichiometry of CK2 holoenzyme.  
 
Fig 3.3 Efficacy of CK2 gene expression knockdown by the specific siRNA 
Cells were transfected with CK2 subunit specific siRNA and incubated for 36 h. Total 
RNA was then prepared, cDNA synthesised and qRT-PCR performed. Relative expression 
of the subunit genes was quantified relative to GAPDH. * P<0.05, ** P<0.01 and *** 
P<0.001. Data represents the average of three biological replicates and each biological 
replicate has two technical replicates. Error bars represent SEM. CSNK2A1 is denoted as 





3.2.4 Effect of CK2 siRNA knockdown on cell viability under zinc 
exposure 
The knockdown of individual CK2 subunit genes revealed their distinct involvements in 
regulating zinc homeostasis reflected by the cancer cell viability (Fig. 3.4). Compared to 
mock transfection plus ZnSO4 IC50, knockdown of CK2α increased cell viability of MDA-
MB-231 cells (P<0.01) but decreased cell viability in MCF-7, PC3 and DU145 cells 
(P<0.001). Knockdown of CK2α’ increased cell viability of MCF-7 and MDA-MB-231 
cells (P<0.001) but decreased cell viability in PC3 and DU145 cells (P<0.001). 
Knockdown of CK2β decreased cell viability of MCF-7 and MDA-MB-231 cells 
(P<0.001) but increased cell viability in PC3 (P<0.01) and DU145 cells (P<0.001). Across 
all three knockdowns, the two prostate cancer cell lines showed consistent effects, the 
same is also true for the two breast cancer cell lines except the knockdown of CK2α. The 
discrepancy of the effect of CK2α knockdown is likely due to the lower knockdown 
efficacy in MDA-MB-231. It is possible that the effects of knockdown of CK2 subunits as 
observed in Fig. 3.4 are due to the involvement of different CK2 tetrameric isoforms with 
different combinations of catalytic subunits with the regulatory subunit such as ααββ, 





Fig 3.4 Effect of CK2 siRNA knockdown on cell viability under zinc exposure 
Transfection of siRNA was carried out in MCF-7, MDA-MB-231, PC3 and DU145 cells, 
followed by treatment of ZnSO4 IC50 and an MTT assay. Mock transfection as well as 
mock plus ZnSO4 IC50 served as two controls. P-values were calculated by one-way 
ANOVA. ** denotes P<0.01 and *** P<0.001. Error bars denote standard deviation of 









3.2.5 Visualisation of intracellular Zn2+ in ZnSO4 treated cells 
under CK2 inhibition and siRNA knockdown 
Apart from performing MTT assays, the effects of CK2 inhibitors and siRNA knockdown 
in MCF-7, MDA-MB-231, PC3 and DU145 cells were further studied by confocal imaging 
with the specific fluorophore (FluoZin-3 AM) for zinc visualisation and quantification 
(Fig. 3.5 and 3.6). Fig. 3.5 shows that zinc levels in all four cell lines were significantly 
increased by the inhibition of CK2 inhibitors TBB or CX-4945 in combination with IC50 
zinc exposure compared to zinc IC50 treatment alone (P<0.001). The cells with inhibitor 
alone (Control panel) and the cells with ZnSO4 only (ZnSO4 panel) serve as controls. 
Notably, the zinc level in the controls of breast cancer cells is higher than the counterparts 
of prostate cancer cells, demonstrating the intrinsic characteristics of these two types of 
cancer cells. 
Visualisation of zinc levels by confocal imaging in the cells transfected with CK2 specific 
siRNA reveals the distinct involvements between each CK2 subunit and intracellular zinc 
level (Fig. 3.6). Under ZnSO4 IC50 treatment, knockdown of CK2β is detrimental to both 
breast cancer cell lines (P<0.001) but is beneficial to both prostate cancer cells (P<0.001), 
particularly PC3 cells. CK2α’ knockdown reduced the zinc level significantly in MCF-7 
and MDA-MB-231 cells (P<0.001), whereas no apparent effect was displayed by PC3 and 
DU145 cells. Knockdown of CK2α increased the zinc level in PC3 and DU145 cell lines 
(P<0.001), while such effect was not apparent for MCF-7 and MDA-MB-231 cells. 
Furthermore, the control images revealed that zinc ions are most likely localised 
surrounding the nuclei. Such a pattern was also obvious in the cells with CK2α’ 
knockdown, particularly in MCF-7 and MDA-MB-231 cells. 
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CK2α’ knockdown coupled with ZnSO4 IC50 treatment in MCF-7 and MDA-MB-231 
breast cancer cells results in increased cell survival, while the opposite effect was 
displayed in PC3 and DU145 prostate cancer cells (Fig. 3.4). The possible explanation for 
such a finding could be traced back to the intrinsic difference of these two types of cancer 
cells, that is, the cytoplasmic zinc level is much higher in breast cancer cells compared to 
the normal breast epithelial cells, whilst the cytoplasmic zinc level in prostate cancer cells 
is much lower than the normal prostate epithelial cells. The gene expression and regulation 
for zinc homeostasis in breast and prostate cancer cells must be different. More light could 




Fig 3.5 Visualisation of Zn2+ in ZnSO4 treated cells under CK2 inhibition 
Cells were grown in confocal imaging dishes for 32 h then treated with either TBB (20 
µM) or CX-4945 (5 µM) for 3 h followed by ZnSO4 IC50 treatment and incubation with 
the fluorescent probe FluoZin-3 AM. The confocal images (A) were taken at 40x 
magnification. The control panel represents the cells treated with the CK2 inhibitor alone 
(either TBB or CX-4945). Fluorescent intensity (B) was quantified for each treatment with 
confocal images at 40x magnification where blue indicates MCF-7 cells, orange MDA-
MB-231 cells, grey PC3 cells and yellow DU145 cells. Error bars denote standard 




Fig 3.6 Visualisation of Zn2+ under siRNA knockdown of CK2 subunit genes 
Cells were treated with each specific siRNA in confocal imaging dishes for 36 h prior to 
ZnSO4 IC50 treatment and confocal imaging with fluorescent probe FluoZin-3 AM (A). 
Fluorescent intensity (B) was quantified for each treatment with confocal images at 40x 
magnification where blue indicates MCF-7 cells, orange MDA-MB-231 cells, grey PC3 
cells and yellow DU145 cells. Error bars denote standard deviation of fluorescence 




Zinc hyper-accumulates in breast cancer cells compared to normal mammary epithelial 
cells (Lopez et al., 2011; Chandler et al., 2016), while prostate cancer cells have much 
lower zinc content than normal prostate cells (Franklin et al., 2005; Song and Ho, 2009). 
Such phenomenon is poorly understood at a molecular level. By using breast and prostate 
cancer cells and manipulating protein kinase CK2 at protein and gene levels, this study 
acquired substantial evidence for the involvement of CK2 in zinc homeostasis of breast 
and prostate cancer cells. 
From the response curves of breast and prostate cancer cells against zinc titration (Fig. 
3.1A), a conspicuous divergence between the two types of cancer cells demonstrates that 
breast cancer cells are more capable of coping with acute zinc exposure than prostate 
cancer cells. No cytotoxicity is evident up to approximately 150 µM ZnSO4 for breast 
cancer cells, whilst prostate cancer cells show little tolerance to 20 µM ZnSO4. This is 
further confirmed by trypan blue staining and cell counting (Fig. 3.1B). Together with the 
control images in Fig. 3.5 and 3.6, the data supports the known phenomenon, that is, breast 
cancer cells have a higher zinc content than prostate cancer cells (Costello and Franklin, 
2006; Alam and Kelleher, 2012). Further experiments done and their findings reported 
here provide some insights into this phenomenon in terms of the involvement of CK2. 
The cancer cell’s response to zinc exposure is underpinned by the regulation of uptake, 
sequestration and efflux of Zn2+. As described at the outset, there are numerous membrane-
bound transport proteins for Zn2+, including 10 ZnT involved in decreasing cytoplasmic 
zinc level and 14 ZIP for increasing cytoplasmic zinc (Margalioth et al., 1983; Nelson, 
1999; Yamasaki et al., 2007). These transporters are either present in the plasma membrane 
or in the membranes of subcellular organelles such as the endoplasmic reticulum (Cousins 
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et al., 2006; Yamasaki et al., 2007). Their regulation by other molecules such as CK2 
(Guerra et al., 1999; Sekler et al., 2007; Taylor et al., 2008; Zaman et al., 2016) and metal 
regulatory transcription factor (Suhy et al., 1999; Lopez et al., 2011) is critical to maintain 
the homeostasis of cytoplasmic zinc, which is estimated to be at picomolar levels in 
eukarya (Outten and O'halloran, 2001; Bozym et al., 2006; Krężel and Maret, 2006; 
Vinkenborg et al., 2009). 
The experiments using CK2 inhibitors demonstrate that CK2 function is required by both 
breast and prostate cancer cells to regulate zinc homeostasis under zinc exposure. The 
reason behind using two inhibitors, TBB and CX-4945, is to enhance the veracity of the 
findings since no inhibitor is absolutely specific against its target enzyme, although both 
TBB and CX-4945 are highly selective against CK2 (Lolli et al., 2012). Both TBB (20 
µM) and CX-4945 (5 µM) showed the same effect, i.e., decreasing the cell viability of all 
four cancer cell lines under ZnSO4 IC50 treatment (Fig. 3.2). Confocal imaging further 
demonstrates that reduction of cell viability was due to the increased accumulation of 
intracellular zinc (Fig. 3.5).  
These findings together indicate CK2 is involved in zinc homeostasis, potentially through 
regulating zinc transport proteins associated with zinc uptake, sequestration, or efflux. It 
is well known that ZIP, ZnT and metallothioneins are the workhorses in zinc homeostasis. 
Zn2+ accumulation in breast cancer cells directly correlates with abnormal expression of 
ZIP6, ZIP7, ZIP10 and ZnT2 (Kagara et al., 2007; Taylor et al., 2008; Lopez et al., 2011), 
whilst decrease of cytoplasmic Zn2+ can be resulted from ZIP1 down-regulation in prostate 
cancer cells (Franklin et al., 2005; Prasad et al., 2009). It should be noted that since CK2 
has many pleiotropic effects on various signal transduction pathways, simple 
interpretations about its role in zinc homeostasis, as stated above may not be the complete 
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picture. Further studies such as phosphoproteomics are needed to see if CK2 regulates the 
expression and/or activity of ZIP and ZnT.   
siRNA mediated knockdown of individual CK2 subunit genes provide significant details 
on the involvement of CK2 in zinc homeostasis. Firstly, we analysed the efficacy of siRNA 
knockdown (Fig. 3.3). The average knockdown efficacy for all three CK2 subunit 
transcripts was 70.15%. Both MTT assay and confocal imaging demonstrate that CK2β 
knockdown is detrimental to both breast cancer cell lines whereas beneficial for both 
prostate cancer cell lines under IC50 Zn
2+ (Fig. 3.4 and 3.6). Because CK2β is essential for 
the tetrameric holoenzyme CK2, these findings therefore suggest that the CK2 tetramer 
might be involved in up-regulating cytoplasmic zinc level in prostate cancer cells, while 
the opposite mode of action is likely the case for breast cancer cells. The varying 
behaviours of breast and prostate cancer cells are also evident in siRNA knockdown of 
CK2α’ (Fig. 3.4 and 3.6). The cell viability was reduced, or zinc accumulation was 
elevated in PC3 and DU145 prostate cancer cells due to knockdown of CK2α’, while the 
opposite was seen in MCF-7 and MDA-MB-231 breast cancer cells. Such opposite effect 
of CK2β and CK2α’ demonstrates that CK2 is involved in zinc homeostasis, also that the 
CK2-related zinc homeostasis in breast and prostate cancer cells are divergent. 
Furthermore, siRNA knockdown of individual CK2 subunits shows that individual 
subunits of CK2 have distinct roles in zinc homeostasis in breast and prostate cancer cells. 
3.4 Conclusion 
In summary, the findings reported here demonstrate that CK2 is involved in zinc 
homeostasis in breast and prostate cancer cells and that individual CK2 subunits play 
distinct roles. The study provides a basis for future works on delineating the molecular 
network of zinc homeostasis involving CK2, zinc transport proteins (ZIP and ZnT), 
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metallothioneins and other players. The involvement of CK2 in zinc homeostasis may also 















4 TRANSCRIPTOMIC INSIGHTS INTO THE ZINC 
HOMEOSTASIS IN MCF-7 BREAST CANCER CELLS 
VIA NEXT-GENERATION RNA SEQUENCING 
4.1 Introduction 
Zinc is one of the most abundant biometal ions in humans, because it is necessary for the 
structure and function of cellular proteins involved in multitudes of biological processes 
such as metabolism, proliferation and apoptosis (Vallee and Auld, 1990; Vallee and Auld, 
1993; Franklin and Costello, 2007). There are at least 3000 zinc-binding proteins in the 
human proteome (Maret, 2003, 2012), many of which are enzymes and DNA-binding 
transcription factors (Vallee, 1983; Vallee and Auld, 1990; Vallee and Auld, 1993; Ebert 
and Altman, 2008). Zinc can also act as a second messenger in signal transduction cascades 
(Hershfinkel et al., 2001; Yamasaki et al., 2007; Maret, 2017). It is therefore plausible for 
the cell to maintain zinc homeostasis by tight control of zinc uptake, sequestration and 
export.  
Impairment of cellular zinc homeostasis is linked to diseases such as breast cancer. It has 
been reported that breast cancer tissues accumulate zinc levels way beyond those observed 
in normal epithelial breast tissue (Ionescu et al., 2006). Such elevation in zinc level in 
cancerous breast tissue has been linked to cancer progression and malignancy (Ionescu et 
al., 2006; Cui et al., 2007; Alam and Kelleher, 2012). However, the molecular 
understanding underlying such a link is lacking. This transcriptomic study aims to fill this 
gap by gaining insights into zinc homeostasis of the luminal MCF-7 breast cancer cells.  
Considerable progress has been made in the past decades on the membrane-bound proteins 
related to cellular zinc homeostasis, including 10 zinc exporting proteins (ZnT) in solute 
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carrier 30A (SLC30A) family for decreasing cytoplasmic concentration of zinc [Zn2+] and 
14 zinc importing proteins (ZIP) in SLC39A for increasing cytoplasmic [Zn2+] (Nelson, 
1999; Guerinot, 2000; Colvin et al., 2003; Kirschke and Huang, 2003; Maret, 2003; 
Desoize, 2004; Cousins et al., 2006; Kagara et al., 2007; Lopez et al., 2011; Choi and Bird, 
2014). Recently, protein kinase CK2 in MCF-7 breast cancer cells was found to 
phosphorylate the zinc channel, ZIP7, which is located in the subcellular membrane of the 
ER (Taylor et al., 2012). The phosphorylation of ZIP7 by CK2 resulted in the release of 
zinc from the ER store to the cytoplasm, triggering a cascade of downstream signal 
transduction. In addition to zinc transport proteins, the cytoplasmic metallothioneins are 
involved in zinc sequestration, playing a critical role in cellular zinc homeostasis (Cousins 
et al., 2006; Vašák and Meloni, 2011; Kimura and Kambe, 2016). 
In this study, we deployed a holistic approach by next-generation RNA sequencing to 
uncover genes involved in the cellular response to zinc exposure in MCF-7 breast cancer 
cells. It is anticipated that upon IC50 zinc exposure the breast cancer cells would up-
regulate the genes related to intracellular zinc sequestration such as metallothionein genes. 
The family of ZIP transporters, responsible for zinc influx situated in the plasma 
membrane, are expected to be down-regulated in an attempt to reduce the influx of 
extracellular zinc. Similarly, ZIP transporters situated in organelles or subcellular 
compartments would likely be down-regulated in order to maintain the equilibrium of 
cytoplasmic zinc levels. Moreover, the gene expression of ZnT transporters would be up-
regulated to efflux any excessive intracellular zinc. The most differentially expressed 
genes identified were then confirmed by quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) and extended to the more malignant basal type of breast cancer 
cells (MDA-MB-231). Herein, we report the acquired dataset, the follow-up findings and 




4.2.1 Determination of IC50 of ZnSO4 for MCF-7 and MDA-MB-
231 breast cancer cells 
IC50 values for MCF-7 and MDA-MB-231 breast cancer cells cultured in 96-well plates 
were firstly determined according to the dose response curves from the MTT assay (Fig. 
4.1). The IC50 values of ZnSO4 for MCF-7 and MDA-MB-231 cells were 320 µM and 350 
µM, respectively. The cell enumeration by trypan blue staining further confirmed these 
IC50 values. The IC50 dose of ZnSO4 for MCF-7 cells (320 µM) was applied to the cells at 
80% confluency in 25 cm2 flasks for RNA-seq transcriptomic analysis. The cells were 
morphologically healthy at T30 and T120 in the time course of treatment. 
 
Fig 4.1 Zinc dose responsive curves of MCF-7 and MDA-MB-231 breast cancer cells 
Cells were grown for 32 h to reach 80% confluency and then treated with 0 to 500 µM of 
ZnSO4. The viability of the cells was quantified by MTT assay at the end of 6 h treatment. 
Blue represents MCF-7 and orange represents MDA-MB-231. The IC50 for each cell line 
was determined according to their response curves. Error bars, too small to be seen, 
represent the standard deviation of six biological replicates. 
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4.2.2 Overview of differentially expressed genes in MCF-7 cells in 
the time course under zinc treatment  
By comparing T30 zinc treatment against the control, 123 up-regulated and 8 down-
regulated genes were identified (Appendices 1.1 and 1.2). At T120 zinc treatment against 
the control revealed 473 up-regulated and 123 down-regulated genes, using edgeR 
(Appendices 1.3 and 1.4). Differentially expressed genes were coloured in red (Log2FC 
˃0.6) and green (Log2FC >1) with a Benjamini-Hochberg corrected p-value less than 0.05 
(Benjamini and Hochberg, 1995). The synoptic overviews of the transcriptomic data for 
T30 and T120 zinc treatment in comparison to control are shown in Fig. 4.2 by differential 














Fig 4.2 Volcano plots for T30 and T120 zinc treatment versus control 
The volcano plots depict the gene expression profiles for T30 zinc treatment against control 
(A) and T120 zinc treatment against control (B). Genes in blue have Log2FC between 0 and 
0.6 or between 0 and -0.6, while genes in red and green are differentially expressed, with 















4.2.3 Top differentially expressed genes in response to zinc 
exposure 
Table 4.1 highlights the 19 up-regulated genes and 1 down-regulated gene for T30 against 
control. Metallothionein genes (MT1B, MT1X, MT1F and MT2A) and ZnT1 gene 
(SLC30A1) are prominent. The expression of MT1B was increased by 45-fold (Log2FC = 
5.4842) compared to the control. This finding suggests that metallothioneins and zinc 
exporter ZnT1 are the first line of response in dealing with extracellular zinc exposure, as 
their functions are to reduce intracellular free zinc by sequestration and export.         
EGR1 and EGR2, encoding the early growth response proteins EGR1 and EGR2, were 
significantly up-regulated at both T30 and T120 zinc treatment shown in Table 4.1 and 4.2. 
EGR1 and EGR2 are zinc finger transcription factors and regulate the expression of 
numerous genes involved in response to extracellular stimuli and endoplasmic reticulum 
stress (Kumbrink et al., 2010). Their up-regulation indicates they are responsive to 
extracellular zinc. Similarly, many other zinc finger protein genes (RNF165, SNAI1, 
ZNF442, ZNF365, ZNF547, ZNF563, ZNF296 and ZBTB2) were up-regulated at T30 and 
T120, whereas ZNF750 and ZNF256 were only up-regulated at T30 zinc treatment. The up-
regulation of RGS16, RASD1, CTGF, NR4A3, NR4A1, TRIB1, NGFR and HES1 genes was 
also observed at T30 (Table 4.1). These genes are related to cell survival (NGFR and 
TRIB1), stress response (HES1, RGS16, RASD1, NR4A3 and NR4A1) and cytoskeletal 
perturbation (CTGF). The increase of histone gene expression (HIST1H4D, HIST1H1D 
and HIST1H2AD) at T30 indicates that the excess of intracellular zinc affected genome 
stability in MCF-7 breast cancer cells.       
The expression of metallothionein genes (MT1B, MT1X, MT1F and MT2A) and ZnT1 gene 
(SLC30A1) continues to increase at T120 (Table 4.2, Fig. 4.3). MT1B expression was 
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elevated dramatically by 869-fold (Log2FC = 9.7648) against control. Fig. 4.3 shows the 
dynamic changes of expression for the 11 up-regulated genes shared by T30 and T120 as 
listed in Table 4.1 and 4.2, exhibiting the increased expression pattern for each of them. 
Furthermore, the genes for heat shock proteins were also significantly up-regulated at T120 
(HSPA6, HSPA1A, HSPA1B, HSPH1, HSPE1, HSP90AA1, HSPA8, HSPA1L, HSP90AB1, 
HSPA4L and HSPD1) (Table 4.2). This demonstrates that heat shock proteins along with 
the other stress-responsive proteins are essential in dealing with extracellular zinc 
exposure.   
PLK2, encoding Polo-like kinase 2, is a prominent down-regulated gene under zinc 
exposure, as its expression was decreased at both T30 (~1.5 arithmetic fold) and T120 (~4 
arithmetic fold). qRT-PCR was used to validate the RNA-seq dataset. Nine genes (MT1B, 
MT1X, MT1F, MT2A, SLC30A1, VMP1, ZNF850, HSP6 and HSP90AA1) were analysed 
and their expression pattern correlates with dynamic changes shown by RNA-seq (Fig. 
4.4). These differentially expressed genes were further quantified in the basal-type breast 
cancer cells (MDA-MB-231) in the same zinc sulfate treatment condition. The result in 
Fig. 4.4 and 4.5 shows the similar pattern as the luminal-type MCF-7 cells, except 
SLC30A1 which was expressed higher in MDA-MB-231 at both T30 and T120 in response 








Table 4.1 Significantly up or down-regulated genes at T30 zinc treatment 
Up-regulated Genes Protein name Log2FC p-value 
MT1B Metallothionein-1B 5.4842 1.3E-06 
MT1X Metallothionein-1X 4.9304 0 
SLC30A1 Zinc transporter 1 4.2508 0 
EGR2 Early growth response protein 2 3.8541 8.11E-52 
MT1F Metallothionein-1F 3.2883 0 
RGS16 





related protein 1 
2.8272 5.94E-61 
CTGF Connective tissue growth factor 2.5543 1.11E-30 
EGR1 Early growth response protein 1 2.1005 7.21E-36 
NR4A3 
Nuclear receptor subfamily 4 
group A member 3 
2.0909 1.35E-24 
TRIB1 Tribbles homolog 1 1.7988 2.6E-244 
NR4A1 
Nuclear receptor subfamily 4 
group A member 1 
1.7706 4.11E-84 
NGFR 
Tumour necrosis factor receptor 
superfamily member 16 
1.6617 1.54E-27 




E3 ubiquitin-protein ligase 
RNF165 
1.5675 7.97E-27 
HIST1H4D Histone H4 1.5438 3.18E-12 
HIST1H1D Histone H1.3 1.5048 1.43E-51 
HIST1H2AD Histone H2A type 1-D 1.4599 2.14E-34 
MT2A Metallothionein-2A 1.4565 2.92E-160 
Down-regulated 
Gene 
Protein name Log2FC p-value 
PLK2 Polo-like kinase 2 -0.6833 0 
 
 
Table 4.2 Significantly up or down-regulated genes at T120 zinc treatment. 
Up-regulated Genes Protein name Log2FC p-value 
MT1B Metallothionein-1B 9.7648 7.30E-82 
HSPA6 Heat shock 70 kDa protein 6 8.1516 1.59E-123 
MT1X Metallothionein-1X 6.2610 0 
MT1F Metallothionein-1F 5.7923 0 
SLC30A1 Zinc transporter 1 5.0368 0 
CHRM4 









HMOX1 Heme oxygenase 1 4.6412 2.41E-308 
MT4 Metallothionein-4 4.5477 1.27E-29 
RGS16 




Solute carrier organic anion 
transporter family member 4A1 
3.6227 0 
EGR1 Early growth response protein 1 3.3742 2.48E-83 
NGFR 
Tumour necrosis factor receptor 
superfamily member 16 
3.2832 3.74E-146 
CNKSR3 
Connector enhancer of kinase 
suppressor of ras 3 
3.1801 3.82E-177 
KBTBD11 
Kelch repeat and BTB domain-
containing protein 11 
3.1410 2.39E-154 
HSPA1A Heat shock 70 kDa protein 1A 3.0934 2.53E-150 
HSPA1B Heat shock 70 kDa protein 1B 3.0474 5.99E-139 
RASD1 
Dexamethasone-induced Ras-
related protein 1 
2.9477 6.00E-66 
SLC2A14 
Solute carrier family 2, facilitated 
glucose transporter member 14 
2.9443 7.79E-47 
CLCF1 
Cardiotrophin-like cytokine factor 
1 
2.8229 4.33E-48 
EGR2 Early growth response protein 2 2.8057 5.36E-19 
MT2A Metallothionein-2A 2.5856 0 
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CHST3 Carbohydrate sulfotransferase 3 2.4900 4.99E-21 
C17orf67 Uncharacterised protein C17orf67 2.4625 1.66E-77 
RAB3A Ras-related protein Rab-3A 2.3841 1.13E-81 
NOTCH1 




DnaJ homolog subfamily B 
member 1 
2.3458 2.13E-113 
TRIB1 Tribbles homolog 1 2.3407 0 
SOCS2 Suppressor of cytokine signaling 2 2.3388 6.41E-68 
HSPH1 Heat shock protein 105 kDa 2.2993 1.03E-131 
CBARP 
Voltage-dependent calcium 




Cysteine and glycine-rich protein 
2 
2.2468 4.62E-19 
ZNF365 Zinc Finger protein 365 2.2367 2.44E-34 
NPL N-acetylneuraminate lyase 2.1705 3.26E-110 
MAP3K8 
Mitogen-activated protein kinase 
kinase kinase 8 
2.0395 3.14E-122 
DUSP6 




Zinc finger and BTB domain-






associated protein 6 
2.0047 1.39E-154 
SLC2A4 
Solute carrier family 2, facilitated 
glucose transporter member 4 
1.9872 8.77E-28 
LRFN4 
Leucine-rich repeat and 
fibronectin type-III domain-
containing protein 4 
1.9871 3.52E-229 
DDIT4 
DNA damage-inducible transcript 
4 protein 
1.9723 0 
ZFP36 Zinc Finger protein 36 1.9661 7.37E-107 
DUSP10 





binding protein 5 
1.9478 1.01E-65 
C2orf54 
Chromosome 2 open reading 
frame 54, otherwise known as 
Mab21L4 
1.9474 2.23E-30 
POLH DNA polymerase eta 1.9040 2.39E-305 
CSRP1 







SERPINE1 Plasminogen activator inhibitor 1 1.8622 1.43E-96 
MCL1 
Induced myeloid leukemia cell 





Nuclear receptor subfamily 4 






SPRY4 Protein sprouty homolog 4 1.7115 7.13E-33 
CALML5 Calmodulin-like protein 5 1.7113 3.12E-39 
DNAJB5 




Tudor-interacting repair regulator 
protein 
1.6808 0.00E+00 
SERPINH1 Serpin H1 1.6788 4.78E-80 





GBP1 Guanylate-binding protein 1 1.5968 4.28E-10 
AKR1C2 




DNA-binding death effector 
domain-containing protein 2 
1.5648 9.95E-89 
SKIL Ski-like protein 1.5291 0 
OSGIN1 
Oxidative stress-induced growth 
inhibitor 1 
1.5265 2.04E-149 
NET1 Nucleolar protein NET1 1.5168 4.97E-261 
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FAM196A Protein FAM196A 1.5037 7.13E-11 
FAM189A2 Protein FAM189A2 1.4979 9.36E-116 
C1orf132 
Chromosome 1 open reading 
frame 132 
1.4976 8.05E-78 
SEMA3F Semaphorin-3F 1.4797 0 
INSIG1 Insulin-induced gene 1 protein 1.4780 1.40E-108 
RND1 
Rho-related GTP-binding protein 
Rho6 
1.4688 1.61E-25 
JUN Transcription factor AP-1 1.4649 8.44E-238 
Down-regulated 
Genes 
Protein name Log2FC p-value 
PLK2 Polo-like kinase 2 -2.0898 0 
MAP10 Microtubule-associated protein 10 -1.7501 3.27E-65 
ANKRD1 








BMP and activin membrane-
bound inhibitor homolog 
-1.6407 0 
IL20 Interleukin-20 -1.6077 4.55E-109 






Fig 4.3 Log2FC of differentially expressed genes shared by T30 and T120 
Summary of overlapping genes between T30 and T120 IC50 zinc treatment (320 µM) in 
MCF-7 breast cancer cells obtained via next-generation RNA sequencing. Red denotes 
Log2FC for T30 zinc treatment while yellow represents Log2FC for T120 zinc treatment. 











Fig 4.4 Quantification of gene expression in MCF-7 breast cancer cells by qRT-PCR 
MCF-7 cells were grown for 32 h to reach 80% confluency and treated with IC50 ZnSO4 
(320 µM) for T30 and T120. Total RNA was then prepared, cDNA synthesised and qRT-
PCR performed. Relative expression of the genes MT1B, MT1F, MT1X, MT2A, SLC30A1, 
VMP1, ZNF850, HSPA6 and HSPA90AA1 was quantified relative to GAPDH. Blue 
represents MCF-7 cells treated with IC50 ZnSO4 for T30 min and orange for T120 min. Data 
represents the average of three biological replicates and each biological replicate has three 









Fig 4.5 Quantification of gene expression in MDA-MB-231 breast cancer cells by 
qRT-PCR 
MDA-MB-231 cells were grown for 32 h to reach 80% confluency and treated with IC50 
ZnSO4 (350 µM) for T30 and T120. Total RNA was then prepared, cDNA synthesised and 
qRT-PCR performed. Relative expression of the genes MT1B, MT1F, MT1X, MT2A, 
SLC30A1, VMP1, ZNF850, HSPA6 and HSPA90AA1 was quantified relative to GAPDH. 
Blue represents MDA-MB-231 cells treated with IC50 ZnSO4 for T30 min and orange for 
T120 min. Data represents the average of three biological replicates and each biological 









A pronounced feature of breast cancer cells is its high intracellular zinc level compared to 
normal breast epithelial cells (Margalioth et al., 1983; Franklin and Costello, 2007; Kagara 
et al., 2007; Franklin and Costello, 2009; Alam and Kelleher, 2012). For the first time, this 
study applies an all-inclusive approach by RNA-seq to explore the transcriptome of breast 
cancer cells in response to zinc exposure. An extensive literature survey indicates RNA-
seq transcriptomic analysis has not been conducted for any cancer cell lines used in this 
study in response to zinc exposure. The dataset in triplicate reported above provides 
snapshots of the genes involved in zinc homeostasis, we see the dynamic changes in gene 
expression over time and further validation was carried out with qRT-PCR, performed in 
triplicate. The findings in MCF-7 breast cancer cells were further extended to the basal 
type of breast cancer cells (MDA-MB-231) through qRT-PCR. 
The biological roles of metallothioneins are still under active research, although they were 
first isolated decades ago (Margoshes and Vallee, 1957). This study demonstrates that 
MT1B, MT1F, MT1X and MT2A are the initial response to zinc exposure. The finding 
agrees with the existing understanding for their role in zinc sequestration (Suhy et al., 
1999; Adams et al., 2002; Coyle et al., 2002; Maret, 2003). Previous studies have reported 
on the involvement of metallothioneins in cancer cell survival and proliferation (Wu et al., 
2016; Baltaci et al., 2018; Rahman and Karim, 2018; Si and Lang, 2018; Sinduja et al., 
2020). However, the degree of the dramatic up-regulation, up to 869-fold, is not expected, 
which highlights the critical role of metallothioneins in zinc homeostasis of breast cancer 
cells. As is known, the zinc level in breast cancer cells is pronouncedly higher than the 
normal breast epithelial cells (Margalioth et al., 1983; Franklin and Costello, 2007; Kagara 
et al., 2007; Franklin and Costello, 2009; Alam and Kelleher, 2012) and the level of 
 
106 
expression for metallothioneins are also found to be increased in breast cancer cells 
(Meskel et al., 1993; Schmid et al., 1993; Goulding et al., 1995; Oyama et al., 1996; Suhy 
et al., 1999; Si and Lang, 2018). The notion that metallothioneins are involved in the 
proliferation of breast cancer cells is fascinating, particularly when we also consider the 
fact that breast cancer cells contain more zinc which incurs higher expression of 
metallothioneins as shown in this study. One might question whether there is a potential 
role of zinc in breast cancer development. It is no doubt that more research on the role of 
metallothioneins in zinc homeostasis and breast cancers will be carried out in the years to 
come. 
Thus far, 11 functional metallothioneins are encoded by a family of genes located on 
chromosome 16q13 (MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1M, MT1X, MT2A, 
MT3 and MT4). The pseudogenes (MT1C, MT1D, MT1I, MT1J and MT1L) cannot encode 
metallothionein (Si and Lang, 2018). While the expression of MT1A, MT1B, MT1E, MT1F, 
MT1G, MT1H, MT1M, MT1X and MT2A are ubiquitous, MT3 and MT4 are normally 
expressed in neurons of the brain and in stratified squamous epithelial cells of the skin 
(Vašák and Meloni, 2011). The significant up-regulation (24-fold) of MT4 upon zinc 
exposure in the breast cancer cells is a novel finding, which shows that MT4 is expressed 
in breast cancer cells and that it is involved in zinc homeostasis.  
The gene for zinc exporter ZnT1 (SLC30A1) was prominently up-regulated in both T30 
(19-fold) and T120 (32-fold). As the ZnT1 protein is a plasma membrane-bound transporter 
(Kambe et al., 2014; Kimura and Kambe, 2016), the finding indicates that ZnT1 is a key 
player in zinc homeostasis by exporting excess intracellular zinc out of the cell. This also 
means that the other nine members of SLC30 family may not be prominent in response to 
extracellular zinc. Intriguingly, SLC30A1 expression is higher in MDA-MB-231 cells than 
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MCF-7 cells according to the qRT-PCR data (Fig. 4.4 and 4.5). This finding shed light on 
the behaviour of these two types of breast cancer cells. The luminal MCF-7 cells are less 
malignant (Lee et al., 2015) and its IC50 of zinc sulfate (320 µM) is lower than the basal 
type MDA-MB-231 cells (350 µM). The IC50 values of zinc sulfate for basal MDA-MB-
231 and luminal MCF-7 breast cancer cells demonstrate their robustness to extracellular 
zinc exposure. The basal MDA-MB-231 breast cancer cells showed greater tolerance to 
zinc exposure compared to luminal MCF-7 breast cancer cells, which may reflect the 
increased aggressiveness of basal type of breast cancer (Liu et al., 2003; Chavez et al., 
2010). As is known, ZnT1 is the sole zinc efflux transporter residing in the plasma 
membrane and is functionally non-redundant in the maintenance of zinc homeostasis 
(Kambe et al., 2015). Its higher expression in MDA-MB-231 cells than MCF-7 explains 
the variation of zinc IC50 for the two cell lines, which may also relate to the degree of their 
malignancy because experimental evidence demonstrates that alterations in ZnT1 
expression and the gene mutations of ZnT1 provide a molecular mechanism for impaired 
zinc homeostasis in cancer development and/or progression (Lehvy et al., 2019).  
Furthermore, one would think that the effective way to control cytoplasmic zinc level is to 
regulate the import of extracellular zinc into the cell by either down-regulation of ZIP 
expression at the transcriptional level or reduction of functional ZIPs in the plasma 
membrane. Intriguingly, the dataset herein did not reveal any down-regulation of ZIP 
genes (SLC39A). The possible explanation for no alteration of ZIP gene expression in 
MCF-7 breast cancer cells following IC50 zinc exposure may be due to the propensity of 
breast cancer cells’ zinc tolerance. MCF-7 cells would initially activate zinc sequestration 
and efflux mechanism to deal with an acute zinc exposure such as the experimental 
condition in this chapter. This notion is demonstrated true by the transcriptomic dataset 
reported in Section 4.2. This might be due to the inherent propensity of breast cancer cells 
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to import zinc via ZIPs at the beginning of the exposure and then there is a time lag for the 
cancer cells to mount a response to regulate ZIPs either at the transcriptomic or protein 
level.  
It is puzzling to see that many zinc finger protein genes, such as RNF165, SNAI1, ZNF442, 
ZNF365, ZNF547, ZNF563, ZNF296, ZBTB2, ZNF750 and ZNF256, were up-regulated in 
response to the increased extracellular zinc, for the roles of these genes in the cell have not 
yet been elucidated. But one obvious property shared by the zinc finger proteins is their 
ability to bind zinc. Hence, their sequestration of zinc could explain their up-regulation. 
Considering together with the increase of gene expression for metallothioneins and ZnT1 
as discussed above, we can now visualise the all-hands-on-deck strategy adopted by the 
breast cancer cells in maintaining zinc homeostasis under the challenge of extracellular 
zinc exposure.    
The up-regulation of the genes for heat shock proteins at T120 (HSPA1A, HSPA1B, 
HSPA1L, HSPA4L, HSPA6, HSPA8, HSPH1, HSP90AA1 and HSP90AB1) along with the 
stress responsive gene VMP1 demonstrates that the zinc exposure results in stress to the 
breast cancer cells and that these chaperone proteins are key responder molecules. The 
finding further points to the known fact that heat shock proteins are the bedrock for the 
robustness of cancer cells (Udono and Srivastava, 1993; Cornford et al., 2000; Isaacs et 
al., 2003; Calderwood et al., 2006). Therefore, they are increasingly targeted for anticancer 
drug development. 
The gene for Polo-like kinase (PLK2) is a prominent down-regulated gene. It belongs to a 
family of genes encoding the structurally related serine/threonine protein kinases that are 
defined by the presence of C-terminal “polo box” domains and are best known as cell cycle 
regulators (Ma et al., 2003). Its significant decrease in gene expression against zinc 
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exposure is reported here for the first time. The underlining reason for this finding might 
be linked to its role in cell cycle regulation. It’s down-regulation would lead to arrest of 
cell cycle progression, allowing the cancer cells to adapt to the stress incurred by zinc 
exposure. The finding could also be linked to zinc-related ER stress because a dramatic 
decrease in PLK2 expression was also discovered in ER stress (Shen et al., 2017).  
Surprisingly, the gene expression levels of protein kinase CK2 subunits (CSNK2A1, 
CSNK2A2 and CSNK2B) were not changed. This suggests that the basal expression of CK2 
subunits is sufficient for MCF-7 breast cancer cells to deal with the zinc exposure. Also 
unchanged is the MTF-1 gene encoding metal response element binding transcription 
factor 1, also called metal regulatory transcription factor 1 (MTF-1), which is known to 
regulate metallothioneins and ZnT1 at the transcript level (Langmade et al., 2000; 
Andrews, 2001; Urani et al., 2010). MTF-1 has a serine and threonine rich region near its 
C-terminus (Potter et al., 2005). This leads to a possibility that it could be phosphorylated 
by protein kinases such as CK2 protein kinase. Indeed, it is found that the phosphorylation 
of MTF-1 plays a critical role in its activation by zinc, and protein kinase CK2 is one of 
the kinases which can phosphorylate MTF-1 (Saydam et al., 2002). The gene expression 
of both MTF-1 and CK2 subunits are not varied by the exposure to zinc in MCF-7 breast 
cancer cells, such a status quo belies their significance in regulating the zinc homeostasis 
of breast cancer cells. 
Metal‐responsive transcription factor 1 (MTF-1) is a highly conserved Cys2-His2 zinc 
finger protein that recognises and binds cis-acting DNA elements, termed metal response 
elements (MRE), to promote the transcription of genes that maintain metal ion homeostasis 
(Giedroc et al., 2001; Laity and Andrews, 2007; Lichten et al., 2011). Acting as a sensor 
for intracellular zinc level and a regulator of zinc homeostasis, MTF-1 translocates from 
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cytoplasm to nucleus in response to zinc overload, and activates the transcription of genes 
for zinc efflux transporter proteins and zinc sequestration proteins such as ZnT1 and 
metallothioneins (Hardyman et al., 2016). Consequently, it is certain for this study that 
MTF-1 is involved in the strong up-regulation of SLC30A1 (ZnT1), MT1B, MT1X, MT1F, 
MT2A and MT4 in MCF-7 breast cancer cells in response to zinc exposure. Jackson et al. 
(2020) identified a list of MTF-1 biomarker genes according to 10 microarray 
transcriptomic datasets representing diverse metal treatments and human cell types, 9 up-
regulated genes (AKR1C2, CLU, ATF3, GDF15, HMOX1, MAP1A, MAFG, SESN2 and 
UBC) of this study are on that list, apart from the common metallothionein genes and 
SLC30A1. AKR1C2 (aldo-keto reductase family 1 member C2), ATF3 (activating 
transcription factor 3), CLU (clusterin) and HMOX1 (heme oxygenase 1) are involved in 
reducing the effects of oxidative stress (Schwochau et al., 1998; Hai et al., 1999; Hansen 
et al., 2000; Permenter et al., 2011; Shirato et al., 2014). GDF15 (growth/differentiation 
factor 15), MAP1A (microtubule-associated protein 1A), MAFG (transcription factor 
MafG), SESN2 (sestrin-2) and UBC (ubiquitin C) are associated with a range of cellular 
stress responses (Katsuoka et al., 2005; Parker et al., 2014; Wollert et al., 2017; Bianchi et 
al., 2018; Wang et al., 2020). The up-regulation of AKR1C2, CLU, ATF3, GDF15, 
HMOX1, MAP1A, MAFG, SESN2 and UBC, together with the genes for heat shock 
proteins described previously, in MCF-7 breast cancer cells upon zinc exposure suggests 
that cell stress was incurred by the zinc overload, and the cancer cells mobilised their stress 
response machinery for survival. The up-regulation of NOTCH1 (neurogenic locus notch 
homolog protein 1) in this study is also likely due to MTF-1 based on the previous study 
(Lichtlen et al., 2001). So is PPP1R18 (protein phosphatase 1 regulatory subunit 18) since 
PPP1R15A is the biomarker gene of MTF-1 (Jackson et al., 2020).  
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Additionally, despite metallothionein genes and SLC30A1 are common responsive genes 
to zinc exposure, the previous transcriptomic data demonstrated that the effects of zinc are 
cell-type specific (Haase et al., 2007; Lin et al., 2009; Ryu et al., 2011). Haase et al. 
compared the transcriptomic responses to zinc exposure of B cells, T cells and monocytes 
by the microarray analysis, only finding four common responsive genes (SLCO1C1, 
SLC30A1, MT1L and MT1H) amongst the three cell types in the immune system (Haase et 
al., 2007). Therefore, the RNA-seq dataset reported here is meaningful for MCF-7 breast 
cancer cells in response to zinc exposure, although SLC30A1 and metallothionein genes 
are also present. A notion must be made that the exact genes for metallothionein isoforms 
in response to zinc exposure vary among cell types.  
Imbalance of zinc homeostasis is harmful to the cell. A substantially greater zinc level has 
been discovered in breast cancer cells compared to normal breast epithelial cells (Alam 
and Kelleher, 2012). Higher intracellular zinc level has been associated with elevated 
malignancy for breast cancer (Margalioth et al., 1983; Rizk and Sky-Peck, 1984; Kagara 
et al., 2007). Its accumulation has been linked with aberrant expression of ZIP6, ZIP7, 
ZIP10, ZnT1 and ZnT2 (Kagara et al., 2007; Taylor et al., 2008; Lopez et al., 2011). In 
contrast, intracellular zinc level has been determined to be lower in prostate cancer cells 
when compared to normal prostate cells, and down-regulation of transporter expression 
such as ZIP1 in malignant prostate tissue correlates with a noticeable decrease of 
intracellular zinc level (Franklin et al., 2005; Song and Ho, 2009).  
Finally, a notion must be made, that is, findings from a transcriptomic study might not 
always be replicated at the protein level. The change in gene expression at mRNA levels 
can be used as an indicator for proteins (Raghavan et al., 2002; Roux and Topisirovic, 
2012; Liu et al., 2016). Regulation at mRNA level for various genes is essential for the 
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cell to respond to the flux of cytoplasmic zinc concentration (Liu et al., 2016). By studying 
mRNA levels, we can gain insight and knowledge into the mechanisms involved in the 
cell’s reaction to zinc stress, thus providing clues into the molecular details of cellular zinc 
homeostasis. Previous studies demonstrated that increased gene expression of ZIP6, ZIP7 
and ZIP10 is directly associated with elevated protein expression (Bafaro et al., 2017; 
Baltaci and Yuce, 2018). However, post-translational modifications such as 
phosphorylation is another regulatory mechanism for the activity of zinc transport proteins 
in the cell. For example, it has been demonstrated that protein kinase CK2 phosphorylates 
the zinc channel, ZIP7, situated in the membrane of the endoplasmic reticulum (Taylor et 
al., 2012). Phosphorylation of ZIP7 leads to the subsequent release of zinc ions in ER 
stores, resulting in elevated intracellular concentration of zinc, thereby sparking a surge of 
downstream signal transduction.  
4.4 Conclusion 
In conclusion, the significance of this study resides in the differentially expressed genes 
uncovered by RNA-seq in MCF-7 breast cancer cells in response to exogenous zinc. It is 
highly significant to discover that ZnT1 gene (SLC30A1) is differentially expressed in the 
aggressive MDA-MB-231 cells compared to MCF-7 cells. The dataset reported in this 
chapter contributes to our knowledge and understanding of zinc homeostasis in breast 
cancer cells. The role of zinc in breast cancer development and treatment is currently an 
area of active research worldwide. The molecular clues described here are a step forward 





5 VALIDATION OF THE DIFFERENTIALLY EXPRESSED 
GENES AND EXPLORATION OF THE ROLE OF CK2 IN 
ZINC HOMEOSTASIS VIA qRT-PCR AND ICP-MS 
ANALYSIS  
5.1 Introduction  
As described in Chapter 4, genes exhibiting differential expression in response to 
extracellular zinc exposure were revealed by RNA-seq. Nine genes at the top of the up-
regulated gene list were further validated by qRT-PCR. The validation was carried out in 
six cell lines, including two breast cancer cell lines (MCF-7, MDA-MB-231) and a normal 
breast cell line (MCF10A), two prostate cancer cell lines (PC3, DU145) and a normal 
prostate cell line (RWPE-1). By using this expanded panel of cell lines, an in-depth 
understanding of those differentially expressed genes in zinc homeostasis of both breast 
and prostate cancer cells was gained. The gene expression of CK2 subunits (CSNK2A1, 
CSNK2A2 and CSNK2B) was also analysed in these six cell lines by means of qRT-PCR 
to better understand the role of CK2 in zinc homeostasis. The cellular zinc content was 
quantified by ICP-MS and provides details of the cellular zinc level in the context of zinc 





5.2 Results  
5.2.1 Determination of inhibitory concentration IC50 of the six cell 
lines  
The IC50 of ZnSO4 for each cell line, MCF-7, MDA-MB-231, MCF10A, PC3, DU145 and 
RWPE-1 was determined according to the dose responsive curves in Fig. 5.1. The IC50 
values of ZnSO4 for MCF-7 and MDA-MB-231 cells were 320 µM and 350 µM, 
respectively. In contrast, the ZnSO4 IC50 for the prostate cancer cells PC3 was 110 µM and 
150 µM for DU145 cells. Additionally, the ZnSO4 IC50 for MCF10A cells was 195.5 µM 
and 187 µM for the RWPE-1 cell line. By comparing the dose response curves of breast 
(Fig. 5.1A) and prostate cell lines (Fig. 5.1B), it is clear that breast and prostate cancer 
cells behave differently in terms of their tolerance to zinc exposure with the cancerous 
cells exhibiting markedly different IC50 values to control lines. Breast cancer cells tolerate 
higher zinc level (320 µM to 350 µM) shown in Fig. 5.1A as dark blue and orange line, 
whilst prostate cancer cells tolerate less (110 µM to 150 µM) represented as grey and 
yellow in Fig. 5.1B. Furthermore, the IC50 values of breast cancer cells are much higher 
than the normal breast cells (195.5 µM), while the IC50 values of prostate cancer cells are 






Fig 5.1 Zinc dose responsive curves of the six cell lines 
Cells were grown for 32 h and treated with 0 to 500 µM of ZnSO4 to determine IC50 for 
each cell line. Presented in panel (A) are MCF-7 cells (dark blue), MDA-MB-231 cells 
(red) and MCF10A cells (light blue). Displayed in panel (B) are PC3 cells (grey), DU145 
cells (yellow) and RWPE-1 cells (green). Error bars represent standard deviation of three 
biological replicates.




5.2.2 Validation of the differentially expressed genes involved in 
zinc homeostasis by qRT-PCR  
Relative expression of MT1B, MT1F, MT1X, MT2A, SLC30A1, VMP1, ZNF850, HSPA6 
and HSPA90AA1 genes was firstly validated in MCF-7 breast cancer cells, in which the 
transcriptomic RNA-seq was carried out as described in Chapter 4. Herein, the expression 
analysis for these genes is expanded to MDA-MB-231 breast cancer cells, PC3 and DU145 
prostate cancer cells, normal breast epithelial cells (MCF10A) and normal prostate 
epithelial cells (RWPE-1). As described in Chapter 2 Section 2.4.6, the gene expression 
was analysed relative to the expression of the housekeeping gene GAPDH. Fold change 1 
means no change of the gene expression. Fold change >1 means increase of the gene 
expression whilst fold change <1 means decrease of the gene expression. Demonstrated in 
Fig. 5.2 are the expression of GAPDH in the cell lines of this study. As shown, GAPDH 








Fig 5.2 Validation of GAPDH expression in the cell lines of this study via qRT-PCR 
Cells were grown for 32 h and treated with appropriate IC50 ZnSO4 at T30 (blue) and T120 
(orange). Total RNA was prepared, cDNA synthesised, qRT-PCR performed and 
expression of GAPDH quantified. Data represents the average of three biological 



















Fig. 5.3 reveals that exposure of MCF-7 cells to zinc IC50 at T30 resulted in increased gene 
expression of MT1B, MT1F, MT1X, SLC30A1 and ZNF850 (P<0.001); MT2A and VMP1 
(P<0.01); HSPA6 and HSPA90AA1 (P<0.05). Furthermore, exposure of MCF-7 cells to 
zinc IC50 at T120 resulted in a significant increase in gene expression of MT1B, MT1F, 
MT1X, MT2A, SLC30A1, VMP1, ZNF850, HSPA2 and HSPA90AA1 (P<0.001). The genes 
MT1B, MT1F, MT2A, VMP1 and ZNF850 showed substantial increase in expression from 
T30 to T120 in response to IC50 zinc treatment. These findings correlate with the RNA-seq 
dataset of Chapter 4.     
 
Fig 5.3 Validation of the differentially expressed genes in MCF-7 cells via qRT-PCR 
MCF-7 cells were grown for 32 h and treated with IC50 ZnSO4 (320 µM) at T30 (blue) and 
T120 (orange). Total RNA was prepared, cDNA synthesised and qRT-PCR performed. 
Relative expression of the genes MT1B, MT1F, MT1X, MT2A, SLC30A1, VMP1, ZNF850, 
HSPA6 and HSPA90AA1 was quantified relative to the housekeeping gene GAPDH. Data 






Similarly, Fig. 5.4 shows that exposure of MDA-MB-231 cells to zinc IC50 at T30 resulted 
in increased gene expression of MT1B, MT1F, MT1X, MT2A, SLC30A1 and ZNF850 
(P<0.001); VMP1, HSPA and HSPA90AA1 (P<0.05). The exposure of MDA-MB-231 
cells to zinc IC50 at T120 resulted in a major increase in gene expression of MT1B, MT1F, 
MT1X, MT2A, SLC30A1, VMP1, ZNF850, HSPA6 and HSPA90AA1 (P<0.001). The genes 
MT1F, SLC30A1, VMP1 and ZNF850 showed the largest increase in expression from T30 
to T120 following IC50 ZnSO4 treatment.    
 
Fig 5.4 Quantification of the differentially expressed genes in MDA-MB-231 cells via 
qRT-PCR 
MDA-MB-231 cells were grown for 32 h and treated with IC50 ZnSO4 (350 µM) at T30 
(blue) and T120 (orange). Total RNA was prepared, cDNA synthesised and qRT-PCR 
performed. Relative expression of the genes MT1B, MT1F, MT1X, MT2A, SLC30A1, 
VMP1, ZNF850, HSPA6 and HSPA90AA1 was quantified relative to the housekeeping 







Fig. 5.5 illustrates that exposure of MCF10A cells to zinc IC50 at T30 resulted in increased 
gene expression of MT2A and HSPA6 (P<0.001); MT1B, MT1F, MT1X, SLC30A1, VMP1, 
ZNF850 and HSPA90AA1 (P<0.01). The exposure of MCF10A cells to zinc IC50 at T120 
resulted in a significant increase in gene expression of MT1B, MT1F, MT1X, MT2A, 
SLC30A1, VMP1, ZNF850, HSPA6 and HSPA90AA1 (P<0.001). Interestingly, SLC30A1 
gene expression in particular and ZNF850 to a less degree demonstrated the most 
significant increase in gene expression from T30 to T120 following IC50 ZnSO4 treatment. 
 
Fig 5.5 Quantification of the differentially expressed genes in MCF10A cells via qRT-
PCR 
MCF10A cells were grown for 32 h and treated with IC50 ZnSO4 (195.5 µM) at T30 (blue) 
and T120 (orange). Total RNA was prepared, cDNA synthesised and qRT-PCR performed. 
Relative expression of the genes MT1B, MT1F, MT1X, MT2A, SLC30A1, VMP1, ZNF850, 
HSPA6 and HSPA90AA1 was quantified relative to the housekeeping gene GAPDH. Data 






Fig. 5.6 shows the exposure of PC3 prostate cancer cells to zinc IC50 at T30 resulted in 
increased gene expression of MT1X, SLC30A1, ZNF850 and HSPA6 (P<0.001); MT1B, 
MT1F, MT2A, VMP1 and HSPA90AA1 (P<0.01). The exposure of PC3 cells to zinc IC50 
at T120 resulted in a significant increase in gene expression of MT1B, MT1X, SLC30A1, 
HSPA6 and HSPA90AA1 (P<0.001). The genes MT1B and HSPA6 showed the greatest 
increase in gene expression from T30 to T120 following IC50 ZnSO4 treatment.     
 
Fig 5.6 Quantification of the differentially expressed genes in PC3 cells via qRT-PCR 
PC3 cells were grown for 32 h and treated with IC50 ZnSO4 (110 µM) at T30 (blue) and 
T120 (orange). Total RNA was prepared, cDNA synthesised and qRT-PCR performed. 
Relative expression of the genes MT1B, MT1F, MT1X, MT2A, SLC30A1, VMP1, ZNF850, 
HSPA6 and HSPA90AA1 was quantified relative to the housekeeping gene GAPDH. Data 







Fig. 5.7 reveals that exposure of DU145 prostate cancer cells to zinc IC50 at T30 resulted 
in increased gene expression of MT1X, SLC30A1, ZNF850, HSPA6 and HSPA90AA1 
(P<0.001); MT1B, MT1F, MT2A and VMP1 (P<0.01). The exposure of DU145 cells to 
zinc IC50 at T120 resulted in a significant increase in gene expression of MT1B, MT1F, 
MT1X, MT2A, SLC30A1, VMP1, ZNF850, HSPA6 and HSPA90AA1 (P<0.001). The genes 
MT1F, MT2A and HSPA6 displayed the largest increase in gene expression from T30 to 
T120 following IC50 ZnSO4 treatment.    
 
Fig 5.7 Quantification of the differentially expressed genes in DU145 cells via qRT-
PCR 
DU145 cells were grown for 32 h and treated with IC50 ZnSO4 (150 µM) for T30 (blue) and 
T120 (orange). Total RNA was prepared, cDNA synthesised and qRT-PCR performed. 
Relative expression of the genes MT1B, MT1F, MT1X, MT2A, SLC30A1, VMP1, ZNF850, 
HSPA6 and HSPA90AA1 was quantified relative to the housekeeping gene GAPDH. Data 






Fig. 5.8 uncovers that exposure of RWPE-1 normal prostate epithelial cells to zinc IC50 at 
T30 resulted in increased gene expression of MT1B, MT1F, MT1X, MT2A, SLC30A1, 
VMP1, ZNF850, HSPA6 and HSPA90AA1 (P<0.001). The exposure of RWPE-1 cells to 
zinc IC50 at T120 resulted in a significant increase in gene expression of MT1B, MT1F, 
MT1X, MT2A, SLC30A1, VMP1, ZNF850, HSPA6 and HSPA90AA1 (P<0.001). The genes 
MT1F, MT1X, MT2A, SLC30A1 and VMP1 showed the greatest increases in gene 
expression from T30 to T120 following IC50 ZnSO4 treatment.   
 
Fig 5.8 Quantification of the differentially expressed genes in RWPE-1 cells via qRT-
PCR 
RWPE-1 cells were grown for 32 h and treated with IC50 ZnSO4 (186.88 µM) for T30 (blue) 
and T120 (orange). Total RNA was prepared, cDNA synthesised and qRT-PCR performed. 
Relative expression of the genes MT1B, MT1F, MT1X, MT2A, SLC30A1, VMP1, ZNF850, 
HSPA6 and HSPA90AA1 was quantified relative to the housekeeping gene GAPDH. Data 






5.2.3 Comparison of the gene expression in cancerous and normal 
cells by qRT-PCR 
The expression of the nine genes (MT1B, MT1F, MT1X, MT2A, SLC30A1, VMP1, 
ZNF850, HSPA6 and HSPA90AA1) was quantified and compared as described in Section 
2.4.7 between cancerous and normal cells by qRT-PCR. Fig. 5.9 compares the gene 
expression between MCF-7 breast cancer cells and MCF10A normal breast epithelial cells, 
which reveals a dramatic elevation in gene expression of MT1B, MT1F, MT1X, MT2A, 
VMP1, ZNF850, HSPA6 and HSPA90AA1 (P<0.001). While the gene SLC30A1 has the 
least difference between cancerous and normal breast epithelial cells.    
 
Fig 5.9 Comparison of gene expression in MCF-7 against MCF10A cells via qRT-
PCR 
MCF-7 breast cancer cells and MCF10A normal breast epithelial cells were grown for 32 
h without any treatment for T120 to serve as control. Total RNA was prepared, cDNA 
synthesised and qRT-PCR performed. Expression of the genes MT1B, MT1F, MT1X, 
MT2A, SLC30A1, VMP1, ZNF850, HSPA6 and HSPA90AA1 under control conditions was 
quantified and compared between MCF-7 and MCF10A cells. Data represents the average 




Fig. 5.10 shows comparison of the gene expression between MDA-MB-231 breast cancer 
cells and MCF10A normal breast epithelial cells demonstrated a spectacular rise in gene 
expression of MT1B, MT1F, MT1X, MT2A, VMP1, ZNF850, HSPA6 and HSPA90AA1 
(P<0.001). While the gene SLC30A1 alone revealed the lowest difference in gene 
expression between cancerous and normal breast epithelial cells.    
 
Fig 5.10 Comparison of gene expression MDA-MB-231 against MCF10A cells via 
qRT-PCR 
MDA-MB-231 breast cancer cells and MCF10A normal breast epithelial cells were grown 
for 32 h without any treatment for T120 to serve as control. Total RNA was prepared, cDNA 
synthesised and qRT-PCR performed. Expression of the genes MT1B, MT1F, MT1X, 
MT2A, SLC30A1, VMP1, ZNF850, HSPA6 and HSPA90AA1 under control conditions was 
quantified and compared between MDA-MB-231 and MCF10A cells. Data represents the 





Fig. 5.11 illustrates comparison of the gene expression between PC3 prostate cancer cells 
and RWPE-1 normal prostate epithelial cells, demonstrating a spectacular rise in gene 
expression of MT1B, MT1F, MT1X, MT2A, VMP1, ZNF850, HSPA6 and HSPA90AA1 
(P<0.001). Whilst the gene SLC30A1 represented the smallest difference in comparison of 
gene expression between cancerous and normal prostate epithelial cells.    
 
Fig 5.11 Comparison of gene expression in PC3 against RWPE-1 cells via qRT-PCR 
PC3 prostate cancer cells and RWPE-1 normal prostate epithelial cells were grown for 32 
h without any treatment for T120 to serve as control. Total RNA was prepared, cDNA 
synthesised and qRT-PCR performed. Expression of the genes MT1B, MT1F, MT1X, 
MT2A, SLC30A1, VMP1, ZNF850, HSPA6 and HSPA90AA1 under control conditions was 
quantified and compared between PC3 and RWPE-1 cells. Data represents the average of 







Fig. 5.12 compares the gene expression between DU145 prostate cancer cells and RWPE-
1 normal prostate epithelial cells, showing a remarkable rise in gene expression of MT1B, 
MT1F, MT1X, MT2A, VMP1, ZNF850, HSPA6 and HSPA90AA1 (P<0.001). Whereas the 
genes SLC30A1 suggested negligible difference in comparison of gene expression between 
cancerous and normal prostate epithelial cells.    
 
Fig 5.12 Comparison of gene expression in DU154 against RWPE-1 cells via qRT-
PCR  
DU145 prostate cancer cells and RWPE-1 normal prostate epithelial cells were grown for 
32 h without any treatment for T120 to serve as control. Total RNA was prepared, cDNA 
synthesised and qRT-PCR performed. Expression of the genes MT1B, MT1F, MT1X, 
MT2A, SLC30A1, VMP1, ZNF850, HSPA6 and HSPA90AA1 under control conditions was 
quantified and compared between DU145 and RWPE-1 cells. Data represents the average 






5.2.3 Quantification of the genes of CK2 subunits under zinc 
treatment by qRT-PCR expression   
Fig. 5.13 reveals that CSNK2A1, CSNK2A2 and CSNK2B genes which encode CK2α, 
CK2α’ and CK2β subunits respectively, were up-regulated at T30 following zinc treatment 
for MCF-7 and MDA-MB-231 breast cancer cells (P<0.001) compared to normal breast 
epithelial cells (MCF10A). At T120 zinc exposure, the expression of CSNK2A1, CSNK2A2 
and CSNK2B genes was up-regulated in MDA-MB-231 breast cancer cells compared to 
normal breast epithelial cells (MCF10A) (P<0.01). The results demonstrated that the 
breast cancer cell line MDA-MB-231 requires the up-regulation of CK2 subunits to 
combat zinc exposure at T120 (P<0.01) compared to the normal breast cells, while the 
MCF-7 breast cancer cells tempered the level of CSNK2A2 gene at T120 (P<0.05) albeit 
still significant compared to the normal breast cells, when CSNK2A1 and CSNK2B genes 
returned to baseline or lower expression. Interestingly, the effect of zinc IC50 treatment at 
T30 and T120 for MCF10A, PC3, DU145 and RWPE-1 cells resulted in baseline expression 





Fig 5.13 CK2 subunit expression profile under zinc IC50 treatment 
Cells were grown for 32 h and treated with IC50 ZnSO4 at T30 (blue) and T120 (orange). Total RNA was prepared, cDNA synthesised and qRT-
PCR performed. Relative expression of CSNK2A1, CSNK2A2 and CSNK2B gene expression was quantified relative to the housekeeping gene 




5.2.4 Comparison of the genes of CK2 subunits without any 
treatment by qRT-PCR expression   
The basal expression of CSNK2A1, CSNK2A2 and CSNK2B genes was compared between 
the cancerous and normal cells. Fig. 5.14 reveals that CSNK2A1, CSNK2A2 and CSNK2B 
genes which encode the CK2α, CK2α’ and CK2β subunits was expressed higher in MCF-
7, MDA-MB-231, PC3 and DU145 cancer cells compared to MCF10A and RWPE-1 
normal cells. Interestingly, the expression of CSNK2A1, CSNK2A2 and CSNK2B genes 
was substantially higher in breast cancer cells compared to prostate cancer cells (P<0.001). 
The results demonstrate that MCF-7 and MDA-MB-231 breast cancer cells possess a 
substantially higher expression of all three CK2 subunits compared to the MCF10A normal 
breast epithelial cells, with CSNK2A1 and CSNK2B showing the highest difference 
(P<0.001). In contrast, PC3 and DU145 prostate cancer cells appear to have a higher 
expression of CSNK2B compared to normal prostate epithelial cells (P<0.001), with 
CSNK2A1 and CSNK2A2 also showing difference in expression (P<0.01).         
 
 







Fig 5.14 Comparison of CK2 subunit gene expression between cancerous and normal 
cells  
Cells were grown without any treatment. Total RNA was prepared, cDNA synthesised and 
qRT-PCR performed. Expression of CSNK2A1, CSNK2A2 and CSNK2B genes was 
quantified and compared between cancerous and normal cells. Data represents the average 






5.2.5 Quantification of cellular zinc content under zinc IC50 
treatment and CK2 inhibition by ICP-MS analysis  
Cells were grown for 32 h and treated with IC50 ZnSO4 for T0, T30 and T120 (blue) and TBB 
(20 µM) plus IC50 ZnSO4 for T0, T30 and T120 (orange). The concentration of TBB (20 µM) 
utilised in this study had little effect on cell viability of all the six cell lines employed here 
(MCF-7, MDA-MB-231, MCF10A, PC3, DU145 and RWPE-1). The cells were then 
harvested, washed, digested and quantified by ICP-MS according to Chapter 2 Section 
2.4.11. The result in Fig. 5.15 demonstrates that normal breast epithelial cells (MCF10A) 
accumulated a much higher level of cellular zinc than MCF-7 and MDA-MB-231 breast 
cancer cells. Inhibition of CK2 resulted in more zinc uptake in all cell lines except the 
normal breast cell line (MCF10A). It is also clear that prostate cancer cells (PC3 and 
DU145) accumulate more zinc than the normal prostate cells (RWPE-1) under zinc 





Fig 5.15 Determination of cellular zinc content through ICP-MS analysis 
Cells were grown for 32 h and treated with IC50 ZnSO4 for T0, T30 and T120 (blue) and TBB (20 µM) plus IC50 ZnSO4 for T0, T30 and T120 





5.3 Discussion  
The findings described in this Chapter validated the RNA-seq data of Chapter 4 and 
extended further to the other breast and prostate cancer cells, as well as the normal breast 
and prostate epithelial cells. Such a sequence of experimental flow was designed from the 
outset because it is cost-efficient. With the constraint of budget, it was feasible to do 
transcriptomic RNA-seq analysis with MCF-7 breast cancer cells first, then validate the 
findings and extend to other normal and cancerous breast and prostate cells.    
The gene expression profiles of, SLC30A1, VMP1, ZNF850, HSPA6 and HSPA90AA1 
genes in all six cell lines showed a similar pattern, i.e., they were up-regulated at both T30 
and T120 IC50 zinc exposure, suggesting that these genes are essential to maintain zinc ion 
homeostasis for both normal and cancerous breast and prostate cells. However, parsing the 
data carefully, some key findings become obvious.   
The metallothionein genes in breast cancer cells were found to be markedly elevated in 
expression level compared to normal breast cells under IC50 zinc exposure which is not 
surprising as studies have determined that metallothionines genes play a role in zinc 
sequestration (Goulding et al., 1995; Coyle et al., 2002). What is extraordinary is the 
degree of basal expression of metallothionine genes, particularly the MT2A gene, in breast 
and prostate cancer cells compared to normal breast and prostate cells. Basal expression 
of metallothionine genes was greatest in the MDA-MB-231 breast cancer cells which 
might be one of the reasons why the basal type of breast cancer cells (MDA-MB-231) are 
much more tolerant to higher cellular zinc (Margalioth et al., 1983; Rizk and Sky-Peck, 




cells (MCF-7 and MDA-MB-231) displayed higher basal expression of metallothionein 
genes compared to prostate cancer cells (PC3 and DU145) when compared to normal cells.   
By comparing the fold changes of ZnT1 gene expression in breast cancer cell lines MCF-
7 (3.58), MDA-MB-231 (4.55), prostate cancer cell lines PC3 (2.61), DU145 (2.76) and 
normal breast MCF10A (5.15) and prostate RWPE-1 (3.55) epithelial cells (Fig. 5.3-5.8), 
it is clear that the expression of ZnT1 (SLC30A1) is higher in normal breast and prostate 
epithelial cells. The elevated expression of ZnT1 expression in MCF10A normal breast 
epithelial cells is likely related to its low intracellular zinc level compared to breast cancer 
cells (Costello and Franklin, 2006; Cousins et al., 2006; Franklin and Costello, 2007; 
Franklin and Costello, 2009; Chandler et al., 2016; Reddy et al., 2018). Higher ZnT1 
expression could mean higher zinc efflux, therefore low intracellular zinc level. However, 
it is intriguing for the higher expression of ZnT1 in the MDA-MB-231 breast cancer cells 
when compared to MCF-7 breast cancer cells. One possible underlying reason for this 
could be that such a higher gene expression of ZnT1 might not be translated to higher 
functional ZnT1 protein transporters, because (Lehvy et al., 2019) found that ZnT1 
displays a markedly increased frequency of loss of function mutations in malignant 
tumours, as compared to a healthy population (Lehvy et al., 2019).  
The lower expression of ZnT1 (SLC30A1) in prostate cancer cells, compared to the normal 
prostate epithelial cells, is rather expected due to the lower zinc level in prostate cancer 
cells (Franklin et al., 2005; Song and Ho, 2009). Since prostate cancer cells have a reduced 
requirement for zinc, the expression of ZnT1 transporter is anticipated to be lower 
accordingly. The findings here confirm that the heat shock protein gene HSPA6 was 
elevated in response to zinc exposure in both normal and cancerous breast cells. This 




be used as a stress indicator. The fact that breast cancer cells have a higher zinc IC50 
compared to normal breast cells, indicates that they can handle much higher zinc stress. 
This notion can be explained by the data in this Chapter and Chapter 4, that is, the breast 
cancer cells are more inherently capable at responding to zinc stress because they depend 
on a broader spectrum of genes from metallothioneins to heat shock proteins compared to 
normal breast cells, which appears to be significantly dependant on ZnT1 efflux.   
Since the next-generation RNA-seq results in Chapter 4 demonstrate that the expression 
levels for CK2 subunits genes (CSNK2A1, CSNK2A2 and CSNK2B) were basically 
unchanged under IC50 zinc exposure at T30 and T120 in the MCF-7 breast cancer cells. By 
the means of qRT-PCR, I explored in this chapter the expression profile of all CK2 
subunits under zinc exposure for all six cell lines (Fig. 5.13) and basal expression of CK2 
subunits in the cells without any treatment (Fig. 5.14). The results demonstrated that the 
expression of CK2 subunits were significantly up-regulated at both T30 and T120 IC50 zinc 
exposure in MDA-MB-231 breast cancer cells. A similar pattern was found at T30 zinc 
exposure for the MCF-7 breast cancer cells, compared to normal breast epithelial cells. 
Taking the findings here together with the data of Chapter 4, the RNA-seq transcriptomic 
finding that the gene expression of CK2 was unchanged in response to zinc exposure (T30 
VS T0 and T120 vs T0) is explicable, when considering the qRT-PCR finding in this Chapter 
that the breast cancer cells have higher gene expression of CK2 than the normal breast 
epithelial cells with no treatment (Fig. 5.14). Such elevated basal level of CK2 subunit 
expression in cancer cells compared to normal cells is therefore likely to be sufficient in 
maintaining zinc homeostasis.  
The findings of this chapter and the previous experimental Chapters 3 and 4 can be related 




that breast cancer tumours express higher expression levels of metallothioneins, ZIP4, 
ZIP14 genes and lower levels of ZIP6, ZIP9, ZIP11 compared to normal breast tissue 
(Coyle et al., 2002; Chandler et al., 2016; Kimura and Kambe, 2016; Si and Lang, 2018). 
The luminal subtype of breast cancer tissue has been shown to display higher expression 
of ZIP6 than basal and HER2 over-expression tumours (Coyle et al., 2002; Chandler et al., 
2016; Kimura and Kambe, 2016; Si and Lang, 2018). In comparison, studies have 
established that prostate cancer tumours show down-regulation of ZIP1 gene expression 
which coincides with marked depletion of intracellular zinc levels (Franklin et al., 2005; 
Song and Ho, 2009). Likewise, it has been revealed that ZIP2, ZIP3, ZIP4 and ZIP9 genes 
are also down-regulated in prostate cancer tissue, while up-regulated in normal prostate 
epithelial tissue (Rishi et al., 2003; Franklin et al., 2005; Costello and Franklin, 2006; 
Franklin and Costello, 2009; Huang and Tepaamorndech, 2013). Interestingly, studies 
have established that CK2 expression is up-regulated in all cancers examined, and this 
correlation has prompted studies on CK2’s role in oncogenesis (Trembley et al., 2009). 
Dysregulation of CK2 invokes unwarranted oncogenic capability on cells even though 
CK2 is not formally classed as an oncogene (Trembley et al., 2009).  
The finding described above is in correlation with the findings of this chapter, where CK2 
expression in breast (MCF-7 and MDA-MB-231) and prostate (PC3 and DU145) cancer 
cells is substantially higher compared to the normal breast (MCF10A) and prostate 
(RWPE-1) epithelial cells. The findings described in this chapter could be potentially 
helpful for cancer prognosis and treatment. For example, by decreasing intracellular zinc 
levels the growth of breast cancer cells might be tempered. Such a strategy could be 
implemented through down-regulation of ZIP gene expression (ZIP4, ZIP6 and ZIP14) in 




cancer cells could be achieved by up-regulation of ZIP gene expression (ZIP1, ZIP2, ZIP3, 
ZIP4 and ZIP9) which could benefit prostate cancer patients.
5.4 Conclusion  
In summary, the work in this chapter validated, by means of qRT-PCR, the nine top 
differentially expressed genes uncovered by RNA-seq, further extension of this discovery 
to the other cancer cells, the normal breast and prostate epithelial cells. By using this 
expanded panel of cell lines, an in-depth understanding of those differentially expressed 
genes in zinc homeostasis of both breast and prostate cancer cells was gained. The gene 
expression of CK2 subunits (CSNK2A1, CSNK2A2 and CSNK2B) was also analysed in 
these six cell lines by the means of qRT-PCR to better understand the role of CK2 in zinc 
homeostasis. The cellular zinc content was quantified by ICP-MS in this chapter, the data 
provides details of the cellular zinc level in the context of zinc exposure and time course, 
which is helpful in the overall data analysis of this chapter. The data here adds to our 










6 FINAL DISCUSSION 
This study investigates the role of CK2 subunits in zinc homeostasis of breast and prostate 
cancer cells and applied a holistic transcriptomic analysis via RNA-seq for uncovering the 
genes involved in zinc homeostasis. The findings described in Chapters 3 to 5 demonstrate 
that protein kinase CK2 is indeed involved in zinc homeostasis of breast and prostate 
cancer cells. To be precise, CK2 plays a role in the impaired zinc homeostasis of the cancer 
cells. This novel discovery adds to the previously known biological functions of CK2 
described in Chapter 1, such as regulating cell proliferation and anti-apoptosis (Guerra and 
Issinger, 1999; Litchfield, 2003; Meggio and Pinna, 2003; Kappes et al., 2004). Revelation 
of the differentially expressed genes in MCF-7 breast cancer cells by RNA-seq is highly 
significant. In-depth understanding of zinc homeostasis in the cancer cells is further gained 
through the extension of these genes to the other breast and prostate cancer cells as well 
as the normal breast and prostate epithelial cells.   
6.1 Involvement of CK2 in zinc homeostasis of breast and prostate cancer 
cells  
Protein kinase CK2 has been regarded as one of the most ubiquitous and pleiotropic 
enzymes in biological systems (Guerra et al., 1999; Litchfield, 2003; Filhol et al., 2004; 
Costello and Franklin, 2006). By employing the experimental approaches of CK2 
inhibition with its specific inhibitors, subunit-specific siRNA-mediated knockdown, 
confocal imaging by zinc specific fluorophores, RNA-seq, ICP-MS analysis and qRT-
PCR, the distinctive details of CK2’s involvement in zinc ion homeostasis were elucidated. 
Inhibition of CK2 activity coupled with IC50 zinc exposure in breast and prostate cancer 




intracellular zinc accumulation as shown by confocal imaging. Furthermore, I discovered 
that zinc accumulation was heightened in prostate cancer cells (PC3 and DU145 cell lines) 
due to knockdown of the gene expression for CK2α’, whilst the contrary was true for breast 
cancer cells. This finding reflects the intrinsic difference between breast and prostate 
cancer cells in terms of cellular zinc accumulation and the expression of CK2α’ gene 
(CSNK2A2) is one factor related to such a difference. Thus, siRNA mediated knockdown 
of specific CK2 subunits demonstrates that individual subunits of CK2 have unique roles 
in zinc homeostasis in breast and prostate cancer cells, providing evidence for the 
involvement of CK2 in zinc homeostasis of breast and prostate cancer cells.  
These discoveries were achieved by using the appropriate dosage of CK2 inhibition via 
TBB (20 µM) and CX-4945 (5 µM) and CK2 subunit knockdown for their gene expression 
with the average knockdown efficiency for all three CK2 subunit transcripts at 
approximately 70.15%. Little effect on the cell viability was observed in the above-
mentioned conditions for CK2 inhibition or knockdown, according to Fig. 3.2, 3.4 and Fig. 
5.14. Such findings could be due to the fact that the CK2 inhibition or its subunit 
knockdown is only partial, the functional portion of CK2 is sufficient for maintaining the 
cell viability.Following on the discovery reported in Chapter 3, I carried out transcriptomic 
analysis by RNA-seq, in order to uncover the genes involved in zinc homeostasis of breast 
cancer cells and to see if the genes of CK2 subunits are differentially expressed in response 
to zinc exposure. Remarkably the expression of CK2 subunit genes (CSNK2A1, CSNK2A2 
and CSNK2B) is basically unchanged, as described in Chapter 4. This suggests that the 
basal expression at the gene level of CK2 is sufficient to sustain the cell’s response to zinc 
challenge. As CK2 is a constitutively active kinase (Litchfield and Luscher, 1993; 




basal expression and activity is enough for the cell to handle the IC50 of zinc sulfate. This 
finding also revealed that any perturbation of the basal CK2 expression or activity should 
affect zinc homeostasis. Such a notion is exactly demonstrated by the findings of Chapter 
3 where CK2 inhibitors and the specific siRNA were used to inhibit CK2 activity and its 
gene expression. 
By looking at the difference of CK2 gene expression level between the cancer cells and 
normal epithelial cells in Chapter 5, I found that the gene expression for CK2 subunits 
varies. CK2 subunit expression appears to be elevated in both breast and prostate cancer 
cells compared to normal breast and prostate cells. This implies that cancer cells of the 
breast and prostate require a higher expression of CK2 subunits at the basal level. The 
finding is in agreement with the published data that CK2 gene expression is up-regulated 
in cancer cells (Faust et al., 1999; Guerra and Issinger, 1999; Faust and Montenarh, 2000; 
Trembley et al., 2009). The higher expression of CK2 subunit genes implies that more 
CK2 is required in cancer cells for growth and perhaps for response to zinc exposure.   
6.2 Holistic view of zinc homeostasis in MCF-7 breast cancer cells 
The RNA-seq findings described in Chapter 4 reveals the prominent genes involved in 
response to zinc exposure in the MCF-7 breast cancer cells. Differential gene expression 
for metallothioneins (MT1B, MT1F, MT1X and MT2A) was observed throughout the time 
course of RNA-seq, implying the reliance of breast cancer cells on metallothioneins in 
response to extracellular zinc challenge. This is understandable because metallothioneins 
are the key players in sequestrating free zinc in cytoplasm (Suhy et al., 1999; Thirumoorthy 
et al., 2011; Kimura and Kambe, 2016). However, the degree of the dramatic up-




metallothionein genes highlights not only the significance of their role in zinc homeostasis, 
but also their potential role in response to any other environmental stressors such as anti-
cancer drugs as previous research demonstrates that metallothioneins are involved in drug 
resistance (Goulding et al., 1995; Coyle et al., 2002; Thirumoorthy et al., 2011; Vašák and 
Meloni, 2011; Si and Lang, 2018).   
Since the only zinc exporter ZnT1 (SLC30A1), amongst 10 ZnTs, was differentially 
expressed in MCF-7 breast cancer cells as revealed by RNA-seq, one could question why 
the other nine zinc efflux transporters (ZnT2-10) were not differentially expressed. The 
fact that ZnT1 is the only ZnT present in plasma membrane could explain the finding. By 
being the plasma membrane zinc exporter, ZnT1 is the main workhorse to get the 
intracellular zinc out of the cell. 
One would think that the effective way to control cytoplasmic zinc level is to regulate the 
import of extracellular zinc into the cell by either down-regulation of ZIP expression at the 
transcriptional level or reduction of functional ZIP in the plasma membrane. Intriguingly, 
the RNA-seq dataset from this study did not reveal any down-regulation of ZIP genes 
(SLC39A). This might be due to the inherent propensity of breast cancer cells to import 
zinc via ZIPs at the beginning of the exposure followed by a time lag where the cancer 
cells mount a response to regulate ZIPs either at the transcriptomic or protein level. The 
finding might point to the regulation of ZIPs at the protein level in response to zinc 
exposure. Indeed, phosphorylation of ZIPs and ZnTs is an important mode of post-
transcriptional modification (Taylor et al., 2008; Taylor et al., 2012; Johnson and Wu, 
2016; Thingholm et al., 2020). Degradation of membrane-bound ZIPs is also demonstrated 
in the previous studies (Sekler et al., 2007; Kambe, 2011; Kambe et al., 2014; Thingholm 




It seems that breast cancer cells also depend on the up-regulation of zinc-binding proteins 
such as zinc finger proteins (RNF165, ZNF365, ZBTB2, SNAI1, ZNF442, ZNF547, 
ZNF563 and ZNF296) and vacuolar membrane protein gene VMP1, in order to lower the 
intracellular free zinc level, ultimately preventing cellular toxicity and damage. This 
finding, together with the up-regulation of metallothioneins and ZnT1, provides us insights 
into the all-hands-on-deck response strategy of the MCF-7 cancer cells. 
6.3 Understanding zinc homeostasis in breast cancer cells   
The differentially expressed genes uncovered by transcriptomic RNA-seq analysis in 
luminal MCF-7 breast cancer cells were extended to the more aggressive MDA-MB-231 
basal type breast cancer cells and normal breast epithelial cells (MCF10A). The findings 
from qRT-PCR analysis provide us an insightful understanding between luminal (MCF-7) 
and basal (MDA-MB-231) breast cancer cells. The gene expression of MT1B, MT1F, 
MT1X, MT2A, VMP1, ZNF850, HSPA6 and HSPA90AA1 is higher in the MDA-MB-231 
cells compared to MCF-7 cells. Their differential expression in response to zinc exposure 
reveals the different behaviour between luminal and basal breast cancer cells. The higher 
expression in MDA-MB-231 provides evidence to explain the higher IC50 of zinc sulfate 
in MDA-MB-231 cells (350 µM) against MCF-7 (320 µM). As metallothioneins and heat 
shock proteins play key roles in stress response, their high expression in basal MDA-MB-
231 cells may underpin the malignancy of basal breast cancers. Indeed, previous 
publications demonstrate that basal breast cancers have much higher expression of 





The ZnT1 gene SLC30A1, is expressed higher in MDA-MB-231 cells than MCF-7 cells 
according to the qRT-PCR data (Fig. 5.3 and 5.4). This feature again highlights the 
difference between the luminal MCF-7 cells which are less malignant and MDA-MB-231 
cells which are more aggressive (Franklin and Costello, 2007; Lee et al., 2015). As 
mentioned previously, ZnT1 is the sole zinc efflux transporter residing in the plasma 
membrane and is functionally non-redundant in the maintenance of zinc homeostasis 
(Kambe et al., 2015). The higher expression of ZnT1 in MCF-7 cells than MDA-MB-231 
cells could be related to the degree of their malignancy because experimental evidence 
demonstrates that alterations in ZnT1 expression and the gene mutations of ZnT1 provide 
a molecular mechanism for impaired zinc homeostasis in cancer development and/or 
progression (Lehvy et al., 2019).           
What is interesting is the degree of ZnT1 up-regulation in MCF10A normal breast 
epithelial cells in response to extracellular zinc exposure, which is comparable to MDA-
MB-231 breast cancer cells. This suggests that ZnT1 is a key player in zinc homeostasis 
of both cancerous and normal breast cells. Considering that the differentially expressed 
genes uncovered by RNA-seq such as MT1B, MT1F, MT1X, MT2A, VMP1, ZNF850, 
HSPA6 and HSPA90AA1 are expressed higher in MCF-7 and MDA-MB-231 breast cancer 
cells, compared to MCF10A normal breast epithelial cells, we can conclude that zinc 
homeostasis involves a bevy of molecules related to zinc sequestration, efflux and stress 
response.   
6.4 Understanding zinc homeostasis in prostate cancer cells   
The findings in Chapter 3 demonstrates that PC3 and DU145 prostate cancer cells were 




The determined IC50 values for PC3 and DU145 cells were 110 µM and 150 µM, 
respectively. This provides a characteristic feature of prostate cancer cells on zinc 
exposure. The differentially expressed genes revealed by transcriptomic RNA-seq analysis 
in luminal MCF-7 breast cancer cells were extended to the PC3 and DU145 prostate cancer 
cells and normal prostate epithelial cells (RWPE-1). The discoveries from qRT-PCR 
analysis provides an understanding of PC3 and DU145 prostate cancer cells in response to 
zinc exposure. The gene expression of MT2A, VMP1, ZNF850, HSPA6 and HSPA90AA1 
is higher in the DU145 cells compared to PC3 prostate cancer cells. This might reflect the 
malignancy of these two types of prostate cancer cells, that is, PC3 cells are more 
metastatic than DU145 cells.  
It is important to recall that metallothioneins genes are responsible for buffering excessive 
cytoplasmic zinc, whereas zinc-finger protein (ZNF850) genes are known to be associated 
with zinc-binding, the genes for vacuolar membrane protein (VMP1) and heat shock 
protein (HSPA6 and HSPA90AA1) genes are involved in zinc stress response. Collectively, 
it seems that up-regulation of MT2A, VMP1, ZNF850, HSPA6 and HSPA90AA1 genes are 
essential in response to elevated cytoplasmic zinc in prostate cancer cells. In contrast with 
the breast cancer cells, the gene expression of prostate cancer cells related to zinc exposure 
is not as robust. This implies that prostate cancer cells are naturally programmed to inhabit 
in low-zinc environments compared to breast cancer cells. Intriguingly, up-regulation of 
ZnT1 (SLC30A1) coupled with MT1B, MT1F, MT1X, MT2A, VMP1, ZNF850, HSPA6 and 
HSPA90AA1 gene expression was observed in the normal prostate cells (RWPE-1) 
compared to cancerous prostate cells. This suggests that non-cancerous prostate cells are 




6.5 Proposed molecular mechanisms of zinc homeostasis  
Based on the results reported in this thesis, zinc homeostasis involves a network of 
molecules responsible for zinc uptake, sequestration, efflux and stress response. The 
mechanism by which zinc ion homeostasis is maintained is illustrated in Fig. 6.1. Zinc ions 
enter the cell via zinc importers such as ZIP1. While the intracellular zinc level gradually 
rises, the cell responds by coordinating the expression of numerous genes involved in zinc 
sequestration and efflux. It is proposed that elevated intracellular zinc level is sensed by 
the cell through the transcription factor MTF-1. As discussed in Chapter 4, RNA-seq 
demonstrated that the expression level of MTF-1 is not changed in MCF-7 cells upon zinc 
exposure. Such a status quo is important for MTF-1 to regulate zinc homeostasis. CK2 
could be involved in this as well, for, MTF-1 has been demonstrated to be phosphorylated 
by CK2. Once MTF-1 is phosphorylated by CK2, cytoplasmic MTF-1 translocates to the 
nucleus where it binds metal responsive elements of the genes such as SLC30A1 and 
metallothionein genes, leading to the activation of transcription of ZnT1 and 
metallothioneins.   





Fig 6.1 Schematic description for molecular details in zinc homeostasis 
Zinc ions enter the cell through zinc importers such as ZIP1. The increase of cytoplasmic 
zinc concentration is sensed by MTF-1, which is then translocated into nucleus, triggering 
expression of a range of genes involved in zinc sequestration and export. These genes, as 
uncovered by RNA-seq, include MT1B, MT1F, MT1X, MT2A, SLC30A1, VMP1 and 
ZNF850. Excess zinc in cytoplasm causes cellular stress and the heat shock protein genes 








Up-regulation of ZnT1 and metallothionine genes consequently results in increased zinc 
efflux and sequestration. This is supported by my RNA-seq findings represented in 
Chapter 4, where I identified that ZnT1 gene (SLC30A1) and metallothionein genes MT1B, 
MT1F, MT1X and MT2A in MCF-7 breast cancer cells were significantly up-regulated at 
both T30 and T120 zinc exposure. Apart from phosphorylating MTF-1, CK2 may be directly 
involved in the activation of zinc transporters (ZIPs and ZnTs), similar to CK2’s role in 
the phosphorylation of endoplasmic reticulum zinc channel ZIP7 which results in the gated 
release of Zn2+ from intracellular stores (Taylor et al., 2012).      
The findings in Chapters 3-5 reveal that breast cancer cells (MCF-7 and MDA-MB-231) 
have a higher tolerance to zinc exposure compared to normal breast (MCF10A) epithelial 
cells as manifested by their IC50 values for zinc sulfate. This phenotypic observation is 
likely due to the increase of gene expression in breast cancer cells (MT1B, MT1F, MT1X, 
MT2A, SLC30A1, VMP1, ZNF850, HSPA6 and HSPA90AA1) as described in the results 
of Chapter 4. In comparison, prostate cancer cells (PC3 and DU145) exhibit lower 
tolerance to zinc exposure compared to normal prostate epithelial cells (RWPE-1). The 
decreased expression level of the genes (MT1B, MT1F, MT1X, MT2A, SLC30A1, VMP1, 
ZNF850, HSPA6 and HSPA90AA1) in these two prostate cancer cells was observed, which 
lends support to the above explanation for the zinc tolerance of breast cancer cells. The 
findings demonstrate that breast cancer cells are better equipped at responding to high 






6.6 The significance of this study and future work  
In summary, the findings described in this thesis demonstrate that CK2 is engaged in zinc 
ion homeostasis in breast and prostate cancer cells. Individual CK2 subunits play 
distinctive roles in response to zinc exposure. The uncovered differentially expressed 
genes of the cancer cells in response to zinc exposure provide us insightful knowledge and 
understanding of zinc homeostasis in breast and prostate cancer cells. The employment of 
two cancerous and one normal breast epithelial cell line, and two cancerous and one normal 
prostate epithelial cell line, is strategically important for this study.  
The role of zinc in breast and prostate cancer development and treatment is currently an 
area of active research worldwide. The molecular clues described in this thesis are a step 
forward in this endeavour. For example, this project as well as the previous studies 
demonstrated that the cellular zinc level in breast cancer cells is elevated in comparison to 
the normal breast epithelial cells (Costello and Franklin, 2006; Cousins et al., 2006; 
Franklin and Costello, 2007; Franklin and Costello, 2009; Chandler et al., 2016; Reddy et 
al., 2018), and the zinc level is considerably lower in prostate cancer cells compared to 
their normal prostate epithelial cells (Rishi et al., 2003; Franklin et al., 2005; Costello and 
Franklin, 2006; Franklin and Costello, 2009; Huang and Tepaamorndech, 2013). It could 
be a viable treatment strategy if one could lower the intracellular zinc level of breast cancer 
cells or elevate the intracellular zinc level of prostate cancer cells. The findings of this 
study could contribute to making such a treatment strategy a reality. When targeting breast 
cancer cells such a strategic treatment approach would entail down-regulation of ZIP 
(ZIP4, ZIP6 and ZIP14) and ZnT1 gene expression in breast cancer cells. Contrastingly, 
the up-regulation of ZIP gene expression (ZIP1, ZIP2, ZIP3, ZIP4 and ZIP9) would make 




The discoveries of this thesis open a new avenue for cancer research. Future studies should 
focus on the molecular details between CK2 and zinc transport proteins (ZIP and ZnT). 
The interaction between CK2 and MTF-1 should also be investigated. The breast and 
prostate cancers should be studied together for zinc homeostasis, because of their 
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8.1 Up-regulated genes at T30 zinc treatment 
Up-regulated 
genes 




MT1B Metallothionein-1B 4490 5.484 -0.102 1.3E-06 
MT1X Metallothionein-1X 4501 4.930 8.448 0 
SLC30A1 Zinc transporter 1 7779 4.250 8.997 0 
EGR2 Early growth response protein 2 1959 3.854 0.037 8.11E-52 








51655 2.827 2.275 5.94E-61 
CTGF Connective tissue growth factor 1490 2.554 0.657 1.11E-30 
EGR1 Early growth response protein 1 1958 2.100 5.174 7.21E-36 
NR4A3 
Nuclear receptor subfamily 4 group A 
member 3 
8013 2.090 0.506 1.35E-24 
TRIB1 Tribbles homolog 1 10221 1.798 6.625 2.6E-244 
NR4A1 
Nuclear receptor subfamily 4 group A 
member 1 
3164 1.770 4.365 4.11E-84 
NGFR 
Tumour necrosis factor receptor 
superfamily member 16 
4804 1.661 2.122 1.54E-27 
HES1 Transcription factor HES-1 3280 1.645 6.317 0 
RNF165 E3 ubiquitin-protein ligase RNF165 4944 1.567 3.637 7.97E-27 
HIST1H4D Histone H4 8360 1.543 0.485 3.18E-12 
HIST1H1D Histone H1.3 3007 1.504 2.303 1.43E-51 
HIST1H2AD Histone H2A type 1-D 3013 1.459 2.762 2.14E-34 
MT2A Metallothionein-2 4502 1.456 9.290 2.92E-160 
GBP1 Guanylate-binding protein 1 2633 1.366 -0.021 1.17E-07 
CHST3 Carbohydrate sulfotransferase 3 9469 1.337 -0.440 1.52E-05 
DUSP6 Dual specificity protein phosphatase 6 1848 1.284 2.289 4.05E-14 
SNAI1 Zinc finger protein SNAI1 6615 1.277 1.486 1.6E-17 
HIST4H4 Histone H4 1215 1.249 2.726 8.67E-56 
SPRY4 Protein sprouty homolog 4 8184 1.218 1.785 1.69E-16 
DUSP1 Dual specificity protein phosphatase 1 1843 1.217 5.219 1.3E-159 
HIST1H2BF Histone H2B type 1-C/E/F/G/I 8343 1.169 2.290 3.78E-23 
DUSP10 Dual specificity protein phosphatase 10 1122 1.155 3.107 1.31E-41 
MAFF Transcription factor MafF 2376 1.148 2.933 1.48E-26 
FOSB Protein fosB 2354 1.136 0.193 8.21E-09 
ZNF442 Zinc finger protein 442 7997 1.128 3.360 7.11E-39 
ID1 DNA-binding protein inhibitor ID-1 3397 1.118 3.244 3.39E-57 
MYC Myc proto-oncogene protein 4609 1.091 7.799 1.5E-127 
EGR3 Early growth response protein 3 1960 1.036 6.095 3.61E-74 
HIST2H2BF Histone H2B type 2-F 4406 1.032 5.463 1.14E-89 
ARRDC3 Arrestin domain-containing protein 3 5756 1.030 7.806 1.8E-145 
DLL4 Delta-like protein 4 5456 1.017 0.564 5.59E-08 
DUSP4 Dual specificity protein phosphatase 4 1846 1.009 4.231 3.86E-43 
HIST1H3B Histone H3.1 8358 0.995 0.909 2.02E-08 
JUN Transcription factor AP-1 3725 0.990 7.381 2.5E-110 
HIST1H2BG Histone H2B type 1-C/E/F/G/I 8339 0.983 4.507 1.46E-64 
CSRP1 Cysteine and glycine-rich protein 1 1465 0.971 8.698 4.2E-171 
EPPK1 Epiplakin 8348 0.940 6.460 2.28E-62 




ZNF365 Protein ZNF365 2289 0.914 0.316 4.45E-05 
VMP1 Vacuole membrane protein 1 8167 0.908 9.771 1.75E-76 
ID2 DNA-binding protein inhibitor ID-2 3398 0.889 6.473 6.55E-72 
SLC2A4 SLC2A4 regulator 6517 0.879 0.527 2.58E-05 
HIST1H2BL Histone H2B type 1-L 8340 0.871 0.500 8.73E-07 
HIST1H4E Histone H4 8367 0.870 1.347 6.38E-09 
MCL1 
Induced myeloid leukemia cell 
differentiation protein Mcl-1 
4170 0.870 9.618 4.3E-153 
GEM GTP-binding protein GEM 2669 0.868 2.586 3.26E-21 
ZFP36 mRNA decay activator protein ZFP36 7538 0.863 6.389 1.24E-22 
CALML5 Calmodulin-like protein 5 5180 0.846 2.440 5.29E-10 
ATF3 
Cyclic AMP-dependent transcription 
factor ATF-3 
4670 0.837 4.588 2.38E-51 
HIST1H3J Histone H3.1 8356 0.820 1.557 1.14E-12 
GADD45B 
Growth arrest and DNA damage-
inducible protein GADD45 beta 
4616 0.809 6.746 7.1E-111 
EDN1 Endothelin-1 1906 0.791 2.664 1.9E-11 
ZNF750 Zinc finger protein 750 7975 0.790 2.701 5.72E-24 
IER5L 
Immediate early response gene 5-like 
protein 
3897 0.785 5.900 2.93E-79 




8870 0.778 4.819 4.75E-37 
DUSP5 Dual specificity protein phosphatase 5 1847 0.772 4.968 9.33E-47 
MAP3K8 
Mitogen-activated protein kinase 
kinase kinase 8 
1326 0.769 3.157 1.54E-15 
ID3 DNA-binding protein inhibitor ID-3 3399 0.756 5.241 7.01E-47 
RND1 Rho-related GTP-binding protein Rho6 2728 0.755 1.990 2.49E-07 
C1GALT1C1L 
C1GALT1-specific chaperone 1-like 
protein 
7288 0.744 0.214 7.79E-05 
PLK3 Serine/threonine-protein kinase PLK3 1263 0.743 2.691 5.54E-18 
RAB3A Ras-related protein Rab-3A 5864 0.735 1.938 6.69E-07 
ELF3 ETS-related transcription factor Elf-3 1999 0.734 5.449 1.42E-55 
PCDH8 Protocadherin-8 5100 0.731 -0.021 0.003 
PRICKLE2 Prickle-like protein 2 1663 0.728 5.253 1.06E-53 




8545 0.721 3.584 5.76E-23 
CLDN23 Claudin-23 1370 0.708 2.751 3.28E-18 
ZNF547 Zinc finger protein 547 2843 0.704 -0.168 0.003 
HMOX1 Heme oxygenase 1 3162 0.701 5.512 1.13E-08 
HIST1H2BD Histone H2B type 1-D 3017 0.699 5.177 8E-44 




1052 0.693 3.278 3.29E-17 
HIST1H2BN Histone H2B type 1-N 8341 0.677 3.536 2.53E-23 
ZNF563 Zinc finger protein 563 1478 0.676 2.482 2.54E-14 
TLR2 Toll-like receptor 2 7097 0.676 1.146 6.57E-05 
GADD45G 
Growth arrest and DNA damage-
inducible protein GADD45 gamma 
1091 0.674 3.317 3.24E-19 
ZNF256 Zinc finger protein 256 1017 0.671 3.106 1.35E-23 
NET1 
Neuroepithelial cell-transforming gene 
1 protein 
1027 0.670 9.251 8.1E-54 
EPHA2 Ephrin type-A receptor 2 1969 0.658 4.090 5.47E-39 
OR2B6 Olfactory receptor 2B6 2621 0.657 1.590 2.98E-08 
VPS37D 
Vacuolar protein sorting-associated 
protein 37D 





Zinc finger and BTB domain-
containing protein 2 
5762 0.650 6.622 2.14E-63 
HIST1H3G Histone H3.1 8355 0.648 3.257 2.36E-11 
HAP1 Huntingtin-associated protein 1 9001 0.642 -0.005 0.002 
SOCS2 Suppressor of cytokine signaling 2 8835 0.641 2.376 1.64E-05 
C3orf80 
Uncharacterised membrane protein 
C3orf80 
4010 0.638 0.371 0.005 
PXDC1 Plexin domain-containing protein 1 2217 0.635 0.076 0.005 
ZNF296 Zinc finger protein 296 1629 0.633 2.188 1.08E-05 
FAM43A Protein FAM43A 1315 0.630 3.743 1.86E-17 
C2orf54 Uncharacterised protein C2orf54 7991 0.629 0.404 0.002 
VASN Vasorin 1149 0.627 5.140 3.01E-31 
SGK1 Serine/threonine-protein kinase Sgk1 6446 0.627 1.195 4.01E-06 
HIST1H3H Histone H3.1 8357 0.624 6.134 5.1E-35 
KLF6 Krueppel-like factor 6 1316 0.622 6.141 1.16E-55 
HIST3H2BB Histone H2B type 3-B 1283 0.614 2.184 5.06E-11 




2323 0.607 3.280 7.56E-09 
GPRC5A Retinoic acid-induced protein 3 9052 0.606 6.341 2.14E-46 













































Coiled-coil domain-containing protein 
17 
1494 -0.774 0.584 2.11E-07 
FBXO48 S-phase kinase-associated protein 1 5542 -0.741 0.842 1.04E-07 
HERC2P3 Putative HERC2-like protein 3 2837 -0.660 0.049 0.001 
NFKBIZ NF-kappa-B inhibitor zeta 6433 -0.604 3.680 1.79E-18 
PLK2 Serine/threonine-protein kinase PLK2 1076 -0.683 6.380 1.83E-93 
PPP1R3C 
Protein phosphatase 1 regulatory 
subunit 3C 
5507 -0.622 4.773 1.12E-29 






















8.3 Up-regulated genes at T120 zinc treatment 
Up-regulated 
genes 




MT1B Metallothionein-1B 4490 9.764 -0.102 7.30E-82 
HSPA6 Heat shock 70 kDa protein 6 3310 8.151 3.536 1.59E-123 
MT1X Metallothionein-1X 4501 6.261 8.448 0 
MT1F Metallothionein-1F 4494 5.792 7.202 0 
SLC30A1 Zinc transporter 1 7779 5.036 8.997 0 
CHRM4 Muscarinic acetylcholine receptor M4 1132 4.997 -0.914 1.28E-35 
RNF165 E3 ubiquitin-protein ligase RNF165 4944 4.985 3.637 0 
HMOX1 Heme oxygenase 1 3162 4.641 5.512 2.41E-308 
MT4 Matrix metalloproteinase-17 8456 4.547 -0.944 1.27E-29 
RGS16 Regulator of G-protein signaling 16 6004 3.818 5.252 0 
SLCO4A1 
Solute carrier organic anion transporter 
family member 4A1 
2823 3.622 6.131 0 
EGR1 Early growth response protein 1 1958 3.374 5.174 2.48E-83 
NGFR 
Tumour necrosis factor receptor 
superfamily member 16 
4804 3.283 2.122 3.74E-146 
CNKSR3 
Connector enhancer of kinase 
suppressor of ras 3 
1540 3.180 2.528 3.82E-177 
KBTBD11 
Kelch repeat and BTB domain-
containing protein 11 
9920 3.141 1.969 2.39E-154 
HSPA1A Heat shock 70 kDa protein 1A 3303 3.093 7.487 2.53E-150 




5165 2.947 2.275 6.00E-66 
SLC2A14 
Solute carrier family 2, facilitated 
glucose transporter member 14 
1441 2.944 0.268 7.79E-47 
CLCF1 Cardiotrophin-like cytokine factor 1 2352 2.822 0.990 4.33E-48 
EGR2 Early growth response protein 2 1959 2.805 0.037 5.36E-19 
MT2A Metallothionein-2 4502 2.585 9.290 0 
CHST3 Carbohydrate sulfotransferase 3 9469 2.490 -0.440 4.99E-21 
C17orf67 Uncharacterised protein C17orf67 3392 2.462 2.177 1.66E-77 
RAB3A Ras-related protein Rab-3A 5864 2.384 1.938 1.13E-81 
NOTCH1 
Neurogenic locus notch homolog 
protein 1 
4851 2.354 6.307 0 
DNAJB1 DnaJ homolog subfamily B member 1 3337 2.345 7.280 2.13E-113 
TRIB1 Tribbles homolog 1 1022 2.340 6.625 0 
SOCS2 Suppressor of cytokine signaling 2 8835 2.338 2.376 6.41E-68 
HSPH1 Heat shock protein 105 kDa 1080 2.299 8.864 1.03E-131 
CBARP 
Voltage-dependent calcium channel 
beta subunit-associated regulatory 
protein 
2550 2.286 -0.028 1.31E-19 
CSRP2 Cysteine-rich protein 2-binding protein 1466 2.246 0.514 4.62E-19 
ZNF365 Protein ZNF365 2289 2.236 0.316 2.44E-34 
NPL 
Nuclear protein localisation protein 4 
homolog 
8089 2.170 2.584 3.26E-110 
MAP3K8 
Mitogen-activated protein kinase 
kinase kinase 8 
1326 2.039 3.157 3.14E-122 
DUSP6 Dual specificity protein phosphatase 6 1848 2.030 2.289 4.37E-34 
ZBTB2 
Zinc finger and BTB domain-
containing protein 2 
5762 2.025 6.622 0 
SPACA6 
Sperm acrosome membrane-associated 
protein 6 





Solute carrier family 2, facilitated 
glucose transporter member 4 
6517 1.987 0.527 8.77E-28 
LRFN4 
Leucine-rich repeat and fibronectin 
type-III domain-containing protein 4 
7899 1.987 5.449 3.52E-229 
DDIT4 
DNA damage-inducible transcript 4 
protein 
5454 1.972 7.635 0 
ZFP36 mRNA decay activator protein ZFP36 7538 1.966 6.389 7.37E-107 
DUSP10 Dual specificity protein phosphatase 10 1122 1.952 3.107 1.41E-136 
CREB5 
Cyclic AMP-responsive element-
binding protein 5 
9586 1.947 1.760 1.01E-65 
C2orf54 Uncharacterised protein C2orf54 7991 1.947 0.404 2.23E-30 
POLH DNA polymerase eta 5429 1.904 5.254 2.39E-305 
CSRP1 Cysteine and glycine-rich protein 1 1465 1.898 8.693 0 
C3orf80 
Uncharacterised membrane protein 
C3orf80 
4010 1.880 0.371 5.36E-21 
SERPINE1 Plasminogen activator inhibitor 1 5054 1.862 2.216 1.43E-96 
MCL1 
Induced myeloid leukemia cell 
differentiation protein Mcl-1 
4170 1.857 9.618 0 
NR4A3 
Nuclear receptor subfamily 4 group A 
member 3 
8013 1.750 0.506 9.53E-16 
PKDCC 
Extracellular tyrosine-protein kinase 
PKDCC 
9146 1.723 0.527 2.28E-23 
SPRY4 Protein sprouty homolog 4 8184 1.711 1.785 7.13E-33 
CALML5 Calmodulin-like protein 5 5180 1.711 2.440 3.12E-39 
DNAJB5 DnaJ homolog subfamily B member 5 2582 1.708 1.870 5.57E-28 
NUDT16L1 
Tudor-interacting repair regulator 
protein 
8430 1.680 5.381 0.00E+00 
SERPINH1 Serpin H1 8710 1.678 6.999 4.78E-80 




1052 1.614 3.278 4.45E-102 
GBP1 Guanylate-binding protein 1 2633 1.596 -0.021 4.28E-10 
AKR1C2 
Aldo-keto reductase family 1 member 
C2 
1646 1.584 -0.127 1.51E-12 
DEDD2 
DNA-binding death effector domain-
containing protein 2 
1629 1.564 4.882 9.95E-89 
SKIL Ski-like protein 6498 1.529 7.177 0 
OSGIN1 
Oxidative stress-induced growth 
inhibitor 1 
2994 1.526 5.578 2.04E-149 
NET1 
Neuroepithelial cell-transforming gene 
1 protein 
1027 1.516 9.251 4.97E-261 
FAM196A Protein FAM196A 6429 1.503 -0.222 7.13E-11 
FAM189A2 Protein FAM189A2 9413 1.497 3.457 9.36E-116 
SEMA3F Semaphorin-3F 6405 1.479 7.629 0 
INSIG1 Insulin-induced gene 1 protein 3638 1.478 7.645 1.40E-108 
RND1 Rho-related GTP-binding protein Rho6 2728 1.468 1.990 1.61E-25 
JUN Transcription factor AP-1 3725 1.464 7.381 8.44E-238 
WNT6 Protein Wnt-6 7475 1.442 -0.118 2.38E-11 
BDKRB2 B2 bradykinin receptor 6241 1.440 2.170 3.56E-43 
MAFF Transcription factor MafF 2376 1.440 2.933 1.96E-41 
SH2D5 SH2 domain-containing protein 5 4007 1.433 -0.419 2.31E-09 
KLHL23 Kelch-like protein 23 1512 1.433 3.671 7.38E-101 
SLC16A6 Monocarboxylate transporter 7 9120 1.420 6.217 1.91E-302 
SEMA7A Semaphorin-7A 8482 1.412 1.022 1.83E-18 
WNT9A Protein Wnt-9a 7483 1.412 2.897 7.36E-74 
DUSP1 Dual specificity protein phosphatase 1 1843 1.411 5.219 7.10E-215 




ITGB8 Integrin beta-8 3696 1.395 1.448 2.44E-28 
DNAJB4 DnaJ homolog subfamily B member 4 1108 1.382 2.637 6.33E-41 




2323 1.377 3.280 1.11E-41 




3778 1.344 2.314 1.69E-36 
ATOH8 Protein atonal homolog 8 8491 1.342 1.019 1.11E-15 
FJX1 Four-jointed box protein 1 2414 1.335 1.242 8.81E-27 
PLEKHO2 
Pleckstrin homology domain-
containing family O member 2 
8030 1.334 1.792 2.09E-24 
GPANK1 
G patch domain and ankyrin repeat-
containing protein 1 
7918 1.325 4.463 5.22E-90 
CSF1 
Macrophage colony-stimulating factor 
1 receptor 
1435 1.324 0.484 1.60E-12 
KCNF1 
Potassium voltage-gated channel 
subfamily F member 1 
3754 1.308 0.605 1.80E-13 
HSPE1 
10 kDa heat shock protein, 
mitochondrial 
3336 1.290 4.304 1.48E-32 
NAB2 NGFI-A-binding protein 2 4665 1.283 7.365 9.54E-270 
EPPK1 Epiplakin 8348 1.282 6.460 3.71E-114 
TMEM37 
Voltage-dependent calcium channel 
gamma-like subunit 
1407 1.281 0.13 4.29E-08 
FOSL2 Fos-related antigen 2 2355 1.280 8.011 0 
DNAJA1 DnaJ homolog subfamily A member 1 3301 1.273 7.679 1.08E-70 
KCNN4 
Intermediate conductance calcium-
activated potassium channel protein 4 
3783 1.273 0.537 1.38E-13 
HSP90AA1 Heat shock protein HSP 90-alpha 3320 1.252 10.636 1.14E-46 
SOX12 Protein SOX-15 6666 1.250 6.113 1.38E-255 
HIST1H4D Histone H4 8360 1.244 0.485 7.46E-08 
CHORDC1 
Cysteine and histidine-rich domain-
containing protein 1 
2697 1.244 4.918 5.82E-46 
PTHLH Parathyroid hormone-related protein 5744 1.243 0.675 1.11E-12 
ODC1 Ornithine decarboxylase 4953 1.229 6.584 2.03E-304 
RNF125 E3 ubiquitin-protein ligase RNF125 5494 1.227 2.423 4.57E-47 
ARVCF 
Armadillo repeat protein deleted in 
velo-cardio-facial syndrome 
4212 1.225 4.757 4.55E-91 
IL15RA Interleukin-15 receptor subunit alpha 3601 1.222 2.189 2.96E-34 
PHLDA2 
Pleckstrin homology-like domain 
family A member 2 
7262 1.221 4.284 6.50E-38 
MACC1 
Metastasis-associated in colon cancer 
protein 1 
3463 1.213 4.241 3.50E-122 
SERTAD4 
Putative uncharacterised protein 
SERTAD4-AS1 
5625 1.213 6.365 1.82E-247 
VEGFA Vascular endothelial growth factor A 7422 1.204 8.346 1.31E-179 
ZNF442 Zinc finger protein 442 7997 1.202 3.360 2.28E-43 
EDN1 Endothelin-1 1906 1.202 2.664 4.02E-25 
FAM212B PAK4-inhibitor INKA2 5592 1.201 3.922 3.36E-92 
HBEGF 
Proheparin-binding EGF-like growth 
factor 
1839 1.197 -0.092 3.39E-09 
RIMS3 
Regulating synaptic membrane 
exocytosis protein 3 










Amiloride-sensitive sodium channel 
subunit gamma 
6340 1.182 0.475 2.45E-13 
POLR3G 
DNA-directed RNA polymerase III 
subunit RPC7 




1669 1.178 2.724 4.02E-51 
CCNE1 G1/S-specific cyclin-E1 8981 1.177 1.758 2.09E-12 
BAG2 
BAG family molecular chaperone 
regulator 2 
9532 1.172 2.239 6.81E-25 
HAP1 Huntingtin-associated protein 1 9001 1.168 -0.051 5.56E-09 
ATF3 
Cyclic AMP-dependent transcription 
factor ATF-3 
4673 1.160 4.588 2.57E-99 
JMJD6 
Bifunctional arginine demethylase and 
lysyl-hydroxylase JMJD6 
2321 1.149 3.842 3.65E-45 
TPST1 Protein-tyrosine sulfotransferase 1 8460 1.148 1.743 3.63E-18 
ENC1 Ectoderm-neural cortex protein 1 8507 1.145 4.854 7.19E-137 
DDIT3 
DNA damage-inducible transcript 3 
protein 
1649 1.144 6.451 1.05E-101 
DUSP5 Dual specificity protein phosphatase 5 1847 1.123 4.968 6.78E-99 
TRIM16L 
Tripartite motif-containing protein 16-
like protein 
1471 1.117 1.906 4.88E-14 
LIF Leukemia inhibitory factor receptor 3976 1.115 0.329 2.06E-06 
SPSB2 
SPRY domain-containing SOCS box 
protein 2 
8472 1.110 3.232 3.67E-50 
GFOD1 
Glucose-fructose oxidoreductase 
domain-containing protein 1 
5443 1.106 3.696 1.01E-61 
C11orf95 Uncharacterised protein C11orf95 6599 1.106 3.047 4.14E-60 
ZNF547 Zinc finger protein 547 2843 1.102 -0.161 2.86E-06 
SH2B3 SH2B adapter protein 3 1001 1.100 0.475 7.76E-08 




4414 1.098 3.872 9.55E-42 
RIPOR3 RIPOR family member 3 1408 1.092 4.368 5.69E-71 
NREP Neuronal regeneration-related protein 9315 1.081 3.674 3.23E-58 
ZNF296 Zinc finger protein 296 1629 1.081 2.188 2.15E-14 
NAT8L N-acetylaspartate synthetase 3399 1.078 2.276 3.76E-33 
SLC5A3 Sodium/myo-inositol cotransporter 6526 1.076 5.238 1.69E-48 
PLK3 Serine/threonine-protein kinase PLK3 1263 1.076 2.691 1.20E-37 
HIST1H2BF Histone H2B type 1-C/E/F/G/I 8343 1.072 2.290 6.96E-19 
DUSP8 Dual specificity protein phosphatase 8 1850 1.068 5.033 5.21E-95 




5141 1.059 -0.366 2.10E-06 
FAM167A Protein FAM167A 8364 1.059 3.834 5.64E-41 
KREMEN2 Kremen protein 2 7941 1.058 0.263 2.64E-06 
SNX32 Sorting nexin-32 2541 1.054 0.129 0.003 
FAM46A Terminal nucleotidyltransferase 5A 5560 1.052 5.662 2.79E-46 
PAIP2B 
Polyadenylate-binding protein-
interacting protein 2B 
4009 1.048 4.383 7.74E-89 
MAP1A Microtubule-associated protein 1A 4130 1.045 0.929 6.11E-11 
OVOL1 Putative transcription factor Ovo-like 1 5017 1.044 5.792 6.95E-127 
IER5 
Immediate early response gene 5 
protein 




7909 1.041 4.662 2.70E-87 
GLI1 Zinc finger protein GLI1 2735 1.040 -0.062 1.29E-06 




MXD1 Max dimerization protein 1 4084 1.037 5.276 1.55E-63 
HIST1H4E Histone H4 8367 1.033 1.347 5.31E-12 
TRIM16 Tripartite motif-containing protein 16 1062 1.033 3.289 3.58E-26 
ZNF460 Zinc finger protein 460 1079 1.026 2.418 2.04E-18 
ERF 
Eukaryotic peptide chain release factor 
GTP-binding subunit ERF3A 
2077 1.021 6.673 2.05E-150 
FKBP4 
Peptidyl-prolyl cis-trans isomerase 
FKBP4 
2288 1.020 9.819 1.11E-105 
AKR7A3 
Aflatoxin B1 aldehyde reductase 
member 3 





3955 1.018 5.458 2.45E-120 
MAFK Transcription factor MafK 7975 1.017 5.521 2.33E-135 
DUSP15 Dual specificity protein phosphatase 15 1288 1.007 0.096 3.00E-07 
PCDH8 Protocadherin-8 5100 1.006 -0.021 6.40E-07 
UBC SUMO-conjugating enzyme UBC9 7316 1.005 10.351 4.06E-103 
MB21D1 Cyclic GMP-AMP synthase 1150 1.005 3.032 1.41E-29 
DGKE Diacylglycerol kinase epsilon 8526 0.992 5.942 2.33E-80 
HIST2H2BF Histone H2B type 2-F 4406 0.987 5.463 1.87E-80 
DOK7 Protein Dok-7 2854 0.986 6.482 4.81E-156 
TLR2 Toll-like receptor 2 7097 0.983 1.146 3.83E-09 
MYEOV COP9 signalosome complex subunit 9 2657 0.981 0.712 2.96E-09 
GCAT 
2-amino-3-ketobutyrate coenzyme A 
ligase, mitochondrial 
2346 0.973 3.090 3.13E-29 
CYR61 Protein CYR61 3491 0.971 3.943 4.17E-36 
VMP1 Vacuole membrane protein 1 8167 0.970 9.771 8.69E-87 
TFEB Transcription factor EB 7942 0.966 1.015 9.45E-10 
RELT 
Tumour necrosis factor receptor 
superfamily member 19L 
8495 0.962 2.879 3.52E-18 
SERTAD1 SERTA domain-containing protein 1 2995 0.959 4.028 1.87E-76 
ELK3 ETS domain-containing protein Elk-3 2004 0.959 4.476 1.62E-55 
ZNF483 Zinc finger protein 483 1583 0.954 0.832 4.88E-10 
MAFG Transcription factor MafG 4097 0.951 5.086 3.68E-114 
SELENOW Selenoprotein N 6415 0.951 6.430 2.33E-85 
DPF1 Zinc finger protein neuro-d4 8193 0.950 -0.001 1.94E-06 
HSPA1L Heat shock 70 kDa protein 1-like 3305 0.947 0.892 4.04E-12 
ZNF408 Zinc finger protein 408 7979 0.945 4.700 5.34E-61 
KCTD12 
BTB/POZ domain-containing protein 
KCTD12 
1152 0.940 1.334 8.58E-15 
ERRFI1 ERBB receptor feedback inhibitor 1 5420 0.936 4.831 1.75E-58 




5209 0.932 5.910 6.78E-89 
SMTNL2 Smoothelin-like protein 2 3425 0.931 1.507 2.24E-12 
LRP8 
Low-density lipoprotein receptor-
related protein 8 
7804 0.926 4.209 3.19E-08 




8545 0.924 3.584 5.94E-37 
ETS2 Protein C-ets-2 2114 0.924 5.313 6.58E-87 
DLL4 Delta-like protein 4 5456 0.918 0.564 2.08E-06 
ZNF682 Zinc finger protein 682 9112 0.914 3.315 1.07E-24 
SLC38A3 
Sodium-coupled neutral amino acid 
transporter 3 
1099 0.907 -0.097 2.37E-05 





Potassium voltage-gated channel 
subfamily KQT member 4 
9132 0.906 0.685 1.66E-07 
HCN4 
Potassium/sodium hyperpolarisation-
activated cyclic nucleotide-gated 
channel 4 
1002 0.903 0.850 1.07E-08 
HRK Activator of apoptosis harakiri 8739 0.903 3.470 9.43E-37 
TRIM47 Tripartite motif-containing protein 47 9110 0.898 0.868 1.09E-07 
RHOBTB1 
Rho-related BTB domain-containing 
protein 1 
9886 0.898 3.709 6.17E-37 
TP53RK 
EKC/KEOPS complex subunit 
TP53RK 
1128 0.897 5.486 5.53E-79 
ZBTB21 
Zinc finger and BTB domain-
containing protein 21 
4985 0.897 5.719 7.26E-123 
LDLR Sortilin-related receptor 3949 0.897 7.009 4.04E-50 
SYNGR3 Synaptogyrin-3 9143 0.894 2.323 2.32E-16 
PITPNM2 
Membrane-associated 
phosphatidylinositol transfer protein 2 
5760 0.892 5.176 6.96E-95 
CRYBG2 
Beta/gamma crystallin domain-
containing protein 2 
5505 0.891 0.534 1.52E-08 
ARID3A 
AT-rich interactive domain-containing 
protein 3A 
1820 0.888 4.642 1.40E-75 
FGFR3 Fibroblast growth factor receptor 3 2261 0.888 1.963 7.09E-09 
GPRC5C 
G-protein coupled receptor family C 
group 5 member C 
5589 0.882 4.792 4.95E-79 
ZNF346-IT1 N/A NA 0.881 0.176 5.30E-05 
MAPRE2 
Microtubule-associated protein RP/EB 
family member 2 
1098 0.881 1.518 4.46E-15 
ISL2 Insulin gene enhancer protein ISL-2 6484 0.883 1.021 2.48E-08 
DAGLB Sn1-specific diacylglycerol lipase beta 2219 0.880 4.496 1.04E-61 




8987 0.880 0.454 1.90E-07 
ZNF16 Zinc finger protein 16 7564 0.879 4.318 6.36E-69 
SESN2 Sestrin-2 8366 0.877 6.246 1.27E-121 
OSER1 
Oxidative stress-responsive serine-rich 
protein 1 
5152 0.876 6.664 5.04E-147 
SPRED2 
Sprouty-related, EVH1 domain-
containing protein 2 
2007 0.876 6.354 9.22E-125 
ZNF555 Zinc finger protein 555 1482 0.875 2.344 3.24E-18 
DUSP7 Dual specificity protein phosphatase 7 1849 0.875 2.974 1.22E-23 
S100P Protein S100-P 6286 0.868 0.523 8.42E-06 
TUBA4A Tubulin alpha-4A chain 7277 0.866 0.022 0.008 
BMP7 Bone morphogenetic protein 7 6552 0.866 4.597 5.21E-51 




2583 0.859 3.376 2.28E-08 
ZC3H12A Endoribonuclease ZC3H12A 8014 0.859 4.443 6.09E-31 
KLHL25 Kelch-like protein 25 6441 0.859 4.129 3.93E-26 
AHDC1 
AT-hook DNA-binding motif-
containing protein 1 
2724 0.858 4.343 5.43E-43 
CELF5 CUGBP Elav-like family member 5 6068 0.856 0.006 2.00E-05 
HIST1H2AK Histone H2A type 1 8330 0.852 1.570 3.11E-13 
SCD Stearoyl-CoA desaturase 5 6319 0.852 10.487 1.38E-31 
CTGF Connective tissue growth factor 1490 0.848 0.657 0.001 
C1GALT1C1L 
C1GALT1-specific chaperone 1-like 
protein 






containing protein 2 
1533 0.842 5.123 9.59E-85 
CAVIN1 Caveolae-associated protein 1 2841 0.842 1.558 6.51E-14 




2326 0.834 4.923 9.43E-42 
ASB13 
Ankyrin repeat and SOCS box protein 
13 
7975 0.832 5.373 6.63E-84 
BCOR BCL-6 corepressor 5488 0.823 6.659 1.40E-121 
GZF1 GDNF-inducible zinc finger protein 1 6441 0.827 5.741 6.29E-85 
LRRC10B 
Leucine-rich repeat-containing protein 
10B 
3902 0.826 1.259 7.43E-08 
MCAM Cell surface glycoprotein MUC18 4162 0.824 0.781 2.89E-07 
HIST1H3B Histone H3.1 8358 0.822 0.909 7.81E-06 
NSMF 
NMDA receptor synaptonuclear 
signaling and neuronal migration factor 
2601 0.822 5.914 3.47E-68 
FBXL18 F-box/LRR-repeat protein 18 8002 0.822 4.475 3.12E-52 
DIXDC1 Dixin 8545 0.817 3.515 1.75E-45 
PCDH1 Protocadherin-1 5097 0.813 6.368 3.11E-120 
MEX3B RNA-binding protein MEX3B 8420 0.813 3.173 1.99E-26 
FHL3 Four and a half LIM domains protein 3 2275 0.812 1.372 2.70E-10 
TP53INP2 
Tumour protein p53-inducible nuclear 
protein 2 
5847 0.809 1.166 8.93E-08 
C11orf84 SPIN1-docking protein 1440 0.807 5.579 1.47E-28 
FAM105A 
Inactive ubiquitin thioesterase 
FAM105A 
5449 0.809 0.803 9.23E-07 
THEG 
Testicular haploid expressed gene 
protein 
5129 0.805 0.821 5.57E-06 
SERTAD3 SERTA domain-containing protein 3 2994 0.806 5.440 2.14E-90 
HIST1H2BG Histone H2B type 1-C/E/F/G/I 8339 0.803 4.507 1.55E-41 
ABCB6 
ATP-binding cassette sub-family B 
member 6, mitochondrial 
1005 0.794 0.212 1.55E-06 
NES Nestin 1076 0.793 1.819 1.06E-05 
LY6G5B 
Lymphocyte antigen 6 complex locus 
protein G5b 
5849 0.792 1.005 9.58E-10 
SLC16A9 Monocarboxylate transporter 9 2209 0.788 3.739 7.79E-28 
EN2 Homeobox protein engrailed-2 2020 0.784 0.397 9.95E-06 
WNT3 Proto-oncogene Wnt-3 7473 0.787 0.604 5.67E-06 
SYNM Synemin 2333 0.783 3.128 1.61E-16 
GRHL3 Grainyhead-like protein 3 homolog 5782 0.782 2.696 1.13E-14 
ID1 DNA-binding protein inhibitor ID-1 3397 0.781 3.244 2.56E-25 
AP3B2 AP-3 complex subunit beta-2 8120 0.778 0.770 3.20E-08 
TMEM121 Transmembrane protein 121 8075 0.777 0.739 0.001 
HSP90AB1 Heat shock protein HSP 90-beta 3326 0.776 9.994 1.70E-27 
F2RL1 Proteinase-activated receptor 2 2150 0.774 3.419 7.67E-13 
GADD45B 
Growth arrest and DNA damage-
inducible protein GADD45 beta 
4616 0.774 6.746 4.42E-100 
HCFC1 Host cell factor 1 3054 0.774 7.683 2.43E-88 
FHL2 Four and a half LIM domains protein 2 2274 0.770 5.017 3.20E-54 
TNFRSF12A 
Tumour necrosis factor receptor 
superfamily member 12A 
5131 0.769 7.602 6.18E-95 
HIST1H2AG Histone H2A type 1 8969 0.769 5.001 1.35E-28 
CCDC117 
Coiled-coil domain-containing protein 
117 
1502 0.768 2.297 1.21E-11 
FSTL3 Follistatin-related protein 3 1027 0.766 4.499 7.72E-49 
IER5L 
Immediate early response gene 5-like 
protein 




HIST4H4 Histone H4 1215 0.759 2.726 4.89E-18 
ZNF488 Zinc finger protein 488 1187 0.757 1.414 2.57E-08 
PPP1R18 Phostensin 1709 0.757 2.991 3.27E-16 
ZC3HAV1L 
Zinc finger CCCH-type antiviral 
protein 1-like 
9209 0.753 3.253 1.45E-32 
PRSS53 Serine protease 53 3391 0.751 2.145 1.50E-14 
TCTE3 Tctex1 domain-containing protein 3 6991 0.751 3.320 8.53E-26 
HEY1 
Hairy/enhancer-of-split related with 
YRPW motif protein 1 
2346 0.749 0.588 2.89E-06 
HPCAL1 Hippocalcin-like protein 1 3241 0.747 6.443 1.21E-93 
PADI3 Protein-arginine deiminase type-3 5170 0.747 0.706 3.77E-05 
SAMD10 
Sterile alpha motif domain-containing 
protein 10 
1407 0.746 4.574 2.15E-42 
PPP4R4 
Serine/threonine-protein phosphatase 4 
regulatory subunit 4 
5771 0.744 0.289 0.001 
NR4A1 
Nuclear receptor subfamily 4 group A 
member 1 
3164 0.736 4.365 4.95E-15 
UBALD1 UBA-like domain-containing protein 1 1244 0.731 6.036 7.97E-44 
CBX4 E3 SUMO-protein ligase CBX4 8535 0.730 7.026 4.61E-76 
SYPL2 Synaptophysin-like protein 2 2846 0.729 0.514 0.001 
PLEKHH2 
Pleckstrin homology domain-
containing family H member 2 
1302 0.723 0.872 7.62E-08 
HSH2D 
Hematopoietic SH2 domain-containing 
protein 
8494 0.722 3.358 2.99E-29 
HSPA4L Heat shock 70 kDa protein 4L 2282 0.719 5.130 2.56E-24 
SP6 Transcription factor Sp6 8032 0.713 1.187 2.16E-06 
RAPGEFL1 
Rap guanine nucleotide exchange 
factor-like 1 
5119 0.718 5.567 6.96E-82 
CACYBP Calcyclin-binding protein 2710 0.719 6.951 5.68E-31 
TNS4 Tensin-4 8495 0.717 3.139 1.12E-17 
HIST1H3G Histone H3.1 8355 0.716 3.257 2.23E-13 
ZYX Zyxin 7791 0.712 6.691 3.46E-31 
ZNF181 Zinc finger protein 181 3393 0.718 3.753 2.08E-33 
IFFO2 Intermediate filament family orphan 2 1269 0.714 3.773 2.53E-30 
TUBB2A Tubulin beta-2A chain 7280 0.713 1.722 1.57E-07 
JUNB Transcription factor jun-B 3726 0.712 5.378 3.54E-33 
KLF16 Krueppel-like factor 16 8385 0.718 4.217 2.73E-35 
MLLT11 Protein AF1q 1096 0.711 2.864 4.05E-15 
C16orf71 Uncharacterised protein C16orf71 1465 0.709 1.334 1.83E-09 
TIMP3 Metalloproteinase inhibitor 3 7078 0.707 0.654 0.006 
KRT81 Keratin, type II cuticular Hb1 3887 0.707 0.666 5.91E-06 
SLC29A4 Equilibrative nucleoside transporter 4 2229 0.706 1.356 1.11E-07 
EGLN2 Egl nine homolog 2 1123 0.700 3.801 1.23E-28 
HOXB9 Homeobox protein Hox-B9 3219 0.699 1.102 4.74E-08 
SLC2A6 
Solute carrier family 2, facilitated 
glucose transporter member 6 
1118 0.698 -0.001 0.003 
FAM214B Protein FAM214B 8025 0.697 2.687 2.77E-15 
KRT80 Keratin, type II cytoskeletal 80 1445 0.697 7.807 1.83E-63 




9166 0.694 6.941 1.83E-57 
FZD5 Frizzled-5 7855 0.692 3.968 1.40E-32 
TMEM50B Transmembrane protein 50B 7576 0.687 5.711 3.98E-67 
ZIC5 Zinc finger protein ZIC 5 8541 0.687 1.258 1.16E-06 
FAM169A 
Soluble lamin-associated protein of 75 
kDa 
2604 0.687 3.952 9.53E-35 







2523 0.686 3.801 1.80E-31 
C5orf56 Uncharacterised protein C5orf56 NA 0.685 0.071 0.004 
PLD6 Mitochondrial cardiolipin hydrolase 2011 0.684 3.379 1.62E-24 
S1PR2 Sphingosine 1-phosphate receptor 2 9294 0.682 1.011 2.56E-05 
MKNK2 
MAP kinase-interacting 
serine/threonine-protein kinase 2 
2872 0.682 6.830 1.02E-69 




6477 0.680 3.016 8.58E-11 
C8orf58 Uncharacterised protein C8orf58 5415 0.679 0.809 2.54E-06 
CLU Clusterin 1191 0.679 7.923 2.83E-44 
ASCL2 Achaete-scute homolog 2 4304 0.678 4.899 2.71E-34 




4144 0.676 8.958 3.73E-87 
ZNF563 Zinc finger protein 563 1478 0.669 2.482 1.96E-13 
SCN1B Sodium channel subunit beta-1 6324 0.668 3.125 1.63E-19 
GPR153 
Probable G-protein coupled receptor 
153 
3875 0.667 1.195 2.58E-05 
PPFIA4 Liprin-alpha-4 8497 0.661 2.510 2.85E-14 
STARD4 StAR-related lipid transfer protein 4 1344 0.666 2.703 1.13E-12 
ZNF416 Zinc finger protein 416 5565 0.664 2.035 6.66E-11 
SLC4A11 
Sodium bicarbonate transporter-like 
protein 11 
8395 0.662 -0.005 0.006 
MTURN Maturin 2221 0.662 0.816 4.82E-06 
RHEBL1 GTPase RhebL1 1212 0.662 0.672 7.33E-06 
AZGP1 Zinc-alpha-2-glycoprotein 5637 0.661 0.128 0.002 
RTL5 Retrotransposon Gag-like protein 5 3405 0.660 0.580 3.93E-05 
NBL1 
Neuroblastoma suppressor of 
tumourigenicity 1 
4681 0.660 0.409 0.002 
OR2B6 Olfactory receptor 2B6 2621 0.659 1.590 6.10E-08 
HIST1H2BN Histone H2B type 1-N 8341 0.659 3.536 2.72E-21 
SRF Serum response factor 6722 0.658 6.302 3.27E-54 
ZBTB7A 
Zinc finger and BTB domain-
containing protein 7A 




8638 0.657 1.048 9.07E-05 
ADAMTSL5 ADAMTS-like protein 5 3393 0.653 3.318 2.05E-20 
ARRDC3 Arrestin domain-containing protein 3 5756 0.652 7.806 6.73E-59 
TAP1 Antigen peptide transporter 1 6890 0.650 3.466 2.93E-18 
CDC42EP2 Cdc42 effector protein 2 1043 0.649 3.072 9.67E-16 
UNC5B Netrin receptor UNC5B 2196 0.649 4.568 2.76E-19 
ZSCAN21 
Zinc finger and SCAN domain-
containing protein 21 
7589 0.648 2.756 8.53E-16 
SLC6A8 
Sodium- and chloride-dependent 
creatine transporter 1 
6535 0.646 2.851 2.99E-14 
GDF15 Growth/differentiation factor 15 9518 0.646 4.567 1.20E-23 
ZNF44 Zinc finger protein 44 5171 0.646 4.475 5.53E-29 
ZNF275 Zinc finger protein 275 1083 0.645 4.880 8.05E-45 
GABARAPL1 
Gamma-aminobutyric acid receptor-
associated protein-like 1 
2371 0.6453 0.308 0.003 
ARSJ Arylsulfatase J 7964 0.643 0.679 8.62E-05 
VCL Vinculin 7414 0.642 6.837 9.32E-50 
PLEKHO1 
Pleckstrin homology domain-
containing family O member 1 






family domain-containing protein 1 
8082 0.638 0.238 0.002 
LPAR5 Lysophosphatidic acid receptor 5 5712 0.635 1.701 4.38E-06 
PRR5 Proline-rich protein 5 5561 0.635 2.354 1.17E-07 
AQP3 Aquaporin-3 3606 0.633 1.495 4.27E-08 
KLB Beta-klotho 1528 0.632 1.778 2.59E-09 
ZNF160 Zinc finger protein 160 9033 0.631 5.672 3.41E-47 
HSPD1 
60 kDa heat shock protein, 
mitochondrial 
3329 0.631 9.090 2.57E-30 
DSC2 Desmocollin-2 1824 0.628 0.726 1.28E-05 
PRODH 
Proline dehydrogenase 1, 
mitochondrial 
5625 0.628 2.278 1.33E-11 
ZNF696 Zinc finger protein 696 7994 0.626 2.979 5.63E-12 
SCNN1A 
Amiloride-sensitive sodium channel 
subunit alpha 
6337 0.626 2.875 2.00E-16 
EIF1AD 
Probable RNA-binding protein 
EIF1AD 
8428 0.625 5.303 1.46E-41 
HIST1H3J Histone H3.1 8356 0.625 1.557 3.11E-07 
NUMBL Numb-like protein 9253 0.624 3.544 6.43E-16 
PTCH1 Protein patched homolog 1 5727 0.624 2.416 3.80E-12 
EPDR1 
Mammalian ependymin-related protein 
1 
5474 0.623 1.051 1.00E-05 
ZBTB46 
Zinc finger and BTB domain-
containing protein 46 
1406 0.621 3.672 2.52E-21 
KLHL31 Kelch-like protein 31 4012 0.621 2.081 4.59E-09 
HES1 Transcription factor HES-1 3280 0.618 6.317 1.02E-44 
BCL3 B-cell lymphoma 3 protein 6023 0.618 4.823 3.55E-30 
INHBE Inhibin beta E chain 8372 0.617 1.995 2.95E-08 
ZNF473 Zinc finger protein 473 2588 0.616 4.485 5.39E-28 
RGPD5 
RANBP2-like and GRIP domain-
containing protein 5/6 
8422 0.615 0.088 0.002 
ZNF574 Zinc finger protein 574 6476 0.615 5.267 6.20E-29 
ZNF134 Zinc finger protein 134 7693 0.614 4.412 2.58E-30 
PXDC1 Plexin domain-containing protein 1 2217 0.613 0.076 0.009 
ORAI1 
Calcium release-activated calcium 
channel protein 1 
NA 0.613 5.116 2.11E-27 
CPEB2 
Cytoplasmic polyadenylation element-
binding protein 2 
1328 0.611 4.536 5.20E-27 
RASSF3 
Ras association domain-containing 
protein 3 
2833 0.608 5.450 5.01E-39 
RPS6KL1 Ribosomal protein S6 kinase-like 1 8369 0.608 3.331 4.26E-17 
ZNF850 Zinc finger protein 850 3428 0.608 3.355 3.39E-19 
PRELID3B PRELI domain containing protein 3B 5101 0.608 8.175 6.05E-84 
CNN2 Calponin-2 1265 0.608 5.938 8.76E-38 
MAG Glycerol-3-phosphate acyltransferase 3 4099 0.607 0.762 0.002 
FLT4 
Vascular endothelial growth factor 
receptor 3 
2324 0.606 0.572 0.007 
PDGFA 
Platelet-derived growth factor subunit 
A 
5154 0.605 4.324 3.04E-32 
HIST1H1D Histone H1.3 3007 0.604 2.303 1.16E-07 
FOXO1 Forkhead box protein O1 2308 0.604 3.755 4.12E-24 
NOTCH3 
Neurogenic locus notch homolog 
protein 3 
4854 0.603 6.334 1.10E-52 
PLEKHG2 
Pleckstrin homology domain-
containing family G member 2 






receptor gamma coactivator-related 
protein 1 
2308 0.603 5.827 1.24E-46 
PTK6 Protein-tyrosine kinase 6 5753 0.602 0.988 9.99E-06 




1240 0.601 4.497 7.30E-27 

























































PLK2 Serine/threonine-protein kinase PLK2 1076 -2.089 6.380 0 
MAP10 Microtubule-associated protein 10 5462 -1.750 2.372 3.27E-65 
ANKRD1 
Ankyrin repeat domain-containing 
protein 1 
2703 -1.740 1.331 1.01E-26 
IRX5 
Iroquois-class homeodomain protein 
IRX-5 
1026 -1.696 6.176 0 
BAMBI 
BMP and activin membrane-bound 
inhibitor homolog 
2580 -1.640 6.964 0 
IL20 Interleukin-20 receptor subunit beta 5060 -1.607 4.355 4.55E-109 
DKK1 Dickkopf-related protein 1 2294 -1.541 5.741 0 
ZNF703 Zinc finger protein 703 8013 -1.435 7.558 8.90E-274 
ASCL1 Achaete-scute homolog 1 4293 -1.409 1.726 5.28E-24 
OTUB2 Ubiquitin thioesterase OTUB2 7899 -1.363 0.480 6.62E-10 
IRX3 
Iroquois-class homeodomain protein 
IRX-3 
7919 -1.349 6.640 2.08E-241 
FBXO32 F-box only protein 32 1149 -1.314 2.359 6.64E-38 
NHLRC1 E3 ubiquitin-protein ligase NHLRC1 3788 -1.283 1.152 1.26E-16 
GATA3 
Trans-acting T-cell-specific 
transcription factor GATA-3 
2625 -1.257 9.916 1.52E-149 
IRS1 Insulin receptor substrate 1 3667 -1.252 6.526 2.61E-138 
AKAP5 A-kinase anchor protein 5 9495 -1.200 3.419 1.65E-63 
FILIP1L Filamin A-interacting protein 1-like 1125 -1.153 1.748 2.76E-16 
HTR1E 5-hydroxytryptamine receptor 1E 3354 -1.153 0.484 1.60E-08 
KCNK5 
Potassium channel subfamily K 
member 5 
8645 -1.127 3.363 1.81E-50 
ARHGAP20 Rho GTPase-activating protein 20 5756 -1.120 0.277 2.93E-06 
PARD6B Partitioning defective 6 homolog beta 8461 -1.078 8.748 5.39E-225 
AMOTL2 Angiomotin-like protein 2 5142 -1.075 7.017 6.40E-87 
NEDD9 Enhancer of filamentation 1 4739 -1.070 4.794 1.06E-88 
CITED2 Cbp/p300-interacting transactivator 2 1037 -1.062 6.319 2.05E-113 
PGR Progesterone receptor 5241 -1.057 9.017 3.45E-147 
FAM83B Protein FAM83B 2225 -1.051 4.881 1.92E-93 
RHOB Rho-related GTP-binding protein RhoB 3881 -1.034 7.995 3.15E-195 
PPP1R3C 
Protein phosphatase 1 regulatory 
subunit 3C 
5507 -1.016 4.773 1.38E-69 
NRIP1 Nuclear receptor-interacting protein 1 8204 -0.986 8.171 3.06E-171 
RNF152 E3 ubiquitin-protein ligase RNF152 2204 -0.955 2.949 6.44E-30 
RAB30 Ras-related protein Rab-30 2731 -0.951 6.584 1.52E-138 
REL Proto-oncogene c-Rel 5966 -0.944 5.455 3.87E-95 
ARHGAP32 Rho GTPase-activating protein 32 9743 -0.944 7.011 1.02E-189 
TSPYL5 
Testis-specific Y-encoded-like protein 
5 
8545 -0.939 3.330 3.68E-38 
SHISA2 Protein shisa-2 homolog 3879 -0.929 3.461 4.29E-34 
NR2F2 COUP transcription factor 2 7026 -0.925 6.598 1.29E-148 
KITLG Kit ligand 4254 -0.914 7.354 3.88E-162 
KLHDC7A Kelch domain-containing protein 7A 1277 -0.895 0.157 3.06E-05 
AVIL Advillin 1067 -0.894 2.660 2.85E-14 
DLC1 Rho GTPase-activating protein 7 1039 -0.893 7.140 5.90E-170 
RUSC2 Iporin 9853 -0.883 4.278 4.96E-58 
SLITRK6 SLIT and NTRK-like protein 6 8418 -0.872 2.675 5.79E-17 






regulatory subunit alpha 
5295 -0.869 8.240 2.08E-156 
TTC30B Tetratricopeptide repeat protein 30B 1506 -0.868 2.353 3.35E-16 
IRF2BPL 
Interferon regulatory factor 2-binding 
protein-like 
6420 -0.855 6.313 3.37E-98 
SLFN5 Schlafen family member 5 1623 -0.840 3.343 1.73E-21 
SOCS1 Suppressor of cytokine signaling 1 8651 -0.832 0.955 6.61E-08 
MAFB Transcription factor MafB 9935 -0.829 2.698 7.64E-16 
NAT1 Arylamine N-acetyltransferase 1 9235 -0.826 2.782 5.96E-21 
ZNF614 Zinc finger protein 614 8011 -0.799 3.712 3.74E-31 
GEM GTP-binding protein GEM 2669 -0.796 2.586 1.97E-12 
DNMBP Dynamin-binding protein 2326 -0.792 5.933 1.16E-104 
ANKRD50 
Ankyrin repeat domain-containing 
protein 50 
5718 -0.765 6.211 2.85E-99 
GRPR Gastrin-releasing peptide receptor 2925 -0.761 0.333 0.001 
CDV3 Protein CDV3 homolog 5557 -0.759 10.073 1.93E-73 
CYS1 Cystin-1 1926 -0.750 0.267 5.58E-05 
SNX15 Sorting nexin-15 2990 -0.749 -0.002 0.002 
TPBG Trophoblast glycoprotein 7162 -0.747 8.405 1.44E-121 
SEMA6D Semaphorin-6D 8003 -0.747 0.258 0.001 
DISP1 Protein dispatched homolog 1 8496 -0.744 2.487 2.21E-13 
FKBPL FK506-binding protein-like 6394 -0.739 2.499 8.25E-12 
FBN2 Fibrillin-2 2201 -0.733 1.432 4.50E-09 
ARL4A 
ADP-ribosylation factor-like protein 
4A 
1012 -0.732 3.261 1.96E-23 
CENPQ Centromere protein Q 5516 -0.731 3.535 1.10E-21 
ARID5B 
AT-rich interactive domain-containing 
protein 5B 
8415 -0.730 5.665 7.00E-67 
BCAR3 
Breast cancer anti-estrogen resistance 
protein 3 
8412 -0.730 4.246 2.62E-34 
ACTRT3 Actin-related protein T3 8451 -0.729 1.079 7.52E-06 
ZNF552 Zinc finger protein 552 7981 -0.721 5.337 4.78E-59 
INSIG2 Insulin-induced gene 2 protein 5114 -0.721 3.999 5.92E-32 
COX10 
Protoheme IX farnesyltransferase, 
mitochondrial 
1352 -0.716 3.639 9.27E-28 
TET2 Methylcytosine dioxygenase TET2 5479 -0.715 6.731 2.26E-101 
BNC1 Zinc finger protein basonuclin-1 6461 -0.711 0.175 0.002 
CCDC17 
Coiled-coil domain-containing protein 
17 
1494 -0.704 0.584 3.86E-06 
CTSK Cathepsin K 1513 -0.697 1.660 4.77E-09 
TOB1 Protein Tob1 1014 -0.696 7.963 4.05E-69 
MEGF9 
Multiple epidermal growth factor-like 
domains protein 9 
1955 -0.695 6.278 5.51E-84 
NAPSA Napsin-A 9476 -0.694 0.217 0.002 
LRRK2 
Leucine-rich repeat serine/threonine-
protein kinase 2 
1208 -0.687 1.826 2.59E-09 
GCNA Acidic repeat-containing protein 9395 -0.685 0.142 0.001 
SOCS3 Suppressor of cytokine signaling 3 9021 -0.683 2.996 2.07E-17 
STON1 Stonin-1 1103 -0.680 3.088 1.18E-20 
KCNJ14 
ATP-sensitive inward rectifier 
potassium channel 15 
3770 -0.679 0.131 0.002 
ARHGAP35 Rho GTPase-activating protein 35 2909 -0.677 8.204 3.88E-98 
ACOT1 Acyl-coenzyme A thioesterase 1 6413 -0.677 -0.052 0.008 
HCAR3 Hydroxycarboxylic acid receptor 3 8843 -0.675 2.037 5.70E-10 
DRG1 
Developmentally-regulated GTP-
binding protein 1 
4733 -0.668 5.489 1.78E-54 





Putative protein MSS51 homolog, 
mitochondrial 
1184 -0.666 0.199 0.007 
BHLHB9 Protein BHLHb9 8082 -0.664 2.819 8.03E-18 
WNT5B Protein Wnt-5b 8102 -0.662 0.527 0.005 
SOX4 Transcription factor SOX-4 6659 -0.662 7.241 1.72E-69 
DHFR2 
Dihydrofolate reductase 2, 
mitochondrial 
2008 -0.658 4.173 9.03E-32 
ARRDC4 Arrestin domain-containing protein 4 9194 -0.654 5.468 1.88E-15 
MYB Transcriptional activator Myb 4602 -0.645 7.781 1.33E-65 
CDH18 Cadherin-18 1016 -0.640 1.000 0.001 
ASNSD1 
Asparagine synthetase domain-
containing protein 1 
5452 -0.638 5.566 1.58E-47 
C2orf82 Protein SNORC 3890 -0.637 -0.031 0.004 
TNFSF10 
Tumour necrosis factor ligand 
superfamily member 10 
8743 -0.636 0.899 6.14E-05 
INAVA Innate immunity activator protein 5576 -0.635 1.406 6.55E-07 
KLF5 Krueppel-like factor 5 6881 -0.626 4.701 4.33E-26 
TIAM2 
T-lymphoma invasion and metastasis-
inducing protein 2 
2623 -0.626 1.871 2.80E-07 
FRAT2 GSK-3-binding protein FRAT2 2340 -0.626 5.114 1.95E-44 
GRB7 Growth factor receptor-bound protein 7 2886 -0.625 4.496 1.52E-30 
TSNAXIP1 
Translin-associated factor X-
interacting protein 1 
5581 -0.624 0.579 0.001 
LRFN3 
Leucine-rich repeat and fibronectin 
type-III domain-containing protein 3 
7941 -0.622 2.080 7.60E-10 
STC1 Stanniocalcin-1 6781 -0.620 7.513 1.03E-58 
DOK3 Docking protein 3 7993 -0.620 1.550 2.49E-06 
CENPC Centromere protein C 1060 -0.618 5.015 1.98E-37 
RNF43 E3 ubiquitin-protein ligase RNF43 5489 -0.617 6.286 4.28E-61 
PPP1R10 
Serine/threonine-protein phosphatase 1 
regulatory subunit 10 
5514 -0.615 6.238 3.17E-76 
TP53INP1 
Tumour protein p53-inducible nuclear 
protein 1 
9424 -0.614 5.770 1.26E-44 
RIN2 Ras and Rab interactor 2 5445 -0.605 4.000 5.86E-20 
DBR1 Lariat debranching enzyme 5116 -0.603 4.547 3.89E-28 
KIAA1683 IQ domain-containing protein N 8072 -0.600 2.535 5.70E-10 
 
